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 Ghrelin is a peptide hormone primarily secreted by the stomach that acts as the 
endogenous ligand for the GHSR1a G-protein-coupled receptor. This 28 amino acid peptide 
stimulates appetite and has been associated with the cardiovascular, gastrointestinal, 
neuroendocrine, and immune systems. Ghrelin requires a unique posttranslational modification 
to be biological active. Ghrelin O-acyltransferase (GOAT) is responsible for catalyzing 
octanoylation of the 3rd serine side chain of ghrelin to generate the active form of this hormone. 
Thus, GOAT is considered as a potential therapeutic target for treatment of obesity and other 
disorders linked to the peptide. Yet, the active site architecture and mechanism for GOAT-
catalyzed ghrelin acylation are presently undetermined. Purification of an active form of GOAT 
has been challenging, impeding structural studies of this integral membrane protein. To improve 
on these challenges, we have synergistically combined computational modeling and biochemical 
validation to construct the first structural model of the eukaryotic membrane-bound human 
GOAT protein. Our structure revealed an unforeseen strategy for transmembrane protein 
acylation with catalysis occurring in an internal channel connecting the lumen and cytoplasm. 
Structure-guided studies used in this work, have revealed essential amino acid responsible for 
important substrate-enzyme interactions. Moreover, by using a tight-binding fluorescent ghrelin-
derived peptide, we demonstrate GOAT’s interaction with extracellular ghrelin and facilitation of 
ligand cell internalization. Our work provides a new understanding of GOAT’s catalytic 
mechanism, establishes key substrate-enzyme interactions, and advances structure-guided 
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Chapter 1: Introduction 
1.1 Protein post-translation modifications  
 In the last few decades, scientists have identified a vast number of proteins forms in the 
human proteome, well beyond that encoded in the genome. This proliferation in complexity is 
created by subsequent chemical transformations in a process called post-translational 
modification (PTM). PTMs chemically diversify the proteome beyond the standard 
proteinogenic 20 amino acids to an enormous number of residues,1 changing the properties of a 
protein by the addition of an altered chemical group or another protein to the polypeptide. These 
modifications can create highly dynamic regulatory networks associated in almost all cellular 
processes.2 These modifications can be required for protein folding, protein-protein interactions, 
transcriptional adaptation, metabolism, and cell growth among other key cellular mechanisms.3  
This immense number of known PTMs emphasizes the countless ways that cells can modify their 
proteins to respond to diverse stimuli.  
 PTMs are abundant in the proteome with several hundreds of modifications described,4 
ranging from small chemical modifications (e.g., phosphorylation and acetylation) to the addition 
of proteins (e.g., ubiquitylation).5-6 Alterations such as phosphorylation, which conjugates a 
phosphate group covalently to a serine, threonine, or tyrosine residue, play essential roles in 
relaying a broad spectrum of regulatory oncogenic mechanisms in eukaryotic cells.7 On other 
hand, some of these modifications are involved in correct protein folding, changing the 
biophysical properties of the protein like glycosylation and lipidation.8-10 The addition of 
hydrophobic lipid groups to proteins can play an essential role in regulating protein-membrane 
and protein-protein interactions. Common lipidation modifications include fatty acylation, 
3  
prenylation, palmitoylation, among others that modify charge, hydrophobicity, and other features 
of protein chemistry inside the cell.9, 11  
Protein acylation can occur on amino acid residues like Lys, Cys, and Ser/Thr bearing 
nucleophilic side chains (-NH2, -SH, -OH) with these modifications referred as N-acylation 
(amide linkage), S-acylation (thioester linkage) or O-acylation (ester linkage), respectively. N-
acetylation, the transfer of an acetyl group to a specific site on a polypeptide chain from acetyl-
coenzyme A (CoA), is catalyzed by various acetyltransferases.9 This posttranslational 
modification is broadly distributed in nature and conserved in all kingdoms as a key alteration to 
control protein trafficking, intracellular localization, and other signaling pathways. 12-13 Other 
types of acylation occur at the protein N-terminus, such as N-terminal acetylation, N-
myristoylation on Gly or S-palmitoylation on Cys residues.14 The addition of a 14-carbon fatty 
acid myristate to a N-terminal glycine is a stable bond, which is co-translationally modified.15 In 
contrast, palmitoylation is the posttranslational attachment of palmitic acid (16-carbon) to N-
terminal or internal cysteine residues of proteins via a reversible thioester.11 Cycles of 
palmitoylation and depalmitoylation occur in a controlled fashion for many proteins, implying an 




1.2 Ghrelin – an acylated peptide hormone 
1.2.1 Discovery of ghrelin as the endogenous ligand of the growth hormone secretagogue 
receptor 1a  
 The peptide hormone ghrelin is one of several biological signaling molecules that require 
a lipidation modification for biological function.17 This hormone is an orexigenic peptide that 
acts directly on neurons in the hypothalamus, controlling appetite and energy balance.18 This 
hormone was first identified in 1999 by Kojima and coworkers with numerous studies to 
identifying the endogenous ligand for growth-hormone secretagogue receptor (GHS-R1a).17 The 
ligand discovered was recognized to be the cognate agonist of this receptor when purified from 
rat stomach.17, 19 These studies examined changes for the characteristic intracellular increase in 
calcium concentrations ([Ca2+]i) induced by GHS-R1a activation in rat tissues and found the 
highest to be in the stomach extract. Furthermore, by comparing synthetic 28-residue peptide 
(desacyl ghrelin) to ghrelin extracted from rat stomach via reverse phase HPLC (high 
performance liquid chromatography), there was delay in retention time of natural ghrelin by 10 
minutes. This change in retention time was indicative of the presence of a large hydrophobic 
group that was identified to be the hydroxyl group of the Ser3 residue in ghrelin modified by an 
acyl group. 17 This modification revealed an uncommon eight-carbon fatty acid moiety 
(octanoate) covalently acylated to the ghrelin hormone.  
 The post-translational octanoylation of ghrelin has been demonstrated to be absolutely 
necessary for GHS-R1a receptor identification and activation.20 Desacyl ghrelin is unable to bind 
and activate the receptor, preventing subsequent receptor activation.20 However, desacyl ghrelin 
possesses a distinct profile of biological actions including promotion of bone marrow 
adipogenesis,21 reduction of gastric emptying,22 and suppression of gonadotrophin secretion in 
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male rats,23 but the exact nature and mechanism of this signaling by desacyl ghrelin remains 
unclear.  
 
1.2.2 Ghrelin expression and binding to GHS-R1a receptor 
 The GHS-R1 gene encodes for the human full-length seven transmembrane domain G-
protein coupled protein (GHS-R1a) and its truncated isoform (GHS-R1b).24-25 GHS-R1 mRNA 
expression analysis revealed that the receptor type 1a is found mainly in pituitary with lower 
levels of this receptor found also in the brain and peripheral tissues, thyroid gland, pancreas, 
spleen, myocardium, and adrenal gland.24, 26 Meanwhile, ghrelin mRNA was identified via real-
time PCR in the stomach and several other tissues studied (kidney, liver, colon, fat tissue, breast, 
esophagus, among others).27 Ghrelin is primarily produced and secreted by X/A-like cells in the 
oxyntic glands of the gastric mucosa in rats and P/D1 cells in human,28 with Wierup et al. also 
describing expression of ghrelin in the pancreas of ε-cells.29 Ghrelin expression was also 
identified in the pituitary gland and hypothalamus, where the highest concentration of its 
receptor was determined.24 The widespread distribution of GHS-R1a and ghrelin indicates 
broader implications beyond its well-known appetite stimulating (orexigenic) function. 
 In addition, ghrelin is described as a peptide hormone that can induce growth hormone 
(GH) release from pituitary cells in dose-dependent fashion, without GHS-R1a activation 
stimulating the release of other hormones even at high ghrelin concentrations.17, 30 To further 
investigate specificity of ghrelin induced GH release, Kojima and coworkers injected ghrelin 
intravenously in rats resulting in the high release of only GH.17 These results suggested that 
ghrelin is a specific endogenous ligand for the GHS-R1a receptor.  
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 To reveal structural features of human ghrelin required to activate the GHS-R1a receptor, 
ghrelin analogs containing aliphatic or aromatic groups in the side chain of residue 3 and 
truncated peptides of ghrelin were synthesized and tested for activity.20 This study established 
the importance of a large hydrophobic group in Ser3 required for efficient activation of GHS-
R1a. Moreover, ghrelin is the only peptide known to be octanoylated at serine 3 amino acid, 
which is required for the release of growth hormone in human and rats.12,31,28 Ghrelin analogs 
with shorter and less hydrophobic acyl groups in place of the n-octanoyl group showed decreased 
in receptor binding and activation, whereas medium to long acyl groups up to 16 carbons 
exhibited receptor activation.20 Interestingly, a truncated version of ghrelin only containing the 
first five amino acids was sufficient to be recognized and activated the receptor equivalently to 
that of full-length ghrelin. Moreover, the shorter tetrapeptide GSS(n-octanoyl)F still activated the 
GHS-R1a receptor but to a lesser extent.  
 
1.2.3 Ghrelin signaling and regulation 
 Originally linked to growth hormone secretion and stimulation of appetite18, 32, ghrelin 
was also found to be a potent stimulator of food intake, energy storage, and adiposity.33-34 
Studies had showed that the concentration of ghrelin in rat serum increased by fasting and 
reduced by orally glucose intake.33 Peripheral (subcutaneous and intraperitoneal) daily 
administration of ghrelin triggered weight gain by reduction of fat utilization in mice and rats.33 
Interestedly, studies of ghrelin in humans also supported the stimulation of appetite and food 
intake,35 but plasma ghrelin concentration was inversely related to body fat.36 Ghrelin was also 
proven to increase food intake in obese as well as lean subject groups, with no significant 
difference in basal ghrelin levels indicating that ghrelin sensitivity is preserved in obese groups.37 
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Subsequently, it has been proposed that the dysregulation of ghrelin could be connected to the 
development of obesity and other the metabolic related conditions.38 
 In addition to these functions, this hormone has been shown to be involved in addictive 
behaviors, playing an important role in reward processing.39-40 Studies also linked ghrelin to 
stress-related mechanisms, affecting psychological responses to prolonged exposure to 
stressors.41-43 Moreover, ghrelin is involved in neuroprotection44 as well as memory and learning 
process. 45, 46 All these reinforce the hypothesis of ghrelin’s connection with major brain systems, 
consistent with proposed involvement of ghrelin in generation and/or progression of Alzheimer's 
disease.47 
 Additionally, studies of ghrelin and ghrelin receptor agonists have shown connections to 
other disorders including anorexia nervosa,48 cancer cachexia,49 chronic heart failure,50 and 
regulation of inflammation and inflammatory cytokine expression in humans and rodents. 
Uncovering of the roles that ghrelin and its cognitive receptor play in the immune system have 
opened new treatment options for immunological disorders such as AIDS and organ damages 






















Figure 1.1. Gut-brain connection: The physiological effects of ghrelin activation. Ghrelin is 
mainly produced and released by the stomach with low amounts found in other tissues such as 
the gastrointestinal tract, the pancreas, and the brain. Ghrelin, the “hunger hormone”, regulates 
appetite and plays a significant role in controlling energy homeostasis, memory and learning 
processes, immunological systems, stress mechanisms, among others. 
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1.2.4 Ghrelin maturation and acylation  
 Ghrelin undergoes several maturation steps in a process required to produce functional 
ghrelin peptide to bind and activate its receptor (Figure 1.2). The human ghrelin gene is found on 
chromosome 3p25-26 within the human genome.52 Ghrelin is initially translated into a 117-
amino acid precursor known as preproghrelin that is trafficked to the endoplasmic reticulum 
(ER) by signal recognition particle recognition of an N-terminal signal peptide.19 Following 
translocation into the ER lumen, the 23 amino acid N-terminal signal peptide of preproghrelin is 
cleaved by a signal peptidase,53-54 resulting in a 94 amino acid protein proghrelin.55 Proghrelin 
undergoes a unique post-translation octanoylation modification on the third serine from the N-
terminus of the 94-amino acid sequence.54 This addition of a n-octanoic acid group to the 
hydroxyl group of the serine residue increases the hydrophobicity of the ghrelin molecule, which 
is necessary for the biological activity of ghrelin through the GHS-R1a receptor.56 This 94-
amino-acid precursor is cleaved proteolytically by prohormone convertase 1/3 to release mature 
28 amino acid ghrelin (Figure 1.2).54  
 The cleavage of proghrelin results into two different 28 amino acid forms of ghrelin: 
acylated and des-acylated (no serine octanoyl ester) ghrelin. Both are released into the 
bloodstream, with some earlier studies suggesting that des-acyl ghrelin represents the major form 
of circulating peptide.57-60 Acylated ghrelin is inactivated by hydrolysis of the ester bond, leading 
to a limited lifetime in circulation for the octanoyl serine ester modification. Ester hydrolysis was 
studied in human serum with acylated ghrelin (1-28 and 1-23) peptides, yielding exclusive 
production of des-acyl ghrelin in 240 minutes.61 Serum studies using carboxylesterase and 
butyrylcholinesterase (BChE) demonstrated that these enzymes mediated the hydrolysis of acyl 
ghrelin in vitro, as well as platelet-activating factor acetylhydrolase in human serum, and 
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lysophospholipase 1 in fetal bovine serum.61-64 Therefore, more than one enzyme can contribute 
to the hydrolysis of acyl ghrelin or there could be major unidentified ghrelin esterase responsible 
for a bigger portion of the hydrolysis. This important enzyme may vary from species-to-species 
and/or from tissue-to-tissue, and ghrelin-signaling control through esterase-mediated deacylation 
































Figure 1.2. Ghrelin synthesis, maturation and post-translational modification in stomach 
cells. Preproghelin is translated and cleaved to produce proghrelin peptide.  Proghrelin is 
octanoylated on its Ser3 amino acid residue by ghrelin O-acyltransferase. The octanoylated 
proghrelin is cleaved by prohormone convertase 1/3 (PC 1/3) after arginine-28 of proghrelin, 
generating the mature 28 amino acid peptide to be secreted into plasma. Both acylated and des-




1.3 Ghrelin O-acyltransferase (GOAT) 
 To be biologically active, ghrelin requires a unique posttranslational modification of the 
third serine (Ser3) of the precursor des-acyl proghrelin, where this serine is acylated by an 
octanoyl (C8) fatty acid group (Figure 1.3). The enzyme that catalyzes ghrelin octanoylation, 
ghrelin O-acyltransferase (GOAT), was discovered by two research groups independently in 
2008.66-67 GOAT is a 45-kDa multispanning integral membrane protein member of the 
membrane bound O-acyltransferase (MBOAT) enzyme superfamily, with the alternate name 
MBOAT4.68-70  Enzymes in this superfamily catalyze acylation of both protein and small 
molecule substrates, often transferring fatty acids onto hydroxyl groups.68 Three MBOAT 
members - porcupine (PORCN), Hedgehog acyltransferase (Hhat), and ghrelin O-acyltransferase 
(GOAT) - exclusively catalyze the transfer of a fatty acyl moiety onto secreted signaling 
proteins, trafficking through the secretory pathway in the ER lumen.66-67, 70-71 These family 
members share a conserved homology domain that contains a highly conserved 
asparagine/aspartic acid located within a hydrophilic region and invariant histidine (His) that is 
surrounded by a long section of hydrophobic residues.68, 72-73 Mutational studies of the conserved 
His residue has demonstrated a reduction catalytic activity in the respective enzymes. 66, 72, 74 
Even though these residues have been shown to be essential and hypothesized to be involved in 



























Figure 1.3. Ghrelin octanoylation by ghrelin O-acyltransferase (GOAT). Ghrelin O-
acyltransferase catalyzes the acylation of proghrelin by adding an octanoyl moiety to its Ser3 
amino acid residue. This modification activates ghrelin for subsequent receptor binging and 
signaling. Ghrelin in circulation is converted to des-acyl ghrelin by serum esterases. 
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1.3.1 GOAT expression and distribution 
 Ghrelin is the only known protein with an ester-linked octanoyl group and found to be 
expressed mainly in the stomach and small intestine.17, 28, 75 GOAT is the key enzyme modifying 
and regulating ghrelin’s activity.66-67 GOAT mRNA has been found to be highly expressed in the 
stomach and GOAT has been identified within tissues known to express ghrelin as the stomach, 
intestine, colon, and testis.66-67, 76 Similarly, co-expression of GOAT and ghrelin was found to 
high degree in the same gastric mucosal cells and duodenal mucosal.77 Similarly, full length 
monomeric and dimeric GOAT protein was identified in plasma during fasting in both mice and 
humans; suggesting that GOAT can be released into circulation through a currently unknown 
pathway.76, 78 
 GOAT has been found mainly to be expressed in the stomach and pancreas, but also in a 
numerous other tissues, including breast and prostate tissue.79-80 Moreover, studies have detected 
GOAT overexpression in some tumoral tissues (breast pituitary, and endocrine tissues).79, 81-82 
Likewise, overexpression of GOAT was observed in prostate-cancer cells (PCa). It was 
demonstrated that GOAT (mRNA/protein-level) is overexpressing in cancer prostatic tissues and 
plasma/urine samples of PCa patients compared to healthy prostate tissues and plasma samples.83 
Moreover, there was a correlation found between GOAT levels and aggressiveness of the disease 
in PCa patients. This suggests that GOAT holds potential as non-invasive PCa biomarker to 
provide a better PCa diagnosis.  
15  
1.3.2 GOAT topology and structure-activity analysis 
 The active site structure and catalytic machinery of GOAT are not well understood. 
Membrane proteins have been proven to be difficult to study owing to their hydrophobic 
surfaces, flexibility, and lack of stability in the absence of membrane lipids.84-85 In particular, 
crystallization of such membrane proteins is extremely difficult. However, Taylor and coworkers 
constructed the first topological description of GOAT’s structure by combining computational 
calculations, phylogeny, epitope mapping, and induced glycosylation.86 Their studies described 
an 11 transmembrane domain (TMD) model with 1 hydrophobic domain that did not cross the 
membrane, denoted as the re-entry loop (RL) (Figure 1.4). The C-terminus of GOAT was located 
in the cytosol with a detectable 3xFLAG tag and the N-terminus located in the ER lumen.  
 Six MBOAT family members have been mapped topologically: human ACAT1 (acyl-
CoA:cholesterol) acyltransferase, ACAT2, ghrelin O-acyltransferase (GOAT), hedgehog 
acyltransferase (HHAT), yeast glycerol uptake protein 1 (Gup1p), and lysophosphatidylinositol-
acyltransferase-1 (LPIAT1). 73, 86-91 GOAT’s topology described is consistent with topological 
investigations of Hhat and PORCN, the location of the invariant H338 was described lumenal 
and a conserved Asn307 as cytosolic (Figure 1.4). 72-73, 89-90. The location of the invariant H338 
and mutagenesis of this residue, which abolished ghrelin octanoylation, supported the 
importance of this residue in GOAT catalytic activity.86 However, the position and conformation 




Figure 1.4 Ghrelin O-Acyltransferase topology model. Proposed prototypical description of 
GOAT by Taylor et al., showing 11- transmembrane domains (TMDs) and one reentrant loop. 
Invariant residue H338 was found in the ER lumen, consistent with other family members, and 
conserved amino acid N307 was found in the cytosol.  Figure reproduced with permission from 
Reference 86 (Appendix I). © 2013 American Society for Biochemistry and Molecular Biology 
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1.3.3 Crystal structure of a membrane-bound O-acyltransferase 
 In addition to the eukaryotic family members, MBOATs are also found in bacteria.92-97 
The bacterial MBOAT DltB (D-alanyl transferase protein B) is involved in the incorporation of 
D-alanine into teichoic acids (TAs), major components of gram-positive bacterial cell wall.93, 96 
Xu and coworkers determined the first crystal structure of an MBOAT family member in the 
context of full-length DltB from Streptococcus thermophiles (Figure 1.5).98 In this structure, 
DltB contains 11 peripheral transmembrane helices with both the N- and the C- termini located 
in the extracellular space. Additionally, an extracellular funnel is described with a distinct tunnel 
between the bottom of the extracellular side and the cytoplasmic side.98 Inside this tunnel, there 
are highly conserved amino acids amongst DltB proteins as well as in other MBOAT proteins, 
which supports that this tunnel is functionally essential. The conserved histidine found in all 
MBOATs, His 336 in DltB, is located within this tunnel and interacts with other functionally 
essential amino acids consistent with this residue acting as a general base. Mutation of DltB 
residues corresponding either to the DltB His336 or to the DltC-binding site completely 
abolished D-alanylation of TA,98 similar to the mutation of His338 eliminating acylation of 
ghrelin in GOAT.67, 99 Despite a low overall sequence homology between other MBOATs and 
DltB, the amino acid location and structural features of this model suggest a common or similar 














Figure 1.5 Crystal structure of a membrane-bound O-acyltransferase. DltB crystal structure 
is shown in two orientations with rainbow colors from N-terminal (blue) to C-terminal (red) 
termini: a. bottom view and b. side view inside membrane with extracellular top and intracellular 
down. Figures were made with PyMol and the structure was obtained from the protein data bank 





1.4 GOAT substrate selectivity/recognition 
 The discovery of the enzyme GOAT unlocked a new approach to manipulate the octanoyl 
modification of ghrelin, aiding the development of drugs that can potentially treat obesity and 
other ghrelin related disorders.100 To design GOAT inhibitors, a complete understanding of the 
interactions between ghrelin (substrate) and GOAT (enzyme) is essential. The sequence of 
ghrelin in the region near the acyl-modification is highly conserved throughout most vertebrate 
species.18, 101-102 Yang and coworkers investigate important amino acids in the N-terminal 
sequence of the pentapeptide GSSFL-NH2, necessary for GOAT recognition near the region of 
the octanoylated serine.99 Residues glycine-1, serine-3, and phenylalanine-4 were mutated, with 
these alterations resulting in a decrease of activity with GOAT. A much less inhibitory outcome 
was detected with an alanine substitution of leucine-5 and serine-6, and no effect was observed 
when proline-7 was replaced. This recognition specificity is consistent with the conservation of 
these three amino acids in most vertebrate ghrelins.101 Surprisingly, studies made with a short 
four amino acid peptide still demonstrated acyl-modification by GOAT.103 Accordingly, GOAT 
has the ability to recognize the first N-terminal four amino acids motif of the ghrelin peptide. 
Similarly, studies using structure-activity analysis of ghrelin-mimetic peptides showed the 
importance of the α amino group of N-terminal glycine.104-105 Mutation of this amine entirely 
abolished peptide octanoylation by hGOAT. Moreover, studies showed hGOAT does not accept 
negative charge at any site at N-terminus of GSSFL ghrelin, requiring positive charge and/or 
hydrogen bond donor character at its substrate.105  
 To investigate the binding efficiency of longer sequences than the pentapeptide, 
intermediate lengths of ghrelin (5-mer), (10-mer), (18-mer), and (28-mer) peptide were studied 
as competitive hGOAT inhibitors in an octanoylation reaction.105 As expected, the 18-mer and 
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28-mer exhibited a greater inhibitory behavior than the smaller counterpart, with a tighter 
binding affinity. Similar studies with in vitro microsomal ghrelin octanoylation of 10-mer and 
27-mer ghrelin substrates by GOAT, displayed lower affinity towards the 10-mer substrate.106 
These results indicate the potential importance of interactions downstream of the N-terminal 
sequence of ghrelin, which is necessary for GOAT binding.     
 In addition to the ghrelin peptide, GOAT also recognizes the other substrate n-octanoyl-
CoA to form the acylated product. Studies to determine the length of the acyl donor necessary 
for ghrelin octanoylation used numerous n-acyl-CoAs, including n-hexanoyl-CoA (C6-CoA), n-
decanoyl-CoA (C10-CoA), n-myristoyl-CoA (C14-CoA), and n-palmitoyl-CoA (C16-CoA).103 
Octanoylation was observed with C6- and C10-CoA, demonstrating that GOAT can accept a 
range of acyl-CoA substrates. However, longer acyl donors like myristoyl-CoA or palmitoyl-
CoA are not efficiently accepted by GOAT,99, 103, 107 contrasting behavior observed with other 
MBOAT family members.68, 108  In a different study implementing acylated product-mimetic 
inhibitors with a amide-linked chain, acyl length effect was monitored by binding affinities of 2 
(acetyl) to 10 (decanoyl) carbons in the acyl chain. Inhibition binding affinities increased as the 
acyl chain was extended from 0 to 8-carbon and decreased from 9 to 10-carbons.105 These studies 
support the existence of a discrete acyl group-binding site within GOAT that selects for medium 
chain fatty acids, with a particular preference for octanoyl groups. 
 
1.5 GOAT inhibitors/ therapeutic effects 
 Since GOAT is essential for the production of the active form of ghrelin for signaling 
through the GHS-R1a receptor, inhibition of GOAT represents a novel approach to control 
ghrelin-signaling activity. Yang and coworkers reported the first peptide-based analogue 
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inhibitors of GOAT by using an octanoylated peptapeptide (1-5) [Dap3]-ghrelin ([2,3-
diaminopropanoic acid]-ghrelin) (Figure 1.6a) and the entire 28-amino acid sequence [Dap3]-
ghrelin, both of which exhibited GOAT inhibition (IC50 = 1 µM and IC50 = 0.2 µM, 
respectively).99 However, these substrate mimetics can also bind to the ghrelin receptor, acting as 
potent agonists and posing a challenge as a target for further inhibitor development. Zhao and 
coworkers investigated more biostable and potentially cell permeable inhibitor analogues of 
acylated ghrelin mimetics.109 These inhibitors are triazole-linked peptapetide ghrelin mimetics 
created using an azidoalanine at the Ser3 residue. Diverse inhibitors with a triazole-linked 
hydrophobic group and aromatic side chain at F4 position of the GSSF ghrelin site were tested 
for activity against GOAT, with the inhibitor containing a phenylpropyl triazole moiety (Figure 
1.6a) having the highest potency (IC50 = 0.7 µM).
109 This class of [Dap3]-ghrelin inhibitors 
displayed tolerance of a triazole linkage in place of the hydrolytically vulnerable ester and amide 
linkages while maintaining potency. A peptide based bi-substrate analog derived from the HIV 
Tat-peptide (GO-CoA-Tat) was developed which demonstrated inhibition of GOAT activity for 
mammalian cells and mice (Figure 1.6a).110 GO-CoA-Tat inhibits synthesis of acyl-ghrelin and 
reduces body weight gain, but as another peptide-base inhibitor GO-CoA-Tat also faces serious 
pharmacodynamic and pharmacokinetic challenges.  
 Moving towards non-peptide small molecule inhibitors of GOAT, Garner and Janda 
identified small molecule inhibitors employing a catalytic assay using enzyme-linked click 
chemistry (cat-ELCCA). Using this assay to screen a small compound library, two compounds 
were discovered (3a and 3b) (Figure 1.6b) as potential GOAT antagonist with IC50 = 7.5 µM and 
13.1 µM, respectively.111 Structural analysis of these small molecules suggests that they inhibit 
the acylation of ghrelin by blocking binding of octanoyl-CoA to GOAT.  
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 “Druglike” small molecule analogues of CDDO family compounds from the Diversity 
Set IV library (Developmental Therapeutics Program / NIH) were tested for inhibition of ghrelin 
acylation of the hGOAT using a fluorescence-based in vitro assay. CDDO derivatives effectively 
inhibited hGOAT in the micromolar range, functioning as covalent reversible inhibitors of 
hGOAT.112 CDDO compounds have been showed to covalently modify nucleophilic thiols in a 
reversible manner113, these studies can provide insight of the interaction of these compounds to a 
functionally essential cysteine residue in ghrelin octanoylation by hGOAT (Figure 1.6b). CDDO 
(2-cyano-3, 12-dioxooleana-1,9-dien-28-oic acid) and its derivatives, which are created by 
manipulation of functional groups within naturally occurring triterpenoids like oleanolic acid, 
have proven to improve diabetes in high fat diet-fed type 2 diabetic mice and reduced total body 
fat which potentially supports effects in ghrelin signaling.114 Nakajima and coworkers 
investigated the inhibitory effect of triterpenes on octanoylated ghrelin production in the ghrelin-
expressing cell line (AGS-GHRL8). Asiatic acid, corosolic acid, glycyrrhetinic acid, oleanolic 
acid, and ursolic acid suppressed octanoyl ghrelin production in these cells as well as 
octanoylated ghrelin in mice,115 but similar derivatives lacking cysteine-reactive groups proved 
ineffective against GOAT in enzyme-based assays.112   
 Presently, there are at least two classes of small molecule inhibitors targeting GOAT 
acylation that have been developed by industrial research groups at Takeda Pharmaceuticals and 
Eli Lilly.104-106 With a high-throughput assay system and enzyme-linked immunosorbent assay 
(ELISA), Takeda researchers identified multiple inhibitor hits in an in-house compound 
library.116 The novel lead compound (4-chloro-6-{[2-methyl-6-(trifluoromethyl)pyridin-3-
yl]methoxy}-1-benzothiophen-3-yl)acetic acid) was synthesized and demonstrated to be a GOAT 
inhibitor with high biochemical potency and bioavailability, showed to decrease acyl ghrelin 
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concentrations in the plasma and stomach of mice (Figure 1.6b).116 The Eli Lilly team reported a 
potent piperidyl-ethyl-pyrimidine GOAT inhibitor discovered using a high-throughput GOAT 
activity-screening assay. The information in their patent denotes that this compound (Figure 
1.6b) has potency in enzymatic and animal findings; however, further in vivo studies are needed 



























Figure 1.6 Ghrelin O-acyltransferase inhibitors incorporating lipid mimetic groups and 
small molecules. a) Peptide-based inhibitors of GOAT prior to this work. b) Small molecule 
GOAT inhibitors.  
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1.6 Aims of this work  
 
 Ghrelin, the 28 amino acid “hunger hormone”, provides a neuroendocrine connection 
between the brain and the digestive system as it regulates metabolism and energy homeostasis. 
GOAT is the enzyme that modulates ghrelin signaling by octanoylation of ghrelin’s 3rd serine in 
the peptide sequence. The involvement of GOAT in ghrelin’s maturation presents an attractive 
target of inhibition for the treatment of ghrelin-related diseases like type II diabetes and other 
metabolic disorders. This protein post-translational octanoylation is unique to ghrelin, but little is 
known about the mechanism of GOAT-ghrelin modification, or other related MBOAT proteins. 
Purification of soluble, active form of the membrane-bound proteins like GOAT has been 
challenging. However, many in vitro analyses have established active preparations of the GOAT 
enzyme using microsomes from insect cells and humans. 66, 86, 104-105, 110-111, 117 These previous 
studies have determined important aspects of ghrelin such as the N-terminal sequence 
requirement for recognition by GOAT, and have enabled identification of numerous peptide and 
small-molecule inhibitors. However, mechanistic and structural information regarding the 
machinery of catalysis of GOAT is still sorely lacking. Determination of the structure of 
functionally important domains within GOAT is a critical step to define how GOAT binds its 
substrate and catalyzes its octanoylation.  
 The main goal of the research detailed in this thesis is to understand the biological 
structure and activity of human GOAT. Towards this goal, we have engineered an 
interdisciplinary computational-biochemical approach to generate a structural model of GOAT 
with biochemical validation. This computationally derived structure of GOAT was parallel with 
the published topological model of the mouse GOAT ortholog86 and revealed significant 
similarities with the crystal structure of a bacterial MBOAT alanyl transferase, DltB.98 Our 
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model has exposed a contiguous internal channel through the enzyme core that transposes from 
the ER lumen to the cytoplasm. Not only this channel possesses the conserved H338, but we 
were able to demonstrate a range of significant amino acids affecting GOAT’s activity within 
this pore.  
 Computational docking experiments into our hGOAT structure have described a binding 
site for octanoyl-CoA, underlying contacts with both the coenzyme A and acyl chain fragments 
of the acyl-CoA substrate. Alanine mutagenesis of residues with predicted contact to the acyl 
donor has led the alteration of acyl donor selectivity, providing constraints defining the acyl 
chain-binding site within hGOAT. 
 We have also identified hGOAT residues contacting ghrelin substrate by a cross-mutation 
alanine contact approach. Rescue of hGOAT alanine mutations by altered substrates was 
established by reactivity enhancements for each enzyme-substrate mutation pair relative to the 
wild type enzyme and substrate. Rescue signals of hGOAT alanine variants by mutated 
substrates were obtained, revealing significant hGOAT residues in or near the ghrelin-binding 
site.  
 To understand fundamental contributions for enzymatic function of a conserved hGOAT 
loop domain linking helices 7 and 8 of the enzyme, we designed a bacterial expression system of 
the circularized loop protein to determine loop’s function in the ghrelin acylation process. The 
circularized loop was expressed in high levels and we were able to obtain a functional 
characterization with circular dichroism (CD) of the purified domain, demonstrating a partial α-
helical structure.  
 We have developed a selective peptide ligand with nanomolar binding affinity for GOAT 
through sequence mutagenesis and chemical modifications. This potent ligand confirmed high 
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selectivity for ghrelin O-acyltransferase (GOAT) over the ghrelin GHS-R1a receptor. 
Furthermore, we optimized this inhibitor to create a fluorescent ghrelin-derived peptide for 
ligand detection.  By utilizing transiently transfected HEK 293 cells, we were able to 
demonstrate GOAT’s interaction with extracellular fluorescent ghrelin peptide and potential 
facilitation of ligand cell internalization.  
  The studies proposed in this work have facilitated the elucidation of the acyl donor and 
ghrelin binding sites within hGOAT. Functional essential amino acids within the GOAT core has 
been analyzed and identified as potential interactions with substrate binding. Likewise, these 
analyses have been focusing in the investigation of the mechanism for acylation of the ghrelin 
serine residue and the involvement of a catalytic general base or other associated residues. These 
studies have provided the first molecular-scale structural information of this important enzyme, 
accelerated inhibitor development aiming ghrelin signaling, and possibly identify new 




1.7 References  
1. Walsh, C. T.; Garneau-Tsodikova, S.; Gatto, G. J., Jr., Protein posttranslational 
modifications: the chemistry of proteome diversifications. Angew Chem Int Ed Engl 2005, 44 
(45), 7342-72. 
2. Venne, A. S.; Kollipara, L.; Zahedi, R. P., The next level of complexity: crosstalk of 
posttranslational modifications. Proteomics 2014, 14 (4-5), 513-24. 
3. Deribe, Y. L.; Pawson, T.; Dikic, I., Post-translational modifications in signal integration. 
Nat Struct Mol Biol 2010, 17 (6), 666-72. 
4. Minguez, P.; Letunic, I.; Parca, L.; Bork, P., PTMcode: a database of known and 
predicted functional associations between post-translational modifications in proteins. Nucleic 
Acids Res 2013, 41 (Database issue), D306-11. 
5. Kole, H. K.; Abdel-Ghany, M.; Racker, E., Specific dephosphorylation of 
phosphoproteins by protein-serine and -tyrosine kinases. Proc Natl Acad Sci U S A 1988, 85 
(16), 5849-53. 
6. Pickart, C. M., Mechanisms underlying ubiquitination. Annu Rev Biochem 2001, 70, 503-
33. 
7. Ardito, F.; Giuliani, M.; Perrone, D.; Troiano, G.; Lo Muzio, L., The crucial role of 
protein phosphorylation in cell signaling and its use as targeted therapy (Review). Int J Mol Med 
2017, 40 (2), 271-280. 
8. Shental-Bechor, D.; Levy, Y., Folding of glycoproteins: toward understanding the 
biophysics of the glycosylation code. Curr Opin Struct Biol 2009, 19 (5), 524-33. 
29  
9. Jiang, H.; Zhang, X.; Chen, X.; Aramsangtienchai, P.; Tong, Z.; Lin, H., Protein 
lipidation: cccurrence, mechanisms, biological functions, and enabling technologies. Chem Rev 
2018, 118 (3), 919-988. 
10. Sola, R. J.; Rodriguez-Martinez, J. A.; Griebenow, K., Modulation of protein biophysical 
properties by chemical glycosylation: biochemical insights and biomedical implications. Cell 
Mol Life Sci 2007, 64 (16), 2133-52. 
11. Resh, M. D., Palmitoylation of ligands, receptors, and intracellular signaling molecules. 
Sci STKE 2006, 2006 (359), re14. 
12. Stael, S.; Bayer, R. G.; Mehlmer, N.; Teige, M., Protein N-acylation overrides differing 
targeting signals. FEBS Lett 2011, 585 (3), 517-522. 
13. Chamberlain, L. H.; Shipston, M. J., The physiology of protein S-acylation. Physiol Rev 
2015, 95 (2), 341-76. 
14. Thinon, E.; Hang, H. C., Chemical reporters for exploring protein acylation. Biochem Soc 
Trans 2015, 43 (2), 253-61. 
15. Farazi, T. A.; Waksman, G.; Gordon, J. I., The biology and enzymology of protein N-
myristoylation. J Biol Chem 2001, 276 (43), 39501-4. 
16. Guan, X.; Fierke, C. A., Understanding protein palmitoylation: biological significance 
and enzymology. Sci China Chem 2011, 54 (12), 1888-1897. 
17. Kojima, M.; Hosoda, H.; Date, Y.; Nakazato, M.; Matsuo, H.; Kangawa, K., Ghrelin is a 
growth-hormone-releasing acylated peptide from stomach. Nature 1999, 402 (6762), 656-60. 
18. Kojima, M.; Kangawa, K., Ghrelin: structure and function. Physiol Rev 2005, 85 (2), 
495-522. 
30  
19. Muller, T. D.; Nogueiras, R.; Andermann, M. L.; Andrews, Z. B.; Anker, S. D.; Argente, 
J.; Batterham, R. L.; Benoit, S. C.; Bowers, C. Y.; Broglio, F.; Casanueva, F. F.; D'Alessio, D.; 
Depoortere, I.; Geliebter, A.; Ghigo, E.; Cole, P. A.; Cowley, M.; Cummings, D. E.; Dagher, A.; 
Diano, S.; Dickson, S. L.; Dieguez, C.; Granata, R.; Grill, H. J.; Grove, K.; Habegger, K. M.; 
Heppner, K.; Heiman, M. L.; Holsen, L.; Holst, B.; Inui, A.; Jansson, J. O.; Kirchner, H.; 
Korbonits, M.; Laferrere, B.; LeRoux, C. W.; Lopez, M.; Morin, S.; Nakazato, M.; Nass, R.; 
Perez-Tilve, D.; Pfluger, P. T.; Schwartz, T. W.; Seeley, R. J.; Sleeman, M.; Sun, Y.; Sussel, L.; 
Tong, J.; Thorner, M. O.; van der Lely, A. J.; van der Ploeg, L. H.; Zigman, J. M.; Kojima, M.; 
Kangawa, K.; Smith, R. G.; Horvath, T.; Tschop, M. H., Ghrelin. Mol Metab 2015, 4 (6), 437-
60. 
20. Bednarek, M. A.; Feighner, S. D.; Pong, S. S.; McKee, K. K.; Hreniuk, D. L.; Silva, M. 
V.; Warren, V. A.; Howard, A. D.; Van Der Ploeg, L. H.; Heck, J. V., Structure-function studies 
on the new growth hormone-releasing peptide, ghrelin: minimal sequence of ghrelin necessary 
for activation of growth hormone secretagogue receptor 1a. J Med Chem 2000, 43 (23), 4370-6. 
21. Thompson, N. M.; Gill, D. A.; Davies, R.; Loveridge, N.; Houston, P. A.; Robinson, I. 
C.; Wells, T., Ghrelin and des-octanoyl ghrelin promote adipogenesis directly in vivo by a 
mechanism independent of the type 1a growth hormone secretagogue receptor. Endocrinology 
2004, 145 (1), 234-42. 
22. Asakawa, A.; Inui, A.; Kaga, T.; Katsuura, G.; Fujimiya, M.; Fujino, M. A.; Kasuga, M., 
Antagonism of ghrelin receptor reduces food intake and body weight gain in mice. Gut 2003, 52 
(7), 947-52. 
23. Martini, A. C.; Fernandez-Fernandez, R.; Tovar, S.; Navarro, V. M.; Vigo, E.; Vazquez, 
M. J.; Davies, J. S.; Thompson, N. M.; Aguilar, E.; Pinilla, L.; Wells, T.; Dieguez, C.; Tena-
31  
Sempere, M., Comparative analysis of the effects of ghrelin and unacylated ghrelin on 
luteinizing hormone secretion in male rats. Endocrinology 2006, 147 (5), 2374-82. 
24. Howard, A. D.; Feighner, S. D.; Cully, D. F.; Arena, J. P.; Liberator, P. A.; Rosenblum, 
C. I.; Hamelin, M.; Hreniuk, D. L.; Palyha, O. C.; Anderson, J.; Paress, P. S.; Diaz, C.; Chou, 
M.; Liu, K. K.; McKee, K. K.; Pong, S. S.; Chaung, L. Y.; Elbrecht, A.; Dashkevicz, M.; 
Heavens, R.; Rigby, M.; Sirinathsinghji, D. J.; Dean, D. C.; Melillo, D. G.; Patchett, A. A.; 
Nargund, R.; Griffin, P. R.; DeMartino, J. A.; Gupta, S. K.; Schaeffer, J. M.; Smith, R. G.; Van 
der Ploeg, L. H., A receptor in pituitary and hypothalamus that functions in growth hormone 
release. Science 1996, 273 (5277), 974-7. 
25. Leung, P. K.; Chow, K. B.; Lau, P. N.; Chu, K. M.; Chan, C. B.; Cheng, C. H.; Wise, H., 
The truncated ghrelin receptor polypeptide (GHS-R1b) acts as a dominant-negative mutant of the 
ghrelin receptor. Cell Signal 2007, 19 (5), 1011-22. 
26. Guan, X. M.; Yu, H.; Palyha, O. C.; McKee, K. K.; Feighner, S. D.; Sirinathsinghji, D. J.; 
Smith, R. G.; Van der Ploeg, L. H.; Howard, A. D., Distribution of mRNA encoding the growth 
hormone secretagogue receptor in brain and peripheral tissues. Brain Res Mol Brain Res 1997, 
48 (1), 23-9. 
27. Gnanapavan, S.; Kola, B.; Bustin, S. A.; Morris, D. G.; McGee, P.; Fairclough, P.; 
Bhattacharya, S.; Carpenter, R.; Grossman, A. B.; Korbonits, M., The tissue distribution of the 
mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab 
2002, 87 (6), 2988. 
28. Date, Y.; Kojima, M.; Hosoda, H.; Sawaguchi, A.; Mondal, M. S.; Suganuma, T.; 
Matsukura, S.; Kangawa, K.; Nakazato, M., Ghrelin, a novel growth hormone-releasing acylated 
32  
peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and 
humans. Endocrinology 2000, 141 (11), 4255-61. 
29. Wierup, N.; Svensson, H.; Mulder, H.; Sundler, F., The ghrelin cell: a novel 
developmentally regulated islet cell in the human pancreas. Regul Pept 2002, 107 (1-3), 63-9. 
30. Cheng, K.; Chan, W. W.; Barreto, A., Jr.; Convey, E. M.; Smith, R. G., The synergistic 
effects of His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 on growth hormone (GH)-releasing factor-
stimulated GH release and intracellular adenosine 3',5'-monophosphate accumulation in rat 
primary pituitary cell culture. Endocrinology 1989, 124 (6), 2791-8. 
31. Callaghan, B.; Furness, J. B., Novel and conventional receptors for ghrelin, desacyl-
ghrelin, and pharmacologically related compounds. Pharmacol Rev 2014, 66 (4), 984-1001. 
32. Cummings, D. E.; Purnell, J. Q.; Frayo, R. S.; Schmidova, K.; Wisse, B. E.; Weigle, D. 
S., A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. 
Diabetes 2001, 50 (8), 1714-9. 
33. Tschop, M.; Smiley, D. L.; Heiman, M. L., Ghrelin induces adiposity in rodents. Nature 
2000, 407 (6806), 908-13. 
34. Nakazato, M.; Murakami, N.; Date, Y.; Kojima, M.; Matsuo, H.; Kangawa, K.; 
Matsukura, S., A role for ghrelin in the central regulation of feeding. Nature 2001, 409 (6817), 
194-8. 
35. Wren, A. M.; Seal, L. J.; Cohen, M. A.; Brynes, A. E.; Frost, G. S.; Murphy, K. G.; 
Dhillo, W. S.; Ghatei, M. A.; Bloom, S. R., Ghrelin enhances appetite and increases food intake 
in humans. J Clin Endocrinol Metab 2001, 86 (12), 5992. 
33  
36. Ravussin, E.; Tschop, M.; Morales, S.; Bouchard, C.; Heiman, M. L., Plasma ghrelin 
concentration and energy balance: overfeeding and negative energy balance studies in twins. J 
Clin Endocrinol Metab 2001, 86 (9), 4547-51. 
37. Druce, M. R.; Wren, A. M.; Park, A. J.; Milton, J. E.; Patterson, M.; Frost, G.; Ghatei, M. 
A.; Small, C.; Bloom, S. R., Ghrelin increases food intake in obese as well as lean subjects. Int J 
Obes (Lond) 2005, 29 (9), 1130-6. 
38. Wren, A. M.; Small, C. J.; Abbott, C. R.; Dhillo, W. S.; Seal, L. J.; Cohen, M. A.; 
Batterham, R. L.; Taheri, S.; Stanley, S. A.; Ghatei, M. A.; Bloom, S. R., Ghrelin causes 
hyperphagia and obesity in rats. Diabetes 2001, 50 (11), 2540-7. 
39. Jerlhag, E.; Egecioglu, E.; Dickson, S. L.; Andersson, M.; Svensson, L.; Engel, J. A., 
Ghrelin stimulates locomotor activity and accumbal dopamine-overflow via central cholinergic 
systems in mice: implications for its involvement in brain reward. Addict Biol 2006, 11 (1), 45-
54. 
40. Vengeliene, V., The role of ghrelin in drug and natural reward. Addict Biol 2013, 18 (6), 
897-900. 
41. Abizaid, A., Stress and obesity: The ghrelin connection. J Neuroendocrinol 2019, 
e12693. 
42. Lutter, M.; Sakata, I.; Osborne-Lawrence, S.; Rovinsky, S. A.; Anderson, J. G.; Jung, S.; 
Birnbaum, S.; Yanagisawa, M.; Elmquist, J. K.; Nestler, E. J.; Zigman, J. M., The orexigenic 
hormone ghrelin defends against depressive symptoms of chronic stress. Nat Neurosci 2008, 11 
(7), 752-3. 
34  
43. Yousufzai, M.; Harmatz, E. S.; Shah, M.; Malik, M. O.; Goosens, K. A., Ghrelin is a 
persistent biomarker for chronic stress exposure in adolescent rats and humans. Transl 
Psychiatry 2018, 8 (1), 74. 
44. Frago, L. M.; Baquedano, E.; Argente, J.; Chowen, J. A., Neuroprotective actions of 
ghrelin and growth hormone secretagogues. Front Mol Neurosci 2011, 4, 23. 
45. Carlini, V. P.; Monzon, M. E.; Varas, M. M.; Cragnolini, A. B.; Schioth, H. B.; 
Scimonelli, T. N.; de Barioglio, S. R., Ghrelin increases anxiety-like behavior and memory 
retention in rats. Biochem Biophys Res Commun 2002, 299 (5), 739-43. 
46. Carlini, V. P.; Varas, M. M.; Cragnolini, A. B.; Schioth, H. B.; Scimonelli, T. N.; de 
Barioglio, S. R., Differential role of the hippocampus, amygdala, and dorsal raphe nucleus in 
regulating feeding, memory, and anxiety-like behavioral responses to ghrelin. Biochem Biophys 
Res Commun 2004, 313 (3), 635-41. 
47. Moon, M.; Choi, J. G.; Nam, D. W.; Hong, H. S.; Choi, Y. J.; Oh, M. S.; Mook-Jung, I., 
Ghrelin ameliorates cognitive dysfunction and neurodegeneration in intrahippocampal amyloid-
beta1-42 oligomer-injected mice. J Alzheimers Dis 2011, 23 (1), 147-59. 
48. Schalla, M. A.; Stengel, A., The role of ghrelin in anorexia nervosa. Int J Mol Sci 2018, 
19 (7). 
49. Khatib, M. N.; Gaidhane, A.; Gaidhane, S.; Quazi, Z. S., Ghrelin as a Promising 
Therapeutic Option for Cancer Cachexia. Cell Physiol Biochem 2018, 48 (5), 2172-2188. 
50. Ledderose, C.; Kreth, S.; Beiras-Fernandez, A., Ghrelin, a novel peptide hormone in the 
regulation of energy balance and cardiovascular function. Recent Pat Endocr Metab Immune 
Drug Discov 2011, 5 (1), 1-6. 
35  
51. Hattori, N., Expression, regulation and biological actions of growth hormone (GH) and 
ghrelin in the immune system. Growth Horm IGF Res 2009, 19 (3), 187-97. 
52. MP Wajnrajch, I. T., JM Gertner, RL Leibel, Genomic Organization of the Human 
GHRELIN Gene. J Endorc Gent 2000, 1, 231-233. 
53. Zhou, A.; Webb, G.; Zhu, X.; Steiner, D. F., Proteolytic processing in the secretory 
pathway. J Biol Chem 1999, 274 (30), 20745-8. 
54. Zhu, X.; Cao, Y.; Voogd, K.; Steiner, D. F., On the processing of proghrelin to ghrelin. J 
Biol Chem 2006, 281 (50), 38867-70. 
55. Zhang, J. V.; Ren, P. G.; Avsian-Kretchmer, O.; Luo, C. W.; Rauch, R.; Klein, C.; 
Hsueh, A. J., Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food 
intake. Science 2005, 310 (5750), 996-9. 
56. Kojima, M.; Hosoda, H.; Matsuo, H.; Kangawa, K., Ghrelin: discovery of the natural 
endogenous ligand for the growth hormone secretagogue receptor. Trends Endocrinol Metab 
2001, 12 (3), 118-22. 
57. Hosoda, H.; Kojima, M.; Matsuo, H.; Kangawa, K., Ghrelin and des-acyl ghrelin: two 
major forms of rat ghrelin peptide in gastrointestinal tissue. Biochem Biophys Res Commun 
2000, 279 (3), 909-13. 
58. Raff, H., Total and active ghrelin in developing rats during hypoxia. Endocrine 2003, 21 
(2), 159-61. 
59. Stengel, A.; Keire, D.; Goebel, M.; Evilevitch, L.; Wiggins, B.; Tache, Y.; Reeve, J. R., 
Jr., The RAPID method for blood processing yields new insight in plasma concentrations and 
molecular forms of circulating gut peptides. Endocrinology 2009, 150 (11), 5113-8. 
36  
60. Patterson, M.; Murphy, K. G.; le Roux, C. W.; Ghatei, M. A.; Bloom, S. R., 
Characterization of ghrelin-like immunoreactivity in human plasma. J Clin Endocrinol Metab 
2005, 90 (4), 2205-11. 
61. De Vriese, C.; Gregoire, F.; Lema-Kisoka, R.; Waelbroeck, M.; Robberecht, P.; Delporte, 
C., Ghrelin degradation by serum and tissue homogenates: identification of the cleavage sites. 
Endocrinology 2004, 145 (11), 4997-5005. 
62. Satou, M.; Nishi, Y.; Yoh, J.; Hattori, Y.; Sugimoto, H., Identification and 
characterization of acyl-protein thioesterase 1/lysophospholipase I as a ghrelin 
deacylation/lysophospholipid hydrolyzing enzyme in fetal bovine serum and conditioned 
medium. Endocrinology 2010, 151 (10), 4765-75. 
63. Schopfer, L. M.; Lockridge, O.; Brimijoin, S., Pure human butyrylcholinesterase 
hydrolyzes octanoyl ghrelin to desacyl ghrelin. Gen Comp Endocrinol 2015, 224, 61-8. 
64. De Vriese, C.; Hacquebard, M.; Gregoire, F.; Carpentier, Y.; Delporte, C., Ghrelin 
interacts with human plasma lipoproteins. Endocrinology 2007, 148 (5), 2355-62. 
65. Cleverdon, E. R.; McGovern-Gooch, K. R.; Hougland, J. L., The octanoylated energy 
regulating hormone ghrelin: An expanded view of ghrelin's biological interactions and avenues 
for controlling ghrelin signaling. Mol Membr Biol 2016, 33 (6-8), 111-124. 
66. Yang, J.; Brown, M. S.; Liang, G.; Grishin, N. V.; Goldstein, J. L., Identification of the 
acyltransferase that octanoylates ghrelin, an appetite-stimulating peptide hormone. Cell 2008, 
132 (3), 387-96. 
67. Gutierrez, J. A.; Solenberg, P. J.; Perkins, D. R.; Willency, J. A.; Knierman, M. D.; Jin, 
Z.; Witcher, D. R.; Luo, S.; Onyia, J. E.; Hale, J. E., Ghrelin octanoylation mediated by an 
orphan lipid transferase. Proc Natl Acad Sci U S A 2008, 105 (17), 6320-5. 
37  
68. Hofmann, K., A superfamily of membrane-bound O-acyltransferases with implications 
for wnt signaling. Trends Biochem Sci 2000, 25 (3), 111-2. 
69. Chen, M. H.; Li, Y. J.; Kawakami, T.; Xu, S. M.; Chuang, P. T., Palmitoylation is 
required for the production of a soluble multimeric Hedgehog protein complex and long-range 
signaling in vertebrates. Genes Dev 2004, 18 (6), 641-59. 
70. Takada, R.; Satomi, Y.; Kurata, T.; Ueno, N.; Norioka, S.; Kondoh, H.; Takao, T.; 
Takada, S., Monounsaturated fatty acid modification of Wnt protein: its role in Wnt secretion. 
Dev Cell 2006, 11 (6), 791-801. 
71. Buglino, J. A.; Resh, M. D., Hhat is a palmitoylacyltransferase with specificity for N-
palmitoylation of Sonic Hedgehog. J Biol Chem 2008, 283 (32), 22076-88. 
72. Buglino, J. A.; Resh, M. D., Identification of conserved regions and residues within 
Hedgehog acyltransferase critical for palmitoylation of Sonic Hedgehog. PLoS One 2010, 5 (6), 
e11195. 
73. Rios-Esteves, J.; Haugen, B.; Resh, M. D., Identification of key residues and regions 
important for porcupine-mediated Wnt acylation. J Biol Chem 2014, 289 (24), 17009-19. 
74. Rios-Esteves, J.; Resh, M. D., Stearoyl CoA desaturase is required to produce active, 
lipid-modified Wnt proteins. Cell Rep 2013, 4 (6), 1072-81. 
75. Stengel, A.; Tache, Y., Ghrelin - a pleiotropic hormone secreted from endocrine x/a-like 
cells of the stomach. Front Neurosci 2012, 6, 24. 
76. Stengel, A.; Goebel, M.; Wang, L.; Tache, Y.; Sachs, G.; Lambrecht, N. W., Differential 
distribution of ghrelin-O-acyltransferase (GOAT) immunoreactive cells in the mouse and rat 
gastric oxyntic mucosa. Biochem Biophys Res Commun 2010, 392 (1), 67-71. 
38  
77. Sakata, I.; Yang, J.; Lee, C. E.; Osborne-Lawrence, S.; Rovinsky, S. A.; Elmquist, J. K.; 
Zigman, J. M., Colocalization of ghrelin O-acyltransferase and ghrelin in gastric mucosal cells. 
Am J Physiol Endocrinol Metab 2009, 297 (1), E134-41. 
78. Goebel-Stengel, M.; Hofmann, T.; Elbelt, U.; Teuffel, P.; Ahnis, A.; Kobelt, P.; 
Lambrecht, N. W.; Klapp, B. F.; Stengel, A., The ghrelin activating enzyme ghrelin-O-
acyltransferase (GOAT) is present in human plasma and expressed dependent on body mass 
index. Peptides 2013, 43, 13-9. 
79. Gahete, M. D.; Cordoba-Chacon, J.; Hergueta-Redondo, M.; Martinez-Fuentes, A. J.; 
Kineman, R. D.; Moreno-Bueno, G.; Luque, R. M.; Castano, J. P., A novel human ghrelin 
variant (In1-ghrelin) and ghrelin-O-acyltransferase are overexpressed in breast cancer: potential 
pathophysiological relevance. PLoS One 2011, 6 (8), e23302. 
80. Seim, I.; Jeffery, P. L.; de Amorim, L.; Walpole, C. M.; Fung, J.; Whiteside, E. J.; 
Lourie, R.; Herington, A. C.; Chopin, L. K., Ghrelin O-acyltransferase (GOAT) is expressed in 
prostate cancer tissues and cell lines and expression is differentially regulated in vitro by ghrelin. 
Reprod Biol Endocrinol 2013, 11, 70. 
81. Ibanez-Costa, A.; Gahete, M. D.; Rivero-Cortes, E.; Rincon-Fernandez, D.; Nelson, R.; 
Beltran, M.; de la Riva, A.; Japon, M. A.; Venegas-Moreno, E.; Galvez, M. A.; Garcia-Arnes, J. 
A.; Soto-Moreno, A.; Morgan, J.; Tsomaia, N.; Culler, M. D.; Dieguez, C.; Castano, J. P.; 
Luque, R. M., In1-ghrelin splicing variant is overexpressed in pituitary adenomas and increases 
their aggressive features. Sci Rep 2015, 5, 8714. 
82. Luque, R. M.; Sampedro-Nunez, M.; Gahete, M. D.; Ramos-Levi, A.; Ibanez-Costa, A.; 
Rivero-Cortes, E.; Serrano-Somavilla, A.; Adrados, M.; Culler, M. D.; Castano, J. P.; Marazuela, 
M., In1-ghrelin, a splice variant of ghrelin gene, is associated with the evolution and 
39  
aggressiveness of human neuroendocrine tumors: Evidence from clinical, cellular and molecular 
parameters. Oncotarget 2015, 6 (23), 19619-33. 
83. Hormaechea-Agulla, D.; Gomez-Gomez, E.; Ibanez-Costa, A.; Carrasco-Valiente, J.; 
Rivero-Cortes, E.; F, L. L.; Pedraza-Arevalo, S.; Valero-Rosa, J.; Sanchez-Sanchez, R.; Ortega-
Salas, R.; Moreno, M. M.; Gahete, M. D.; Lopez-Miranda, J.; Requena, M. J.; Castano, J. P.; 
Luque, R. M., Ghrelin O-acyltransferase (GOAT) enzyme is overexpressed in prostate cancer, 
and its levels are associated with patient's metabolic status: Potential value as a non-invasive 
biomarker. Cancer Lett 2016, 383 (1), 125-134. 
84. Lin, S. H.; Guidotti, G., Purification of membrane proteins. Methods Enzymol 2009, 463, 
619-29. 
85. Smith, S. M., Strategies for the purification of membrane proteins. Methods Mol Biol 
2017, 1485, 389-400. 
86. Taylor, M. S.; Ruch, T. R.; Hsiao, P. Y.; Hwang, Y.; Zhang, P.; Dai, L.; Huang, C. R.; 
Berndsen, C. E.; Kim, M. S.; Pandey, A.; Wolberger, C.; Marmorstein, R.; Machamer, C.; 
Boeke, J. D.; Cole, P. A., Architectural organization of the metabolic regulatory enzyme ghrelin 
O-acyltransferase. J Biol Chem 2013, 288 (45), 32211-28. 
87. Chang, T. Y.; Li, B. L.; Chang, C. C.; Urano, Y., Acyl-coenzyme A:cholesterol 
acyltransferases. Am J Physiol Endocrinol Metab 2009, 297 (1), E1-9. 
88. Pagac, M.; Vazquez, H. M.; Bochud, A.; Roubaty, C.; Knopfli, C.; Vionnet, C.; 
Conzelmann, A., Topology of the microsomal glycerol-3-phosphate acyltransferase Gpt2p/Gat1p 
of Saccharomyces cerevisiae. Mol Microbiol 2012, 86 (5), 1156-66. 
40  
89. Konitsiotis, A. D.; Jovanovic, B.; Ciepla, P.; Spitaler, M.; Lanyon-Hogg, T.; Tate, E. W.; 
Magee, A. I., Topological analysis of Hedgehog acyltransferase, a multipalmitoylated 
transmembrane protein. J Biol Chem 2015, 290 (6), 3293-307. 
90. Matevossian, A.; Resh, M. D., Membrane topology of hedgehog acyltransferase. J Biol 
Chem 2015, 290 (4), 2235-43. 
91. Caddeo, A.; Jamialahmadi, O.; Solinas, G.; Pujia, A.; Mancina, R. M.; Pingitore, P.; 
Romeo, S., MBOAT7 is anchored to endomembranes by six transmembrane domains. J Struct 
Biol 2019, 206 (3), 349-360. 
92. Neuhaus, F. C.; Heaton, M. P.; Debabov, D. V.; Zhang, Q., The dlt operon in the 
biosynthesis of D-alanyl-lipoteichoic acid in Lactobacillus casei. Microb Drug Resist 1996, 2 
(1), 77-84. 
93. Perego, M.; Glaser, P.; Minutello, A.; Strauch, M. A.; Leopold, K.; Fischer, W., 
Incorporation of D-alanine into lipoteichoic acid and wall teichoic acid in Bacillus subtilis. 
Identification of genes and regulation. J Biol Chem 1995, 270 (26), 15598-606. 
94. Peschel, A.; Otto, M.; Jack, R. W.; Kalbacher, H.; Jung, G.; Gotz, F., Inactivation of the 
dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other 
antimicrobial peptides. J Biol Chem 1999, 274 (13), 8405-10. 
95. Neuhaus, F. C.; Baddiley, J., A continuum of anionic charge: structures and functions of 
D-alanyl-teichoic acids in gram-positive bacteria. Microbiol Mol Biol Rev 2003, 67 (4), 686-723. 
96. Reichmann, N. T.; Cassona, C. P.; Grundling, A., Revised mechanism of D-alanine 
incorporation into cell wall polymers in Gram-positive bacteria. Microbiology 2013, 159 (Pt 9), 
1868-1877. 
41  
97. Pasquina, L.; Santa Maria, J. P., Jr.; McKay Wood, B.; Moussa, S. H.; Matano, L. M.; 
Santiago, M.; Martin, S. E.; Lee, W.; Meredith, T. C.; Walker, S., A synthetic lethal approach for 
compound and target identification in Staphylococcus aureus. Nat Chem Biol 2016, 12 (1), 40-5. 
98. Ma, D.; Wang, Z.; Merrikh, C. N.; Lang, K. S.; Lu, P.; Li, X.; Merrikh, H.; Rao, Z.; Xu, 
W., Crystal structure of a membrane-bound O-acyltransferase. Nature 2018, 562 (7726), 286-
290. 
99. Yang, J.; Zhao, T. J.; Goldstein, J. L.; Brown, M. S., Inhibition of ghrelin O-
acyltransferase (GOAT) by octanoylated pentapeptides. Proc Natl Acad Sci U S A 2008, 105 
(31), 10750-5. 
100. Gualillo, O.; Lago, F.; Dieguez, C., Introducing GOAT: a target for obesity and anti-
diabetic drugs? Trends Pharmacol Sci 2008, 29 (8), 398-401. 
101. Kojima, M.; Ida, T.; Sato, T., Structure of mammalian and nonmammalian ghrelins. 
Vitam Horm 2008, 77, 31-46. 
102. Cleverdon, E. R.; Davis, T. R.; Hougland, J. L., Functional group and stereochemical 
requirements for substrate binding by ghrelin O-acyltransferase revealed by unnatural amino acid 
incorporation. Bioorg Chem 2018, 79, 98-106. 
103. Ohgusu, H.; Shirouzu, K.; Nakamura, Y.; Nakashima, Y.; Ida, T.; Sato, T.; Kojima, M., 
Ghrelin O-acyltransferase (GOAT) has a preference for n-hexanoyl-CoA over n-octanoyl-CoA 
as an acyl donor. Biochem Biophys Res Commun 2009, 386 (1), 153-8. 
104. Darling, J. E.; Prybolsky, E. P.; Sieburg, M.; Hougland, J. L., A fluorescent peptide 
substrate facilitates investigation of ghrelin recognition and acylation by ghrelin O-
acyltransferase. Anal Biochem 2013, 437 (1), 68-76. 
42  
105. Darling, J. E.; Zhao, F.; Loftus, R. J.; Patton, L. M.; Gibbs, R. A.; Hougland, J. L., 
Structure-activity analysis of human ghrelin O-acyltransferase reveals chemical determinants of 
ghrelin selectivity and acyl group recognition. Biochemistry 2015, 54 (4), 1100-10. 
106. Taylor, M. S.; Dempsey, D. R.; Hwang, Y.; Chen, Z.; Chu, N.; Boeke, J. D.; Cole, P. A., 
Mechanistic analysis of ghrelin-O-acyltransferase using substrate analogs. Bioorg Chem 2015, 
62, 64-73. 
107. Buglino, J. A.; Resh, M. D., Palmitoylation of Hedgehog proteins. Vitam Horm 2012, 88, 
229-52. 
108. Chang, S. C.; Magee, A. I., Acyltransferases for secreted signalling proteins (Review). 
Mol Membr Biol 2009, 26 (1), 104-13. 
109. Zhao, F.; Darling, J. E.; Gibbs, R. A.; Hougland, J. L., A new class of ghrelin O-
acyltransferase inhibitors incorporating triazole-linked lipid mimetic groups. Bioorg Med Chem 
Lett 2015, 25 (14), 2800-3. 
110. Barnett, B. P.; Hwang, Y.; Taylor, M. S.; Kirchner, H.; Pfluger, P. T.; Bernard, V.; Lin, 
Y. Y.; Bowers, E. M.; Mukherjee, C.; Song, W. J.; Longo, P. A.; Leahy, D. J.; Hussain, M. A.; 
Tschop, M. H.; Boeke, J. D.; Cole, P. A., Glucose and weight control in mice with a designed 
ghrelin O-acyltransferase inhibitor. Science 2010, 330 (6011), 1689-92. 
111. Garner, A. L.; Janda, K. D., A small molecule antagonist of ghrelin O-acyltransferase 
(GOAT). Chem Commun (Camb) 2011, 47 (26), 7512-4. 
112. McGovern-Gooch, K. R.; Mahajani, N. S.; Garagozzo, A.; Schramm, A. J.; Hannah, L. 
G.; Sieburg, M. A.; Chisholm, J. D.; Hougland, J. L., Synthetic triterpenoid inhibition of human 
ghrelin O-acyltransferase: The involvement of a functionally required cysteine provides 
mechanistic insight into ghrelin Aacylation. Biochemistry 2017, 56 (7), 919-931. 
43  
113. Couch, R. D.; Browning, R. G.; Honda, T.; Gribble, G. W.; Wright, D. L.; Sporn, M. B.; 
Anderson, A. C., Studies on the reactivity of CDDO, a promising new chemopreventive and 
chemotherapeutic agent: implications for a molecular mechanism of action. Bioorg Med Chem 
Lett 2005, 15 (9), 2215-9. 
114. Saha, P. K.; Reddy, V. T.; Konopleva, M.; Andreeff, M.; Chan, L., The triterpenoid 2-
cyano-3,12-dioxooleana-1,9-dien-28-oic-acid methyl ester has potent anti-diabetic effects in diet-
induced diabetic mice and Lepr(db/db) mice. J Biol Chem 2010, 285 (52), 40581-92. 
115. Nakajima, K.; Oiso, S.; Uto, T.; Morinaga, O.; Shoyama, Y.; Kariyazono, H., Triterpenes 
suppress octanoylated ghrelin production in ghrelin-expressing human gastric carcinoma cells. 
Biomed Res 2016, 37 (6), 343-349. 
116. Yoneyama-Hirozane, M.; Deguchi, K.; Hirakawa, T.; Ishii, T.; Odani, T.; Matsui, J.; 
Nakano, Y.; Imahashi, K.; Takakura, N.; Chisaki, I.; Takekawa, S.; Sakamoto, J., Identification 
and characterization of a new series of ghrelin O-acyl transferase inhibitors. SLAS Discov 2018, 
23 (2), 154-163. 
117. Garner, A. L.; Janda, K. D., cat-ELCCA: a robust method to monitor the fatty acid 




Chapter 2: Biochemical analysis of predicted contacts within 
the hGOAT structural model by alanine mutagenesis  
 
Portions of this chapter, including figures and experimental results have been 
previously published and reprinted with permission from the publisher, reference 
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Loftus, R.; Ashkar, M.; Escoffery, N.; Navarro, M.; Sieburg, M. A.; Nangia, S.; 
Hougland, J. L., The ghrelin O-acyltransferase structure reveals a catalytic channel 
for transmembrane hormone acylation. J Biol Chem 2019, Vol: 294, 14166-14174. 
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All computational modeling including co-evolutionary contact analysis of hGOAT 
structures, folding simulations, and molecular dynamic analysis were performed by 
Flaviyan Jerome Irudayanathan (Shikha Nangia Laboratory, Biomedical and 
Chemical Engineering at Syracuse University).  There was also a contribution from 
Professor Jason D. Fridley (Professor of Biology, Syracuse University) with 
statistical analysis of hGOAT alanine variant reactivity.  
 
In this chapter, I performed all the biochemical validation and experimentation 
including peptide labeling, construction, expression and analysis of hGOAT 







 The understanding of the structural organization at a molecular level of integral 
membrane proteins (IMPs) has been one of the major targets in the field of structural biology.1 
Exemplified by enzymes, receptors, transporters, among others; these proteins have a large range 
of key functions in cellular physiology and are important targets for pharmaceutical 
development.2-3 A comprehensive understanding of protein structure and function is imperative 
for drug design and the implementation of new modes of cell regulation for the treatment of 
various diseases. However, membrane proteins have been proven to be difficult to study owing 
to their hydrophobic nature, lack of solubility, and dependence on lipids for structural stability.4-5 
Ghrelin O-acyltransferase (GOAT) is an example of an integral membrane protein that is 
involved in the activation of the ghrelin hormone and it is a member of the membrane bound O-
acyltransferase (MBOAT) enzyme family.6-7 While GOAT is a current therapeutic target for the 
treatment of obesity and diabetes,8-9 little was known prior to this work about its structure or the 
acylation process of ghrelin due to the challenging protein solubilization from the membrane 
bilayer.  
 Substantial methods improvements have been developed to overcome membrane protein 
purification difficulties such as engineering fusion partners,10 developing new detergents,11-12 
innovative crystallization techniques,13 improvements in cryo-electron microscopes detectors,14 
among other advancements.15 In this work, we are reporting an innovative structural approach to 
develop a structural model of the unpurified integral membrane protein hGOAT by combining 
co-evolutionary contact constraints and computational modeling with biochemical validation.16 
Previous computational studies of the structure and dynamics of claudins, integral membrane 
proteins which participate in tight junctions forming the blood-brain barrier, identified distinctive 
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dimer interfaces that correlate with cross-linking experiments.17 In this analysis, the authors 
implemented a synergistic approach utilizing in silico multiscale dynamics and in vitro cross-
linking experiments to study claudin-5 interactions.17 Using similar studies and metagenomics 
information available of human GOAT (hGOAT) and related proteins,18 we generated a set of 
co-evolutionary contacts to guide our hGOAT structural modeling to generate a three-
dimensional structural model for hGOAT. Building solely upon the protein’s primary sequence 
and a biochemical assay for its function, the approach provides an accessible and efficient route 
to build structural models of intractable membrane protein targets. 
 Our human hGOAT structure determined is highly consistent with a recently reported 
crystal structure for the bacterial MBOAT homolog D-alanyl transferase DltB,19 supporting the 
novelty of our strategy to aid with the challenge of structure investigation of transmembrane 
proteins. Furthermore, our model was biochemically validated via alanine mutagenesis of amino 
acids predicted to reduce/eliminate enzyme function due to removal of energetically beneficial 
contacts and sites with no impact in GOAT-catalyzed acylation. These computationally targeted 
mutations were tested using our hGOAT activity assay,20-21 resulting in high percentage of the 
mutations matching the predictions of the hGOAT structural computational model.16 
 Surprisingly, a structural investigation of our model predicts a contiguous internal void 
channel within the hGOAT enzyme. Ghrelin octanoylation is proposed to occur in this channel 
where the binding sites for ghrelin (endoplasmic reticulum (ER) exposed pore) and octanoyl-
CoA (cytoplasm exposed) can interact. These studies place the basis for structure-based inhibitor 
design targeting GOAT and other MBOAT family members, while opening a window of 
application for the investigation of other structurally unpurified membrane proteins in hand with 
therapeutic prospective.   
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2.2 Results  
2.2.1 Computational model for human GOAT structure 
 In generating our hGOAT structural model, we utilized state-of-the-art co-evolutionary 
contact predictions with computational protein folding and structure optimization methods 
previously described.18, 22 Co-evolutionary contact analysis exploits the tendency of residues 
interacting with each other within folded proteins to co-evolve to maintain energetically 
beneficial interactions.23-25 Analysis of many protein sequences employing a multiple-sequence 
alignment identifies pairs of co-evolving residues, from which it is inferred that these residues lie 
in proximity to each other. Assigning pairs of residues as co-evolving supports assignment of 
spatial interactions between them, providing constraints that can define major features of protein 
structure. Using metagenomics protein databases, we generated a multiple-sequence alignment to 
predict residues that are potentially in contact (defined as Cβ-Cβ < 8Å) with each other in the 
folded structure of hGOAT.18, 22-26 This set of contacts, represented by the contact map (Figure 
2.1a-b), guided our hGOAT structural modeling.23, 26-27 
 Experimental information on the membrane topology of mouse GOAT and co-
evolutionary contact constraints were iteratively combined in protein folding simulations to 
generate ~30,000 potential hGOAT structures.23, 28-29 The generated structures were clustered, 
and the lowest energy structures that satisfied the contact maps were isolated (Figure 2.2).29 
Representative structures from the top five clusters were then subjected to further structural 
refinement to yield the optimal hGOAT model.30 The optimal model was embedded in a lipid 
membrane and subjected to structural relaxation in explicit solvent using all-atom molecular 
dynamics simulations.17, 31-32 This simulation used an ER-mimetic lipid bilayer to ensure 




















Figure 2.1 Co-evolutionary contact restraints used in hGOAT structural modeling. a) 
Contact map for hGOAT showing the probability for a coevolutionary contact from GREMLIN 
analysis. b) Heat map of co-evolutionary contact constraints mapped onto hGOAT structure (red: 
highest number of co-evolutionary constraints per residue, white: no co-evolutionary 
constraints). Figure is reproduced with permission from Reference 16 (Appendix II). Copyright 

















Figure 2.2. Overlay of top 10 lowest energy structures of hGOAT from folding simulations. 
Figure is reproduced with permission from Reference 16 (Appendix III). Copyright © 2019 The 





2.2.2 Features of the human GOAT structure 
 Our computationally-derived structure for hGOAT is consistent with the previously 
reported topological model of the mouse GOAT ortholog containing a total of eleven 
transmembrane helices with slightly altered helix boundaries (Figure 2.3),28 indicating the two 
sets of constraints from our co-evolutionary contact analysis and previous topological studies 
support a common hGOAT structural model. To determine how strongly our hGOAT structure 
depends on the experimental topological constraints from mouse GOAT,28 we excluded these 
constraints and repeated our analysis, which generated an identical hGOAT membrane topology. 
This indicates co-evolutionary contact constraints alone are sufficient to predict the membrane 
topology of hGOAT, suggesting this approach for topology modeling of integral membrane 
proteins to complement established algorithms for predicting membrane protein topology.  
 Our model forms an ellipsoidal cone composed of transmembrane helices, with the 
narrow end facing the ER lumen (Figure 2.4). The exposed ends of five transmembrane helices 
(TM1, TM4, TM5, TM7, and TM11) converge to form a pore through which the interior of 
hGOAT is connected to the ER lumen. At the cytoplasmic membrane interface, the predicted 
cytoplasmic loops fold up to form a core region bounded by the lipid contacting perimeter 
helices. As a result, there is minimal cytoplasmic exposure of hGOAT residues beyond the plane 
of the membrane. Moreover, the hGOAT structure contains a contiguous internal channel 
through the enzyme core that transits from the ER lumen space to the cytoplasm (Figure 2.5).  
The channel is bent within hGOAT, with the restriction formed by the C-terminal end of helix 
TM8 and N-terminal end of TM9. This positions an absolutely conserved histidine residue 
(H338) in direct contact with the internal channel,34 consistent with proposals for this histidine to 
serve as a general base for catalyzing ghrelin acylation. 35 
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 Following completion of our hGOAT structure and during subsequent biochemical 
validation experiments (described in section 2.2.3), the release of a crystal structure for the 
bacterial MBOAT DltB alanyl transferase provided an independent basis for comparison and 
validation of our hGOAT structure.19 The H338 residue in hGOAT closely matches the location 
of the analogous histidine residue (H336) in the DltB structure (Figure 2.6).7, 19 Further 
comparison of the hGOAT model and the DltB structure reveals remarkable similarities in 
overall topology and structure, with an TM-Score of 0.6 and RMSD of 2.23 Å for ~100 aligned 
conserved residues between the structural models for these distantly related MBOAT family 
members (12.3% sequence identity, 26.8% sequence similarity, EValue 2.7x10−8 and bit score 
48.7; (Table 2.1).36 However, the low overall homology between DltB and hGOAT leads to very 
poor structure prediction for non-homologous sequence positions as would be expected for this 
type of comparison. The demonstrated ability of our hGOAT modeling based on co-evolutionary 
contact restraints to arrive at the same protein fold as DltB, in the absence of any experimental 








Figure 2.3. Computational approach yields structural model of hGOAT. Schematic of 
ghrelin octanoylation by hGOAT showing the predicted transmembrane topology of hGOAT 
containing eleven transmembrane helix domains (TM1-11), two intramembrane domains 
































Figure 2.4. Three-dimension computational organization of a membrane bound O-
acyltransferase protein. Structure of hGOAT in an ER mimetic lipid membrane, correlated to 
color-coded membrane topology in Figure 2.3. Figure is reproduced with permission from 
Reference 16 (Appendix IV). Copyright © 2019 The American Society for Biochemistry and 







Figure 2.5. GOAT model reveals an intermembrane channel within its core. Illustration of 
internal channel within hGOAT (green) transiting from the ER lumen to the cytoplasm, with the 
channel determined by CAVER 3.0 plugin in PyMOL.38 Figure is reproduced with permission 
from Reference 16 (Appendix V). Copyright © 2019 The American Society for Biochemistry 






Figure 2.6. Structural overlay of hGOAT and DltB showing absolutely conserved histidine 
residues (hGOAT H338, teal; DltB H336, purple, PDB ID 6BUG:C) within these 
acyltransferases. Figure is reproduced with permission from Reference 16 (Appendix VI). 





Table 2.1. Statistics and parameters for sequence coevolution analysis of hGOAT. 
 
Human ghrelin O-acyltransferase 
Query sequence Homo sapiens MBOAT (UniProt Q96T53) 
Alignment window 1-435 (15-420) 
Alignment Jackhmmer, HHblits, hhmsearch 
metaclust_2018_01, Uniref100. 
Filtering 90% identity 75 % coverage and filtered columns with >50% 
gaps 













Sequences / L >45; Sequence diversity (√N/L): 0.296 
 
Coevolution algorithm Raptor-X (machine Learning) and Gremlin (Markov Random 
Field pseudo-likelihood maximization) 
Significance cut-off Of the 3L/2 direct Co-evolutionary contacts predicted by 
GREMLIN 93% of the contacts were observed at or below 10Å 
in the final structure; 86% of the contacts were observed at or 
below 8Å 
Comparison with DltB Distant homolog within the same family 




2.2.3 Mutagenesis analysis of hGOAT structural model 
 To validate our computational hGOAT structural model biochemically, we mutated 
approximately 10% of the residues within hGOAT to alanine. We determined the impact of these 
mutations on hGOAT octanoylation activity in a fluorescence peptide-based assay, via reverse-
phase HPLC with fluorescence detection (described in experimental procedures section).20, 39 
These 42 alanine mutations were spread across a range of amino acids and degrees of 
conservation, with the majority of sites chosen conserved at >75% among GOAT orthologs. In 
narrowing the pool of mutations to ~40 positions, residues with surface-exposed side chains were 
deemphasized compared to residues predicted to lie within the enzyme interior. Approximately 
half of the mutation sites were selected based on the residue’s side chain contacting the internal 
void, as we propose this channel will likely contain the substrate binding sites and catalytic 
residues within hGOAT.  
 In this pool of alanine mutants, we observed a range of activities from near wild type 
ghrelin octanoylation activity to complete loss of detectable activity (Figure 2.7, 2.8, and Table 
2.2). When mapped onto the hGOAT structural model, mutations leading to a marked decline 
(>3-fold, purple) or loss of enzyme activity (red) appear clustered within the core of hGOAT 
(Figure 2.7). For quantitative analysis of the impact of these mutations, we determined whether 
alanine mutagenesis of residues contacting the internal void is more likely to yield reduced 
enzyme activity compared to non-void contacting mutations. Within the pool of mutations, the 
void-contacting alanine mutations were significantly more likely to result in loss of enzyme 
activity (p<0.03, Figure 2.9). This mutation activity mapping defines a functionally essential core 
within hGOAT and expands the number of residues within hGOAT known to be required for 




















Figure 2.7. Mutagenesis studies support the location and functional importance of the 
hGOAT internal channel. A-C) Alanine mutations mapped onto the hGOAT structure, with 
each sphere denoting the alpha carbon of the mutated residue; spheres colored as follows: Blue, 
alanine variants with octanoylation activity within 3-fold of WT hGOAT; purple, alanine 
variants with impaired octanoylation activity (>3-fold loss compared to WT hGOAT); red, 
inactive alanine variants. A) View from lumenal face; B) view from cytoplasmic face; C) side 
view in the plane of the ER membrane. Figure is reproduced with permission from Reference 16 





Figure 2.8. hGOAT alanine variant octanoylation activity mapped onto the hGOAT 
topology model. Blue squares, alanine variants with octanoylation activity within 3-fold of WT 
hGOAT; purple diamonds, alanine variants with impaired octanoylation activity (>3-fold loss 
compared to WT hGOAT); red squares, inactive alanine variants. Figure is reproduced with 
permission from Reference 16 (Appendix VIII). Copyright © 2019 The American Society for 
Biochemistry and Molecular Biology, Inc. 
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Table 2.2. hGOAT alanine variant octanoylation activity with the GSSFLCAcDan peptide 
substrate under standard reaction conditions. Reactions were performed, analyzed, and 
normalized as described in the Experimental Methods. Errors reflect the average of a minimum 




(100 - 33% of WT Activity) 
 Impaired Variants 
(33 - 1% of WT Activity) 
 Inactive Variants 
(Undetectable Activity) 
Variant % Activity  Variant % Activity  Variant % Activity 
S179A 60 ± 8  L96A 27 ± 4  H98A 0 
Q191A 92 ± 30  L135A 8.3 ± 0.9  S132A 0 
H258A 56 ± 8  C181A 20 ± 1  Y168A 0 
D262A 61 ± 12  S182A 2.4 ± 0.7  L180A 0 
E281A 74 ± 3  F183A 2.4 ± 0.1  D234A 0 
D289A 58 ± 3  Y255A 21 ± 1  C235A 0 
E294A 43 ± 3  D287A 6 ± 2  D263A 0 
H297A 56 ± 4  S300A 4 ± 1  E282A 0 
Q320A 94 ± 2  F302A 27.4 ± 0.9  Y284A 0 
H341A 44 ± 7  F331A 18.2 ± 0.6  R304A 0 
F348A 67 ± 5  W351A 4.7 ± 0.9  W306A 0 
F364A 94 ± 13  H362A 29 ± 7  N307A 0 
R370A 62 ± 10     R315A 0 
L381A 128 ± 5     H338A 0 






Figure 2.9. Octanoylation activity of hGOAT alanine variants for non-void contacting (black, 
N=21) and void-contacting mutations (green, N=21), with dotted lines denoting the average 
acylation activity for each group; *, p < 0.03. Figure is reproduced with permission from 
Reference 16 (Appendix IX). Copyright © 2019 The American Society for Biochemistry and 




2.3 Discussion and conclusions 
 While structural studies play a central role in understanding protein functions for 
improved inhibitor development, a complete description of the structure and mechanism of 
GOAT is still unknown. A map of the topology of GOAT has described the GOAT's active site 
face near the ER lumen where ghrelin resides like other MBOATs that acylate secreted proteins.7 
Moreover, the description of how acyl-CoA, localized predominantly in the cytoplasm, gain 
access to the ER lumen is still undetermined. The conserved essential residues N307 and 
H338 have been described as “catalytic residues” but with no mechanistic data firmly proving 
this point. The recent crystal structure of the bacterial MBOAT DltB positions the conserved 
histidine (H336) residue in this enzyme within an active site funnel, consistent with this residue 
acting as a potential general base.19 In this work, we demonstrated the development and 
validation of a structural model for the integral membrane human GOAT that utilizes 
bioinformatics constraints from co-evolutionary contact analysis, and model evaluation by 
biochemical analysis while circumventing the requirement of protein purification.  
 To biochemically confirm the computational hGOAT model developed here, we chose 
multiple amino acid sites where alanine incorporation was anticipated to reduce or abolish 
enzyme activity due to elimination of energetically beneficial contacts. We were able to 
accurately match predicted deleterious or inactive residues mutations to experimental data of 
targeted mutations. The remarkable accuracy of predictions obtained from our computational 
model provides strong support for the ability of our approach to generate a representative 
hGOAT structural model. Additionally, our model revealed a striking feature of a contiguous 
internal void space that is located topologically to feasibly serve as the binding region for ghrelin 
and octanoyl-CoA substrates, where most of our mutants reside (Figure 2.7). The analysis of 42 
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residues whose side chains line within this channel space demonstrated to be functionally 
essential residues, supporting this region as a potential substrate-binding site region (Figure 2.8, 
Figure 2.9, Table 2.2).  
 Our model provides indispensable and novel insights into several long-standing questions 
regarding the mechanism for MBOAT-catalyzed transmembrane protein acylation. In this 
structure, the essential conserved H338 residue lies ~20 Å below the ER lumen interface. 
Surprisingly the other essential conserved MBOAT residue (N307) was shown to reside at the 
other end of this void towards the proposed octanoyl-CoA binding site (discussed in Chapter 3). 
The topological separation of these two conserved residues is explained by the two residues 
playing roles distinct roles of GOAT activity. Moreover, the location of H338 is within the 
central channel of GOAT, identical to the position observed for the analogous histidine in DltB.19 
This result is consistent with this residue acting as a general base to activate the ghrelin serine 
hydroxyl side chain for octanoyl transfer (Figure 2.6). Comparison to the DltB crystal structure 
supports the accuracy of both, the overall enzyme architecture and location of specific amino 
acids in our hGOAT model that potentially interact with ghrelin and octanoyl-CoA. The role of 
other alanine mutants in the catalytic mechanism of ghrelin acylation and or ghrelin binding will 
be investigated in later chapters.  
 With the combination of computational and biochemical methods, we were able to 
develop a structural model for hGOAT that accurately reflects the molecular interactions 
essential for substrate interaction. This understanding is crucial for mechanistic studies and 
inhibitor development, targeting multiple members of the MBOAT enzyme superfamily. 
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2.4 Experimental Procedures 
2.4.1 Co-evolutionary contact analysis of hGOAT 
Note: All computational sequence and contact prediction analysis was performed by 
collaborator Flaviyan Jerome Irudayanathan (BMCE, Syracuse University). 
 A multiple sequence alignment (MSA) was performed with the hGOAT sequence against 
the UniRef90 database utilizing the jackhammer tool.40 The MSA parameters were set to eight 
iterative searches (n=8) with an e-value threshold of 1x10-40. The resulting alignment was filtered 
to exclude highly similar sequences using the HHfilter tool with 90% identity and 75% sequence 
coverage cut-offs. This MSA was used as the input for the hmmbuild tool to construct a hidden 
Markov model (hmm) curated specifically for the MSA,41 which would represent the consensus 
sequence of hGOAT and its closest homologs. This hmm was then utilized to search against a 
master database that included uniref100 and metagenome database (metaclust_2018_01) using 
the hmmsearch tool with a bit score cut-off of 27.18, 27 The resulting MSA was filtered again 
using the HHfilter tool with 90% identity and 75% sequence coverage against hGOAT. 
Furthermore, sequences with unidentified amino acids (X, this is to accommodate for RaptorX) 
and sequence positions with >50% gaps were also filtered from the MSA using trimAL.42 The 
resulting MSA for hGOAT was primarily used to perform co-evolutionary contact analysis using 
the RaptorX server and GREMLIN.18, 23, 26, 43 The resulting contact maps are provided as Figure 
2.1a (GREMLIN). The resulting MSA had a Meff0.8/√𝑁 of 551.7 which is greater than the 
recommended value of 64 for reliable model prediction using co-evolutionary contacts.18, 23 
These contacts were used to guide the hGOAT folding. The MSA analysis and curations were 
performed using in-house python scripts and conkit python library.44 
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2.4.2 Folding simulations  
Note: Folding simulations were performed by collaborator Flaviyan Jerome Irudayanathan 
(BMCE, Syracuse University). 
 The folding simulations were performed in two stages as shown in Figure 2.10. In both 
stages, contact restraints were used and the models were iteratively clustered, refined and scored 






















Figure 2.10. Flow chart for computational modeling of hGOAT. Figure is reproduced with 
permission from Reference 16 (Appendix X). Copyright © 2019 The American Society for 
Biochemistry and Molecular Biology, Inc.  
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2.4.3 Refinement and relaxation using molecular dynamics  
Note: All molecular dynamic analysis was performed by collaborator Flaviyan Jerome 
Irudayanathan (BMCE, Syracuse University). 
 The optimized hGOAT model from stage 2 was oriented with respect to a membrane 
bilayer using the PPM server.32 The calculated hydrophobic thickness of the hGOAT structural 
model is 25.2 ± 2.4 Å and the tilt angle of 3° relative to the membrane normal vector. The 
oriented protein was then embedded in a ER-mimetic lipid bilayer (1:1 
dipalmitoylphosphatidylcholine (DPPC) : dioleoyl phosphatidylcholine (DOPC)) using the 
CHARMM-GUI webserver and subject to an allatom equilibration at 310.15 K in explicit solvent 
and 150 mM NaCl counter ions.31, 45 The simulation was carried out for 500 ns using 
GROMACS 2016.4 and the structural deviations were monitored.46 The equilibrated structure 
was isolated and utilized for prediction of internal channels and docking studies.  
 
2.4.4 General experimental methods  
 Data plotting and curve fitting were carried out with Kaleidagraph (Synergy Software, 
Reading, PA, USA). Membrane topology schematics were generated using Protter 
(http://wlab.ethz.ch/protter/start/),37 and structural figures were generated using Chemdraw 
Prime 15.1 and PyMol. Octanoyl coenzyme A (octanoyl-CoA, free acid) were solubilized to 5 
mM in 10 mM TrisHCl (pH 7.0), aliquoted into low-adhesion microcentrifuge tubes, and stored 
at −80 °C. Methoxy arachidonyl fluorophosphonate (MAFP) was purchased from Cayman 
Chemical (Ann Arbor, MI) and solubilized with dimethyl sulfoxide (DMSO). Unlabeled 
GSSFLCNH2 peptide was synthesized by Sigma-Genosys (The Woodlands, TX), solubilized in 
1:1 acetonitrile:H2O, and stored at -80 °C. Acrylodan (Anaspec) for peptide substrate labeling 
67  
was solubilized in acetonitrile with the stock concentration determined by absorbance at 393 nm 
in methanol (ε393 = 18,483 M–1 cm–1 , per the manufacturer’s data sheet). GSSFLCNH2 peptide 
concentrations were determined by reaction of the cysteine thiol with 5,5’-dithiobis(2- 
nitrobenzoic acid) and absorbance at 412 nm, using ε412 = 14,150 M–1 cm–1.47 
 
2.4.5 Peptide substrate fluorescent labeling 
 The GSSFLCNH2 peptide substrate used in the hGOAT acylation assay is derived from the 
N-terminal sequence of ghrelin (GSSFLS) with the C-terminal serine of this peptide (Ser 6) 
mutated to cysteine to allow chemoselective attachment of an acrylodan fluorophore using our 
previously reported protocols.39, 48 Acrylodan-labeled peptides were purified by semipreparative 
reverse phase HPLC (Zorbax Eclipse XDB column, 9.4 x 250 mm) using a gradient mobile 
phase of 30%-100% acetonitrile in aqueous 0.05 % trifluoroacetic acid (TFA) over 30.2 minutes, 
at a flow rate of 4.2 mL/min. Labeled peptide elution was detected by absorbance at 360 nm, and 
collected fractions containing the labeled peptides were dried under vacuum at room temperature 
and resuspended in 1:1 H2O: acetonitrile. GSSFLCNH2 labeling was confirmed by MALDI-TOF 
mass spectrometry (Bruker Autoflex III) using a matrix containing sinapinic acid in 0.1 % TFA 
and 50 mM ammonium phosphate. The concentration of acrylodan labeled GSSFLCNH2 was 
calculated using absorbance of acrylodan at 360 nm (ε= 13,300 M-1cm-1) per previous reports.39, 
49 
 
2.4.6 Construction of hGOAT mutants 
 PCR primers for site-directed mutagenesis were designed from our previously reported 
hGOAT expression construct (Table 2.3).39 This construct was commercially synthesized by 
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Integrated DNA Technologies (Coralville, IA) containing a C-terminal FLAG epitope tag, a 
polyhistidine (His6) tag, and 3x human influenza hemagglutinin (HA) tags appended downstream 
of a TEV protease site.50 Primers were dissolved in H2O and concentrations were measured by 
UV absorbance at 260 nm. PCR mutagenesis reactions (50 μL total volume) contained the 
following components: 10x Pfu reaction buffer (5 μL), template plasmid DNA (10 ng), forward 
primer (125 ng), reverse primer (125 ng), dNTPs (1 μL, 1 mM stock), and Pfu Turbo DNA 
polymerase (1 μL, Agilent). The thermocycler program for PCR mutagenesis proceeded as 
follows: initial denaturation (95 °C, 1 min); 18 cycles of denaturation (95 °C, 50 sec); annealing 
(60 °C, 50 sec); extension (68 °C, 12 min); and final extension (68 °C, 12 min). Reaction were 
digested with DpnI (New England BioLabs, R0176S, 10 units) at 37 °C for 2 hours. After DpnI 
digestion, the PCR reaction mixture (5 μL) was transformed into a 100 L aliquot of chemically 
competent Z-competent DH5 cells (Zymo Research) followed by incubation on ice for 30 
minutes. Transformed bacteria were spread on LB-ampicillin plates (100 μg/mL) and incubated 
at 37 C overnight. Following overnight incubation at 37 °C, single colonies were inoculated into 
LB media (5 mL) containing ampicillin (100 μg/mL) in sterile culture tubes. These cultures were 
incubated overnight at 37 C with shaking (225 rpm). Following overnight growth, plasmids 
were purified from the saturated cultures using EZ-10 Spin Column Plasmid DNA kit (Bio Basic 




Table 2.3 Primers for hGOAT alanine mutagenesis 
 
Mutation Primers 
L96A Forward: CAAACAGCTTGTCACCTGGGACTCCAC 
Reverse: GTGGAGTCCCAGGTGACAAGCTGTTTG 
H98A Forward: GCTGGCAAACACTGTGTGCTCTGGGACTCCACTAC 
Reverse: GTAGTGGAGTCCCAGAGCACACAGTGTTTGCCAGC 
S132A Forward: CTCAGCGCGTGACAGCTTTGTCTCTGGACATC 
Reverse: GATGTCCAGAGACAAAGCTGTCACGCGCTGAG 
L135A Forward: GTGACATCCTTGTCTGCTGACATCTGTGAGGGC   
Reverse: GCCCTCACAGATGTCAGCAGACAAGGATGTCAC   
Y168A Forward: CTGCCCTACTTCTCCGCTCTGCTCTTCTTCCC    
Reverse: GGGAAGAAGAGCAGAGCGGAGAAGTAGGGCAG    
S179A Forward: GCCTTGCTGGGAGGTGCTCTCTGTTCATTCCAG   
Reverse: CTGGAATGAACAGAGAGCACCTCCCAGCAAGGC    
L180A Forward: GCTGGGAGGTAGCGCTTGTTCATTCCAGCG 
Reverse: CGCTGGAATGAACAAGCGCTACCTCCCAGC 
C181A Forward: CTGGGAGGTAGCCTCGCTTCATTCCAGC       
Reverse: GCTGGAATGAAGCGAGGCTACCTCCCAG 
S182A Forward: GAGGTAGCCTCTGTGCTTTCCAGCGTTTCCAAG 
Reverse: CTTGGAAACGCTGGAAAGCACAGAGGCTACCTC 
F183A Forward: GGTAGCCTCTGTTCAGCTCAGCGTTTCCAAGC   
Reverse: GCTTGGAAACGCTGAGCTGAACAGAGGCTACC 
Q191A Forward: CAAGCTAGAGTCGCTGGATCGTCCGCTC 
Reverse: GAGCGGACGATCCAGCGACTCTAGCTTG 
D234A Forward: GCCGGACTGACTGCTTGCCAGCAATTCGAATG   
Reverse: CATTCGAATTGCTGGCAAGCAGTCAGTCCGGC   
C235A Forward: GGAGCCGGACTGACTGATGCCCAGCAATTCGAATG   
Reverse: CATTCGAATTGCTGGGCATCAGTCAGTCCGGCTCC   
E239A Forward: GATTGCCAGCAATTCGCTTGTATCTACGTTG   
Reverse: CAACGTAGATACAAGCGAATTGCTGGCAATC   
Y255A Forward: GGTTGTTCAAGCTGACCGCTTACTCACACTGGATC   
Reverse: GATCCAGTGTGAGTAAGCGGTCAGCTTGAACAACC   
H258A Forward: GCTGACCTACTACTCAGCCTGGATCCTCGACG   
Reverse: CGTCGAGGATCCAGGCTGAGTAGTAGGTCAGC   
D262A Forward: CACACTGGATCCTCGCCGATTCGCTCTTGC 
Reverse: GCAAGAGCGAATCGGCGAGGATCCAGTGTG   
D263A Forward: CTGGATCCTCGACGCTTCGCTCTTGCACG 
Reverse: CGTGCAAGAGCGAAGCGTCGAGGATCCAG   
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E281A Forward: GACAGTCACCAGGAGCGGAAGGTTACGTTCC   
Reverse: GGAACGTAACCTTCCGCTCCTGGTGACTGTC   
E282A Forward: GTCACCAGGAGAGGCAGGTTACGTTCCTG 
Reverse: CAGGAACGTAACCTGCCTCTCCTGGTGAC   
Y284A Forward: CCAGGAGAGGAAGGTGCTGTTCCTGACGCTGATATC   
Reverse: GATATCAGCGTCAGGAACAGCACCTTCCTCTCCTGG   
D287A Forward: GGTTACGTTCCTGCCGCTGATATCTGGACC   
Reverse: GGTCCAGATATCAGCGGCAGGAACGTAACC   
D289A Forward: CGTTCCTGACGCTGCTATCTGGACCCTGG   
Reverse: CCAGGGTCCAGATAGCAGCGTCAGGAACG   
E294A Forward: GATATCTGGACCCTGGCAAGGACTCACAGAATC 
Reverse: GATTCTGTGAGTCCTTGCCAGGGTCCAGATATC 
H297A Forward: CCCTGGAAAGGACTGCCAGAATCTCGGTCTTC 
Reverse: GAAGACCGAGATTCTGGCAGTCCTTTCCAGGG 
S300A Forward: GGACTCACAGAATCGCTGTCTTCTCCCGTAAG 
Reverse: CTTACGGGAGAAGACAGCGATTCTGTGAGTCC 
F302A Forward: CACAGAATCTCGGTCGCTTCCCGTAAGTGGAAC 
Reverse: GTTCCACTTACGGGAAGCGACCGAGATTCTGTG 
R304A Forward: GAATCTCGGTCTTCTCCGCTAAGTGGAACCAAAGC 
Reverse: GCTTTGGTTCCACTTAGCGGAGAAGACCGAGATTC 
W306A Forward: GTCTTCTCCCGTAAGGCTAACCAAAGCACTGCTC 
Reverse: GAGCAGTGCTTTGGTTAGCCTTACGGGAGAAGAC 
N307A Forward: CTCCCGTAAGTGGGCCCAAAGCACTGCTCGC 
Reverse: GCGAGCAGTGCTTTGGGCCCACTTACGGGAG 
R315A Forward: CTGCTCGCTGGCTCGCTCGCTTGGTGTTCC 
Reverse: GGAACACCAAGCGAGCGAGCCAGCGAGCAG 
Q320A Forward: CGCTTGGTGTTCGCTCACAGCCGTGCTTG 
Reverse: CAAGCACGGCTGTGAGCGAACACCAAGCG 
F331A Forward: CCACTGCTCCAAACAGCTGCTTTCTCAGCTTGG 
Reverse: CCAAGCTGAGAAAGCAGCTGTTTGGAGCAGTGG 
H338A Forward: CAGCTTGGTGGGCCGGACTGCACCCTGG 
Reverse: CCAGGGTGCAGTCCGGCCCACCAAGCTG 
H341A Forward: GCACGGACTGGCCCCTGGACAGGTTTTCGG 
Reverse: CCGAAAACCTGTCCAGGGGCCAGTCCGTGC 
F348A Forward: GACAGGTTTTCGGTGCTGTGTGCTGGGCTGTTATG 
Reverse: CATAACAGCCCAGCACACAGCACCGAAAACCTGTC 
W351A Forward: CGGTTTCGTGTGCGCTGCTGTTATGGTGGAG 
Reverse: CTCCACCATAACAGCAGCGCACACGAAACCG 
D358A Forward: GTTATGGTGGAGGCCGCCTACCTGATCCAC 
Reverse: GTGGATCAGGTAGGCGGCCTCCACCATAAC 
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H362A Forward: GCCGACTACCTGATCGCCTCCTTCGCTAACGAG 
Reverse: CTCGTTAGCGAAGGAGGCGATCAGGTAGTCGGC 
R370A Forward: GCTAACGAGTTCATCGCTTCTTGGCCAATGAGG 
Reverse: CCTCATTGGCCAAGAAGCGATGAACTCGTTAGC 
L381A Forward: CTTCTACAGAACAGCTACCTGGGCCCAC 
Reverse: GTGGGCCCAGGTAGCTGTTCTGTAGAAG 
L395A Forward: GCTTACATCATGGCTGCCGTCGAGGTTAG 
Reverse: CTAACCTCGACGGCAGCCATGATGTAAGC 





2.4.7 Expression and enrichment of hGOAT in membrane protein fractions 
 hGOAT wildtype and mutants were expressed in insect (Sf9) cell membrane fractions 
using previously published procedures.39, 51-52 
 
2.4.8 Membrane fraction enrichment 
 Sf9 insect cell expression cultures were transferred to 50 mL conical tubes and harvested 
by centrifugation (500 xg, 5 min, 4°C); the resulting supernatant was discarded. The cell pellet 
was resuspended in 2.5 mL lysis buffer (50 mM Tris-HCl pH 7.0, 150 mM sodium chloride 
(NaCl), 1 mM sodium ethylenediamine (NaEDTA), 1 mM dithiothreitol (DTT), 0.01 μg/mL 
pepstatin A, 10 μM bis (4-nitrophenyl)phosphate, and 1 mini Roche protease inhibitor cocktail 
tablet/10 mL). The cells were then lysed with a 7 mL dounce homogenizer on ice, using 20 
strokes with a small pestle and 20 strokes with a large pestle.  Intact cells and cell debris were 
removed by centrifugation (3000 x g, 10 min, 4°C). The supernatant was transferred to a pre-
tared ultracentrifuge tube and the membrane fraction was isolated by centrifugation (100,000 x g, 
1 hour, 4°C).  The resulting supernatant was discarded, and the pellet was solubilized in 50 mM 
HEPES (pH 7.0) to reach 4 μL/mg of microsomal pellet. Membrane fraction suspensions are 
distributed into 80 μL aliquots in low-adhesion tubes and stored at -80°C. 39 
 
2.4.9. hGOAT expression analysis by anti-FLAG Western Blot 
 hGOAT membrane fractions were thawed on ice and homogenized by passing through an 
18-gauge needle ten times. Membrane fraction protein concentrations were determined by 
Bradford assay using the Quick Start Bradford 1X Dye Reagent (BioRad). Samples for 
polyacrylamide gel analysis and Western blotting were prepared containing 50 μg membrane 
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fraction protein from Sf9 cells transfected with hGOAT, 1x sample buffer (0.33 M Tris HCl, pH 
6.8, 0.1 M SDS, 14% glycerol, and 0.5 M DTT) and 50 mM HEPES pH 7.0 in a total volume of 
45 μL.  Protein samples were heated to 50.2 °C for 5 minutes and then incubated at room 
temperature for 15 min prior to gel loading.  Samples were loaded onto a 12 % Tris-glycine 
SDS-polyacrylamide gel and run at 110 V for 1.5 hrs. Each gel contained an empty vector (EV) 
microsomal protein as negative control and amino-terminal FLAG-BAP Fusion protein as a 
positive control (Millipore Sigma, P7582-100UG, 1:150 dilution, 30 μL total volume) (See 
Figure 2.11). 
Following electrophoretic separation, proteins were transferred to a PVDF membrane for 
Western blotting (BioRad, Trans-Blot turbo RTA transfer kit), with the PVDF membrane 
activated by immersion in methanol for 30 seconds followed by equilibration in transfer buffer 
(20% v/v methanol, 48 mM Tris base, 39 mM glycine and 0.034% v/v SDS) prior to transfer. 
Proteins were transferred to the membrane for 30 minutes at 1.3 A / 25 V using the transfer kit 
per manufacturer’s instructions.  Following electroblotting, the PVDF membrane was blocked 
for 4 hours in 10% v/v nonfat milk in TBST buffer (Tris buffered saline (TBS, 0.05M Tris and 
0.14M NaCl) with 0.1% v/v Tween 20). The membrane was then probed with a Flag antibody 
(HRP-conjugated DYKDDDDK Tag Antibody, Invitrogen catalog number PA1-984B-HRP, 
1:1000 dilution, 10 mL total volume) in 5% nonfat milk in TBST buffer overnight at 4 °C.  The 
membrane was washed with TBST (6 x 5 mL) and treated with West Pico Chemiluminescent 
substrate-imaging reagent (Thermo Scientific), followed by imaging on a ChemiDoc XRS+ gel 
documentation system (BioRad). 
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Variant Blot  Variant Blot  Variant Blot  Variant Blot 
L96A b  C235A b  H297A e  F348A f 
H98A a  Y255A c  S300A e  W351A g 
S132A c  H258A d  F302A e  D358A d 
L135A c  D262A d  R304A e  H362A g 
Y168A a  D263A b  W306A c  F364A g 
S179A a  E281A d  N307A e  R370A e 
L180A a  E282A d  R315A c  L381A g 
S182A b  Y284A a  Q320A f  L423A g 
F183A c  D287A d  F331A f  C181A a 
Q191A b  D289A d  H338A f    
D234A b  E294A a  H341A f    
 
Figure 2.11. hGOAT variant expression confirmation by anti-Flag Western blotting. 
Western blots were performed as described in Materials and Method. WT, wild type hGOAT; 
EV, empty vector baculoviral expression; Flag, Flag-BAP fusion protein. Figure is reproduced 
with permission from Reference 16 (Appendix XI). Copyright © 2019 The American Society for 
Biochemistry and Molecular Biology, Inc. 
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2.4.10. hGOAT activity assay  
Membrane fractions of hGOAT expressed from Sf9 cells were thawed on ice and 
homogenized by passing through an 18-gauge needle ten times. hGOAT activity assays under 
standard conditions were performed with 50 μg of membrane protein, 1.5 μM fluorescent peptide 
substrate, 300 μM octanoyl-CoA, 1 μM MAFP, and 50 μM HEPES pH 7.0  in a total volume of 
50 μL. All components except for the peptide and acyl-CoA substrates were incubated at room 
temperature for 30 minutes prior to reaction initiation by addition of peptide and acyl-CoA 
substrates. Reactions were incubated at room temperature for 2 hour in the dark and then stopped 
by addition of 50 μL of 20% acetic acid in isopropanol. Reaction solutions were clarified by 
protein precipitation with 16.7 μL of 20% trichloroacetic acid followed by centrifugation (1,000 
x g, 2 min). The resulting supernatant was then analyzed by reverse phase HPLC. hGOAT assay 
samples were analyzed on an Agilent 1260 HPLC with a C18 reverse phase HPLC column 
(Zorbax Eclipse XDB, 4.6 x 150 mm) using a gradient of 30% acetonitrile in 0.05 % aqueous 
TFA to 100 % acetonitrile over 30.2 minutes. Fluorescent peptide substrate and acylated 
products were detected by UV absorbance at 360 nm and fluorescence (ex 360 nm, em 485 nm), 
with the peptide substrate eluting with a retention time of 5-6 minutes and the octanoylated 
peptide eluting with a retention time of 11-12 minutes. Chromatogram analysis and peak 
integration was performed using Chemstation for LC (Agilent Technologies).39 Product 
conversion was calculated by dividing the integrated fluorescence for the product peak by the 
total integrated peptide fluorescence (substrate and product) in each run. Percent activity for each 
hGOAT mutant was calculated by normalizing the product conversion for the mutant to that of 
wild type hGOAT in a reaction run in parallel on the same day using the same reagents. 
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2.4.11. Statistical analysis of hGOAT alanine variant reactivity.  
Note: This statistical analysis was performed by Professor Jason D. Fridley (Associate 
Professor of Biology, Syracuse University). 
Each alanine mutation site was assigned as “void contacting” or “non-void contacting” by 
inspection of the hGOAT structural model. The two populations were compared using a 
Wilcoxon signed-rank test (n=42, test statistic W=294.5) and yielded a p-value = 0.02978 against 
the null hypothesis of both populations of alanine mutations being equally likely to yield reduced 
hGOAT activity. The statistical test was executed using the script below executed in R.53 
str(dat) 
median(dat$Y) 
    #overall median is 13.25 
sum(dat$group) 
    #21 values in interest group 
median(dat$Y[dat$group==1]) 
    #interest group median is 4.41 
median(dat$Y[dat$group==0]) 
    #median of other group is 33.72 
actual.diff = median(dat$Y[dat$group==0]) - median(dat$Y[dat$group==1]) 
    #difference of group medians is 29.3 
     
#are the group medians significantly different? 
#procedure: randomly shuffle group membership vector, calculate median difference as 
test statistic 
  
Nperm = 10000 #number of random permutations 
test.stat = rep(0,Nperm) #holding vector 
for(i in 1:Nperm) { 
    rgroup = sample(dat$group) 
    test.stat[i] = median(dat$Y[rgroup==0]) - median(dat$Y[rgroup==1]) 
} 
hist(test.stat); abline(v=actual.diff,lwd=3,col="red") 
length(test.stat[test.stat>actual.diff])/Nperm #P value of null hypothesis of no difference 
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    #P ~ 0.04 (one-tailed) 
  
#compare to t.test of mean difference assuming unequal variances, one-tailed 
t.test(dat$Y[dat$group==0],dat$Y[dat$group==1],alternative="greater") 
    #P=0.013 
#compare to wilcoxon rank sum test (nonparameteric) 
wilcox.test(dat$Y[dat$group==0],dat$Y[dat$group==1],alternative="greater") 
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Chapter 3: Investigation of the acyl donor-binding site 
within hGOAT  
 
 
Portions of this chapter, including figures and experimental results have been 
previously published and reprinted with permission from the publisher, reference 
14, Campana, M. B.; Irudayanathan, F. J.; Davis, T. R.; McGovern-Gooch, K. R.; 
Loftus, R.; Ashkar, M.; Escoffery, N.; Navarro, M.; Sieburg, M. A.; Nangia, S.; 
Hougland, J. L., The ghrelin O-acyltransferase structure reveals a catalytic channel 
for transmembrane hormone acylation. J Biol Chem 2019, Vol: 294, 14166-14174. 
Copyright © 2019 The American Society for Biochemistry and Molecular Biology, 
Inc. 
 
All computational modeling including molecular docking and relaxation of 
octanoyl-CoA: hGOAT complex were performed by Flaviyan Jerome 
Irudayanathan (Shikha Nangia Laboratory, Biomedical and Chemical Engineering 






 The 28-amino acid peptide hormone ghrelin is involved in multiple signaling pathways 
by binding the growth hormone secretagogue receptor (GHS-R1a).1-4 Following expression of 
the 117-amino acid ghrelin precursor preproghrelin, this peptide undergoes several processing 
steps for maturation prior to secretion. One key and unique step essential to activate ghrelin’s 
receptor is the modification of the third serine amino acid (Ser3) in the peptide sequence by the 
addition of an n-octanoic acid catalyzed by GOAT (ghrelin O-acyltransferase).1, 5-6 In humans 
and rodents, the predominant form of the acyl chain that is coupled to ghrelin is a saturated eight-
carbon chain (C8:0).1, 7-8 Other forms of acyl-CoA (acyl coenzyme A) substrates has been 
determined to be accepted by GOAT including n-decanoyl (C10:0), a saturated 10-carbon chain) 
or n-decanoyl (C10:1, a 10-carbon chain with one alkene bond).9-10 Unexpectedly, one early 
study suggested GOAT prefers n-hexanoyl-CoA (C6:0) for acylation of ghrelin over n-octanoyl-
CoA.11 However, the concentration of n-hexanoyl-CoA in ghrelin secreting cells in the stomach 
is thought to be very low compared with that of n-octanoyl, explaining the primarily production 
of the n-octanoyl form of ghrelin.11 Longer acyl donors like myristoyl-CoA (C14:0) or 
palmitoyl-CoA (C16:0) are much less efficiently accepted by GOAT compared to other MBOAT 
(membrane bound O-acyltransferase) members that utilize these longer chain substrates, which 
marks GOAT unique amongst this enzyme superfamily.8, 11-12 The preference of GOAT for 
medium-length fatty acid chains is distinctive, which opens a latent backbone to the design of 
more potent GOAT inhibitors. Previous inhibition studies have described the use of acylated 
ghrelin mimetics with different acyl chain lengths to inhibit the acylation of GOAT by using a 
(1-5) penta-ghrelin peptide with a [Dap3] ((S)-2,3-diaminopropionic acid); replacing the ester 
linkage of the acyl group for an octanoyl-amide stable linkage.8, 21 Inhibitors ranging from 2 to 
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10 carbon chain lengths were able to block GOAT acylation activity with the 8-carbon chain 
exhibiting the highest potency, demonstrating that the acyl chain binds a distinct pocket in the 
hGOAT active site that most tightly binds an 8-carbon acyl chain. 
 Despite the importance of hGOAT in ghrelin signaling, little is understood about the 
identity of catalytically essential amino acids. Topological studies of hGOAT have established 
locations of transmembrane-spanning domains and loops of GOAT.13-14 Topology of Hhat, 
another MBOAT family protein that acylate proteins, have shown remarkable similarities to 
GOAT’s structure.15-16 In both topologies, the invariable His residue was luminal, and the 
conserved Asn/Asp was cytosolic, further augmenting the consensus that all MBOATs have this 
construction for their proposed active sites.15, 17-18 Moreover, it has been predicted the active site 
of GOAT to reside in the ER (endoplasmic reticulum) where ghrelin is trafficked through the 
secretory pathway.19-20 As acyl-CoA synthesis occurs in the cytoplasm, the transmembrane 
topology of GOAT and potential ER-localized active site raises the question of how is the acyl-
CoA donor transported to the ER lumen for acyl transfer? It has been suggested that GOAT and 
other MBOAT enzymes could participate in the transportation of the acyl donor inside the ER to 
the lumenal side or there is an intermediate protein or lipid capable to transfer the acyl-CoA, 
collaborating with GOAT.5, 13 However, such intermediate hosts or mechanisms have not been 
identified.  
 In this chapter, we have investigated the mechanistic construction of GOAT, aiming to 
define the location and nature of the acyl donor-binding site. As described in chapter 2, we have 
developed the first structural model of membrane bound GOAT by combination co-evolutionary 
constraints and computational modeling alongside with mutagenesis validation. 14, 22-23 
Employing these modeling and docking studies, we developed a GOAT structure with the 
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octanoyl-CoA acyl donor showed significant interactions of the 8-carbon chain and coenzyme A 
with multiple GOAT residues within a solvent-exposed binding site.14 Moreover, we have 
utilized a range of acyl-CoA co-substrates in combination with enzyme mutagenesis to 
chemically investigate and validate interactions with amino acids that are predicted to form the 
acyl-binding pocket within GOAT. The development of this first structural model of a MBOAT 
family protein acyltransferase has provided insights into catalysis by GOAT and can potentially 
decipher the architecture of other MBOAT transmembrane acyltransferase, aiding the 
development of new therapeutic methodologies.  
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3.2 Results  
3.2.1. Octanoyl-CoA: hGOAT-modeling complex 
Note: All computational modeling and docking analysis were performed by collaborator 
Flaviyan Jerome Irudayanathan (BMCE, Syracuse University). 
 To study potential interactions between GOAT and acyl-CoA to accommodate this 
molecule within its structure, we have developed a molecular docking complex for octanoyl-
CoA: hGOAT arrangement by using YASARA software with our model described in chapter 
2.14, 24-25 We expected the octanoyl-CoA acyl donor to enter the hGOAT active site through 
interaction with the cytoplasmic face of the enzyme based on the predicted availability of acyl-
CoAs within the cell. When docked into our hGOAT model, octanoyl-CoA was found to bind in 
an exposed site on the cytosolic exposed face of GOAT, with portions of the acyl-CoA solvent 
exposed (Figure 3.1b).14 The acyl-CoA: GOAT complex shows interactions of both its coenzyme 
A and octanoyl chain regions with residues in the transmembrane domains TM6, the TM7-TM8 













Figure 3.1 Computational model complex of hGOAT and Octanoyl-CoA. a) Pymol structure 
of octanoyl-CoA bound within hGOAT from a side view in the plane of the ER membrane. b) 
View from the cytoplasmic face of hGOAT showing the solvent-exposed portions of the 





3.3.2. Octanoyl-CoA interactions within the GOAT pocket 
 
 In the docked complex, the phosphoadenosine group binds into a discrete pocket while 
the phosphopantetheine chain is in contact with multiple amino acid side chains (Figure 3.2a-b). 
The coenzyme A portion forms both polar and nonpolar interactions with several hGOAT 
residues while remaining exposed to the cytoplasm as shown in Figure 3.1. To biochemically 
investigate the impact of these amino acids interacting with the acyl-CoA donor, we performed 
alanine mutagenesis with investigation of hGOAT octanoylation activity in our peptide-based 
assay (Table 3.1).26 Mutations R304A, W306A, N307A, R315A, and D358A (in red) all 
abolished acylation activity of GOAT, consistent with these residues forming functionally 
essential interactions with octanoyl-CoA. Mutations F331A and W351A (in purple) led to 
reductions of GOAT activity, and the mutation shown in blue (H297A) had minimal impact on in 
GOAT acylation activity. Moreover, in the docked complex the acyl chain of octanoyl-CoA 
makes a sharp turn upward from the coenzyme A binding regions on the cytoplasmic face of 
hGOAT following a channel that terminates at W351 and F331 amino acids in GOAT (Figure 
3.2). This channel is spatially distinct from the pocket where the phosphoadenosine group binds, 











(100 - 33% of WT 
Activity) 
(33 - 1% of WT 
Activity) 
(Undetectable Activity) 
Variant % Activity   Variant % Activity   Variant % Activity 
H297A 56 ± 4   F331A 18.2 ± 0.6   R304A 0 
      W351A 4.7 ± 0.9   N307A 0 
            R315A 0 
            W306A 0 









































































Figure 3.2 Interactions between the octanoyl-CoA acyl donor and hGOAT residues. a) Polar 
and nonpolar interactions of octanoyl-CoA with hGOAT. b) Pymol depiction of hGOAT 
residues shown in purple that reduced acylation activity under standard reaction conditions when 
mutated to alanine, residues shown in red abolished acylation activity upon alanine mutation, and 
black residues were not tested. Figure is reproduced with permission from Reference 14 
(Appendix XII). Copyright © 2019 The American Society for Biochemistry and Molecular 
Biology, Inc.  
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3.2.3. Single acyl donor investigation with alanine mutants  
 
 Given the unique preference of hGOAT for an octanoyl acyl donor,6, 8 we examined 
alanine mutagenesis of predicted contacts within this acyl-binding pocket to determine the 
impact of those mutations on hGOAT acyl donor selectivity. As alanine mutagenesis would 
provide additional space within the acyl-binding site, we determined the ability of hGOAT 
alanine variants to accept twelve carbon (lauryl-CoA) and fourteen carbon (myristoyl-CoA) acyl 
donors in place of octanoyl CoA. As described in the Experimental Methods section, we 
incubated hGOAT mutants with ghrelin substrate peptides and a range of acyl donors to 
determine acyl donor preferences. The wild type enzyme and the majority of hGOAT alanine 
variants exhibited the expected preference for an eight-carbon acyl donor, but alanine 
mutagenesis of W351 and F331 resulted in loss of appreciable reactivity with octanoyl-CoA but 
engendered new activity with the longer acyl donors (Figure 3.3 and Figure 3.4). The F331A 
variant gained activity with the C12 donor while W351A mutant could acylate a ghrelin-derived 
peptide with both C12 and C14 acyl chains. This altered selectivity supports the modeled 




Figure 3.3. Acylation activity of WT hGOAT and selected hGOAT alanine variants using 
octanoyl-, lauryl-, or myristoyl-CoA as the sole acyl donor. Activities are normalized to the 
most reactive hGOAT variant with each acyl donor, and error bars reflect the standard deviation 
from a minimum of three independent trials. Reference 14 (Appendix XIII). Copyright © 2019 











































































































































Figure 3.4. Acyl donor reactivity with WT hGOAT and hGOAT alanine variants with C8-
CoA (black), C12-CoA (purple), and C14-CoA (green) acyl donors. Single acyl donor 
reactions were performed, analyzed, and normalized as described in Experimental Methods. a) 
Reactivity with C8-CoA; b) Reactivity with C12-CoA; c) Reactivity with C14- CoA. Three 
independent experimental trials are indicated by individual data points, with a dotted horizontal 
line denoting the average of the three independent trials. Activities are normalized to the most 
reactive hGOAT variant with each acyl donor. Reference 14 (Appendix XIV). Copyright © 2019 
The American Society for Biochemistry and Molecular Biology, Inc.  
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3.2.4 Competition experiments to define GOAT acyl donor selectivity  
 The altered preference for longer acyl donors exhibited by the F331A and W351A 
variants was also observed in a direct competition assay where hGOAT variants were provided 
acyl donors ranging from six to twelve carbons (Figure 3.5). This altered selectivity was not 
observed for any other alanine variants with detectable ghrelin acylation activity (Figure 3.6). 
Acyl donor reengineering upon targeted alanine mutagenesis further supports localizing F331 
and W351 to the distal end of the acyl donor-binding site within hGOAT and provides further 
biochemical validation of our hGOAT structural model.  
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Figure 3.5. Acyl donor competition experiment. Acyl donor competition demonstrates altered 
selectivity to a longer acyl donor for F331A and W351A hGOAT variants compared to the wild 
type enzyme, consistent with the predicted interaction of these amino acid side chains with the 
distal end of the octanoyl acyl chain. Reference 14 (Appendix XV). Copyright © 2019 The 








































Figure 3.6 Acyl competition reactions with WT hGOAT and hGOAT alanine variants with 
C6-CoA, C8-CoA, C10-CoA, and C12-CoA. Reactions were performed, analyzed, and 
normalized as described in the Experimental Methods section. a) WT; b) H98A; c) L135A; d) 
Y168A; e) S179A; f) L180A; g) S182A; h) F183A; i) Y255A, j) Y284A; k) S300A; l) F302A; 
m) W306A; n) R315A; o) F331A; p) F348A; q) W351A; r) R370A. Reference 14 (Appendix 
XVI). Copyright © 2019 The American Society for Biochemistry and Molecular Biology, Inc.  
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3.3 Discussion and conclusion  
 GOAT selection of an octanoyl-CoA as its acyl substrate is unusual compared to other 
related acylation enzymes that preferably accept longer acyl groups such as 14- or 16-carbons.18, 
27 Previous work has shown hGOAT discrimination against acyl chains both longer and shorter 
than eight carbons,8 representative of a distinct acyl binding pocket within hGOAT. We have 
introduced alanine mutations that stretched the computational predicted acyl group-binding site 
of our model. We have determined acyl-binding preferences using a range of acyl donors with 
different acyl chain lengths and reengineer hGOAT acyl pocket by mutating W351 and F331 to 
alanine. Studies of F331A and W351A hGOAT mutants revealed a significant alteration in acyl 
donor, preferring the longer (decanoyl-CoA (C-10) and dodecanoyl-CoA (C-12)) substrates for 
ghrelin acylation. This result confirmed the interaction to the last carbon in the carbon chain to 
these amino acids, acting as a “cap” at the end of the phosphopantetheine chain pocket.  
 Significant polar and non-polar interactions of the fatty acid CoA with GOAT were 
identified by our computational modeling method. Mutations in the predicted binding site for the 
acyl donor (R304A, W306A, D358A, N307A, and R315A) were shown to completely eliminate 
GOAT activity, describing functional residues that are potentially interacting with the acyl-CoA 
substrate. Likewise, this hGOAT: octanoyl-CoA model implicates that the highly MBOAT 
conserved amino acid N307 is in the binding site for the acyl donor, answering the long-lasting 
question of the spatial position of this conserved amino acid. Moreover, the location of the 
binding site for octanoyl-CoA supports the hypothesis of the acyl donor binding to GOAT from 
the cytosolic face of the enzyme; where the acyl-CoA substrate extends through transmembrane 
domains TM6, 7 and 9 to reach the center of the hGOAT.  
103  
 Based on hGOAT: octanoyl-CoA complex model described in chapter 2 and 3, we 
propose that hGOAT catalyzes transmembrane acylation of ghrelin by binding both substrates 
within the hGOAT internal channel and “handing off” the octanoyl group from CoA to ghrelin 
within the revealed channel (Figure 3.7). Ghrelin (GSSFL-ghrelin) and octanoyl-CoA enter the 
GOAT internal channel from the ER lumenal pore and cytoplasmic acyl donor binding sites 
respectively, followed by acyl transfer to the ghrelin serine side chain hydroxyl. Octanoylated 
ghrelin dissociates to the ER lumen resulting in the octanoyl chain transiting through the GOAT 
interior, and coenzyme A is released back to the cytoplasm. While many aspects of this proposed 
pathway such as the ghrelin binding site and location of catalytic residues remain to be 
functionally validated by ongoing studies, the established ability of our hGOAT model to 
efficiently guide biochemical studies demonstrates a novel approach to advance investigations of 























Figure 3.7. Proposed pathway for transmembrane ghrelin octanoylation by GOAT. The red 
and blue cylinders represent perimeter helices, the green cylinder represents intramembrane 
domains forming the cytoplasmic surface of hGOAT, and dotted lines represent binding 
interactions between the octanoyl-CoA acyl donor and its binding site within hGOAT.   
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3.4 Experimental Methods 
 
General methods 
Data plotting and curve fitting were carried out with Kaleidagraph (Synergy Software, 
Reading, PA, USA). Membrane topology schematics were generated using Protter 
(http://wlab.ethz.ch/protter/start/),28 and structural figures were generated using Chemdraw 
Prime 15.1 and PyMol. Hexanoyl coenzyme A (hexanoyl-CoA, free acid) (Crystal Chem Inc.), 
octanoyl coenzyme A (octanoyl-CoA) (AdventBio), decanoyl coenzyme A (decanoyl-CoA, free 
acid) (Crystal Chem Inc.), lauroyl coenzyme A (lauroyl-CoA, dodecanoyl-CoA, free acid) 
(Crystal Chem Inc.), and myristoyl coenzyme A (myristoyl-CoA, tetradecanoyl-CoA, free acid) 
(Crystal Chem Inc.) were solubilized to 5 mM in 10 mM Tris-HCl (pH 7.0), aliquoted into low-
adhesion microcentrifuge tubes, and stored at −80 °C. Methoxy arachidonyl fluorophosphonate 
(MAFP) was purchased from Cayman Chemical (Ann Arbor, MI) and solubilized with dimethyl 
sulfoxide (DMSO). Unlabeled GSSFLCNH2 ghrelin peptide was synthesized by Sigma-Genosys, 
solubilized in 1:1 acetonitrile:H2O, and stored at -80 °C. Acrylodan (Anaspec) for peptide 
substrate labeling, was solubilized in acetonitrile with the stock concentration determined by 
absorbance at 393 nm after dilution in methanol (ε393 = 18,483 M
–1cm–1, per the manufacturer’s 
data sheet). GSSFLCNH2 peptide concentrations were determined by reaction of the cysteine thiol 




3.4.1 Molecular docking and relaxation of octanoyl-CoA: hGOAT complex 
 
Note: All docking and relaxation analysis was performed by collaborator Flaviyan Jerome 
Irudayanathan (BMCE, Syracuse University). 
 To build a model of the octanoyl-CoA•hGOAT bound complex, we performed docking 
using Autodock Vina implemented in the YASARA software suite.24-25 One hundred docking 
runs were carried out with the search space defined as 8 Å cube around the residue lining the 
void space in the model. The top docking pose was further refined with a local search run. The 
final docked ligand-receptor complex was subject to a short energy minimization and molecular 
dynamics refinement for 1ns using the YASARA suite, with the backbone positions being fixed. 
 
3.4.2 Construction of hGOAT mutants 
 
 PCR primers were designed and then synthesized by Integrated DNA Technologies as 
demonstrated in Chapter 2, as previously reported hGOAT expression construct.30 Primers were 
dissolved in upH20 and concentrations were measured by UV absorbance at 260 nm. PCR 
mutagenesis reactions (50 μL total volume) contained the following components: 10x Pfu 
reaction buffer (5 μL), pFBD_MBOT4ix3Tag_RFP template (10 ng), forward primer (125 ng), 
reverse primer (125 ng), dNTPs (1 μL, 1 mM stock), and Pfu Turbo DNA polymerase (1 μL, 
Agilent). The thermocycler program for PCR mutagenesis proceeded as follows: initial 
denaturation (95 °C, 1 min); 18 cycles of denaturation (95 °C, 50 sec); annealing (60 °C, 50 sec); 
extension (68 °C, 12 min); and final extension (68 °C, 12 mins). Reaction were digested with 
DpnI (1 μL, 10 units) at 37 °C for 2 hours. After DpnI digestion, the PCR reaction mixture (5 
L) were then transformed into a 100 L aliquot of chemically competent Z-competent DH5 
107  
cells (Zymo Research) followed by incubation on ice for 30 minutes. Transformed bacteria were 
spread on LB-ampicillin plates (100 g/mL) and incubated at 37 C overnight. Following 
overnight incubation at 37 oC, single colonies were inoculated into LB media (5 mL) containing 
ampicillin (100 g/mL) in sterile culture tubes. These cultures were incubated overnight at 37 C 
with shaking (225 rpm). Following overnight growth, plasmids were purified from the saturated 
cultures using EZ-10 Spin Column Plasmid DNA kit (Bio Basic Inc.) per manufacturer’s 
instructions. Single site mutations were verified by DNA sequencing (Genescript). 
 
3.4.3 Expression and enrichment of hGOAT in membrane protein fractions 
 hGOAT wildtype and alanine mutants were expressed in insect (Sf9) cell membrane 
fractions using previously published procedures with a baculovirus expression system. 8, 30-31 
 
3.4.4. hGOAT expression analysis by anti-FLAG Western Blot 
 hGOAT membrane fractions were thawed on ice and homogenized by passing through an 
18-gauge needle ten times. Membrane fraction protein concentrations were determined by 
Bradford assay using the Quick Start Bradford 1X Dye Reagent (BioRad). Samples for 
polyacrylamide gel analysis and Western blotting were prepared containing 50 μg membrane 
fraction protein from Sf9 cells transfected with hGOAT, 1x sample buffer (0.33 M Tris HCl, pH 
6.8, 0.1 M SDS, 14% glycerol, and 0.5 M DTT) and 50 mM HEPES pH 7.0 in a total volume of 
45 μL.  Protein samples were heated to 50.2 °C for 5 minutes and then incubated at room 
temperature for 15 min prior to gel loading.  Samples were loaded onto a 12 % Tris-glycine 
SDS-polyacrylamide gel and run at 110 V for 1.5 hrs. Each gel contained an empty vector (EV) 
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microsomal protein as negative control and amino-terminal FLAG-BAP Fusion protein as a 
positive control (Millipore Sigma, P7582-100UG, 1:150 dilution, 30 μL total volume). 
Following electrophoretic separation, proteins were transferred to a PVDF membrane for 
Western blotting (BioRad, Trans-Blot turbo RTA transfer kit), with the PVDF membrane 
activated by immersion in methanol for 30 seconds followed by equilibration in transfer buffer 
(20% v/v methanol, 48 mM Tris base, 39 mM glycine and 0.034% v/v SDS) prior to transfer. 
Proteins were transferred to the membrane for 30 minutes at 1.3 A / 25 V using the transfer kit 
per manufacturer’s instructions.  Following electroblotting, the PVDF membrane was blocked 
for 4 hours in 10% v/v nonfat milk in TBST buffer (Tris buffered saline (TBS, 0.05M Tris and 
0.14M NaCl) with 0.1% v/v Tween 20). The membrane was then probed with a Flag antibody 
(HRP-conjugated DYKDDDDK Tag Antibody, Invitrogen catalog number PA1-984B-HRP, 
1:1000 dilution, 10 mL total volume) in 5% nonfat milk in TBST buffer overnight at 4 °C.  The 
membrane was washed with TBST (6 x 5 mL) and treated with West Pico Chemiluminescent 
substrate-imaging reagent (Thermo Scientific), followed by imaging on a ChemiDoc XRS+ gel 
documentation system (BioRad) (Western blots for alanine mutants in these chapter are 




3.4.5 hGOAT activity assay - standard reaction conditions 
Membrane fractions of hGOAT expressed from Sf9 cells were thawed on ice and 
homogenized by passing through an 18-gauge needle ten times. hGOAT activity assays under 
standard conditions were performed with 50 μg of membrane protein, 1.5 μM fluorescent peptide 
substrate, 300 μM octanoyl-CoA, 1 μM MAFP, and 50 μM HEPES pH 7.0  in a total volume of 
50 μL. All components except for the peptide and acyl-CoA substrates were incubated at room 
temperature for 30 minutes prior to reaction initiation by addition of peptide and acyl-CoA 
substrates. Reactions were incubated at room temperature for 2 hour in the dark and then stopped 
by addition of 50 μL of 20% acetic acid in isopropanol. Reaction solutions were clarified by 
protein precipitation with 16.7 μL of 20% trichloroacetic acid followed by centrifugation (1,000 
x g, 2 min). The resulting supernatant was then analyzed by reverse phase HPLC. hGOAT assay 
samples were analyzed on an Agilent 1260 HPLC with a C18 reverse phase HPLC column 
(Zorbax Eclipse XDB, 4.6 x 150 mm) using a gradient of 30% acetonitrile in 0.05 % aqueous 
TFA to 100 % acetonitrile over 30.2 minutes. Fluorescent peptide substrate and acylated 
products were detected by UV absorbance at 360 nm and fluorescence (ex 360 nm, em 485 nm), 
with the peptide substrate eluting with a retention time of 5-6 minutes and the octanoylated 
peptide eluting with a retention time of 11-12 minutes. Chromatogram analysis and peak 
integration was performed using Chemstation for LC (Agilent Technologies).30 Product 
conversion was calculated by dividing the integrated fluorescence for the product peak by the 
total integrated peptide fluorescence (substrate and product) in each run. Percent activity for each 
hGOAT mutant was calculated by normalizing the product conversion for the mutant to that of 
wild type hGOAT in a reaction run in parallel on the same day using the same reagents. 
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3.4.6. Single acyl donor reactivity assay  
To determine the reactivity of hGOAT variants with different length acyl donors, 
hGOAT activity was measured in the presence of 100 μM of a single acyl donor (octanoyl -CoA, 
lauryl (dodecanoyl) -CoA, or myristoyl (tetradecanoyl) - CoA). Characteristic retention times for 
each acylated form of the peptide substrate provided confirmation of the nature of the attached 
acyl chain, with dodecanoyl -GSSFLCAcDan eluting at ~17 minutes and tetradecanoyl - 
GSSFLCAcDan eluting at ~19 minutes. For each acyl donor, relative activity was calculated 
normalized to the highest activity observed across the panel of wildtype hGOAT and hGOAT 
variants (Figure 3.8). 
 
3.4.7 Acyl donor competition assay  
 
To determine the relative preference of each hGOAT variant for acyl donors ranging 
from six to twelve carbons, hGOAT activity was measured in the presence of 100 μM each of 
four potential acyl donors (hexanoyl -CoA, octanoyl -CoA, decanoyl -CoA, and lauryl 
(dodecanoyl) -CoA). Each potential product peak was assigned by retention time compared to a 
standard reaction containing only one acyl donor for each potential product. Competition 
experiments including myristoyl -CoA were unsuccessful, potentially due to low critical micelle 
concentration (CMC) for this acyl donor lying near 100 μM.  
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Figure 3.8 Acyl donor reactivity with WT hGOAT and hGOAT alanine variants with C8-
CoA (black), C12-CoA (purple), and C14-CoA (green) acyl donors. Single acyl donor 
reactions were performed, analyzed, and normalized as described in the Experimental Methods. 
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Chapter 4: Investigation of enzyme-substrate interactions 
using hGOAT variant reactivity alteration with modified 
peptide substrates  
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 Ghrelin acylation is catalyzed by ghrelin O‐acyltransferase (GOAT), which adds an 
octanoyl (eight-carbon) fatty acid group to the third serine in ghrelin’s sequence.1-2 Structural 
understanding of ghrelin acylation is still unknown due to GOAT’s resistance to purification in 
active form. Yet, structural determination is crucial for the development of ghrelin-based 
therapeutics for the treatment of conditions involving this hormone. 3-4 Previous studies of the 
interaction of ghrelin and GOAT have established important chemical signals for the recognition 
of the N-terminal “GSSF” sequence of ghrelin. In an in vitro biochemical assay, alanine 
mutations in the ghrelin peptide sequence revealed that GOAT recognizes the amino acids 
glycine (G1), serine (S3), and phenylalanine (F4) within the ghrelin N-terminal sequence.5 
Conversely, mutation of S2 to alanine resulted in no effect on ghrelin acylation by the mouse 
isoform of GOAT.5 More targeted structure-activity analysis of GOAT reactivity demonstrated 
the α amino group of the essential N-terminal glycine residue of ghrelin to be required for 
substrate recognition. Acetylation of this group reduced reactivity and elimination of this amine 
completely abolished peptide recognition.6-7 Likewise, replacement of glycine 1 with 
methoxyacetic acid which removes the nitrogen atom of the amino group resulted in the loss of 
peptide reactivity with GOAT.6 These studies suggested that a positive charge or/and a hydrogen 
bond is required for GOAT recognition at the G1 position of ghrelin.  
 Investigation of the recognition pattern for the second serine (S2) in ghrelin by GOAT 
revealed a potential steric contact at S2, where the enzyme did not tolerate mutations that 
introduced large amino acids like phenylalanine and tryptophan.7 There is a negative effect in 
increasing the volume of the residue at S2, consisting with a small binding pocket at this site. 
Additional investigation of reactivity with positive charged amino acids like histidine and lysine 
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demonstrated reduced activity but still detectable octanoylation with hGOAT, with this loss of 
activity ascribed to the known steric selectivity at this position rather than the side chain positive 
charge.7 Mutation of S2 to threonine resulted in no loss of reactivity, which supports recognition 
of the hydroxyl group at S2, potentially through hydrogen bonding.  
 Mutagenesis studies of phenylalanine-4 (F4) with alanine substitution resulted in a loss of 
substrate octanoylation in both in vitro and cell-based ghrelin octanoylation assays using mouse 
GOAT.5 Alanine modification in the human isoform of GOAT similarly resulted in reduced 
reactivity.6 Surprisingly, analysis of an array of mutations at this position revealed broad 
tolerance for steric/bulky residues, in contrast to the steric discrimination detected at G1 and S2 
sites. However, introduction of charged amino acids glutamate and lysine led to a loss of 
detectable activity.6 These results reflect a sterically accommodating binding site with tolerance 
towards uncharged amino acids.  
 Ghrelin sequence studies identified an amphibian form of ghrelin in the stomach of 
bullfrog, which is also modified with an n-octanoic acid group.8-10 However, this modification 
take place on a unique threonine amino acid at position 3 (T3) in bullfrog. This amino acid varies 
from the serine present in mammalian ghrelin counterparts.9 A S3T mutation in the human 
ghrelin-derived peptide substrate (GSTFLCAcDan) was investigated based on bullfrog ghrelin. 
Threonine substitution at serine 3 reduced peptide octanoylation but did not entirely abolish it,6 
indicating that hGOAT tolerates a methyl substituent in place of one of the hydrogens on the β 
carbon in serine at this position.  
 These previous studies have generated a profile of chemical properties for ghrelin 
recognition by hGOAT at each location in the N-terminal “GSSF” sequence of ghrelin (Figure 
4.1). In this analysis, we have used our biochemical tools and previous understanding of 
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hGOAT-substrate interactions to examine our computationally predicted substrate binding sites 
within hGOAT described in chapter 2 of this work. Initial investigations of our model revealed 
an internal channel with two contiguous voids (Figures 2.5 and 4.2). These spaces are proposed 
to be topologically arranged to serve as binding sites for ghrelin (blue, ER lumen exposed) and 
octanoyl-CoA (red, cytoplasm exposed) (Figure 4.2). Using the profiles for ghrelin recognition 
by hGOAT described above coupled with simultaneous mutations in both enzyme and substrate, 
we have identified a subset of residues within this internal channel that play functional roles in 
ghrelin interaction and binding. These interactions between ghrelin and GOAT can serve as 
constraints for validating and refining our hGOAT structure to understand ghrelin binding and 
catalysis by this enzyme. Similarly, these findings lay the foundation for the identification of the 





Figure 4.1 Schematic illustration of identified substrate-binding-site interactions within the 
hGOAT active site. This diagram summarizes important interactions between hGOAT active 
site and the ghrelin peptide. Recognition of the N-terminal amine, the α carbon of G1, the side-
chain hydroxyl of S2, the β carbon of S3, and the side chain of F4 of the ghrelin peptide are 




















Figure 4.2. Structural modeling of human ghrelin O-acyltransferase reveals a 
transmembrane channel within GOAT. An internal void was discovered with potential 
binding sites for ghrelin (blue) and octanoyl-CoA (red). These proposed binding sites are 
topologically connected by a channel passing through the protein from the ER lumen to the 
cytoplasm, with this model allowing identification of amino acids within hGOAT that contact 




4.2.1. hGOAT mutant reactivity enhancement and loss with mutated peptide substrates 
 As described above, previous studies have shown that GOAT recognizes the size of the 
amino acid at several sites within ghrelin. 6-7 For example, increasing the size of the amino acid 
at the second position (S2) of the GSSFL sequence led to a loss of enzyme activity with the 
mutated substrate.6 To investigate regions of hGOAT predicted by our structural model to 
potentially interact with the ghrelin substrate, we have investigated the reactivity of peptide 
substrates containing site-specific mutations with both wild type hGOAT and hGOAT variants 
containing alanine mutations within the enzyme core. By comparing the reactivity of these 
hGOAT alanine variants with both the mutated and wild type peptide substrates, hGOAT 
residues that specifically alter reactivity of the mutated substrates can be identified. Such specific 
enhancement or loss of reactivity with a mutated substrate will thereby identify hGOAT residues 
contacting ghrelin at the site of the substrate mutation. The peptide substrates for these studies 
were designed by altering the “GSSF” sequence (G1, S2, and F4) as shown in Figure 4.3.   
 For these studies, hGOAT alanine variants described in chapter 2 were selected to 
investigate their reactivity with mutated peptide substrates. These hGOAT variants exhibit a 
wide range of activity with the wild type (unmutated) peptide substrate (GSSFLCacdan); from 
comparable to wild type hGOAT to complete loss of detectable activity (Table 2.2 or Figure 2.7 
in chapter 2).12 Rescue or enhancement of acylation activity was determined by measurements of 
reactivity for each hGOAT variant-mutant substrate pair relative to the wild-type enzyme and 
mutant substrate as shown in Figure 4.4. To calculate this enhancement, we described the change 
in reactivity between the alanine (ala) variant and WT (wild type) hGOAT enzymes with each 
mutated ghrelin peptide substrate and then subsequent measurements of reactivity of alanine 
123  
variant and WT hGOAT with the unmutated ghrelin peptide (GSSFLCacdan) (Figure 4.4a). The 
ratio of these two measurements will indicate the specific impact on reactivity with the mutated 
substrate due to each alanine mutation within hGOAT. An illustration of this analysis is shown in 
Table 4.1, where fold enhancement has been calculated for different hGOAT ala variants. 
Likewise, reactivity loss was calculated by inverting the equation described above to identify 
variants that are detrimental to hGOAT acylation activity towards specific mutated substrates 
(Figure 4.4b). Similarly, activity loss calculations are shown in Table 4.2.  Activity of each 
hGOAT variant was determined using our fluorescently-labeled ghrelin mimetic substrates, 
monitoring octanoylation by an increase in retention time on reverse-phase HPLC as described in 





Figure 4.3. Mutated peptide substrates for structure-activity studies of hGOAT alanine 
variants. Peptide substrates used in this study to establishing GOAT’s selectivity within the 
“GSSF” ghrelin sequence. Model of the GSSFL substrate indicating the G1, S2, and F4 positions 
with specified modifications. An alanine (Ala) mutation was introduced at the G1 position. 
Valine (Val), phenylalanine (Phe), and tryptophan (Trp) mutations were added at S2 position. At 
the F4 position Tryptophan (Trp), unnatural amino acids cyclohexylalanine (Cha), and a 




















Figure 4.4. Analyses to determine specific enhancement and loss of hGOAT variant 
reactivity with mutated peptide substrates. Detection of specific hGOAT variant reactivity a) 
enhancement or b) loss with a mutated peptide substrate provides evidence of a biochemical 
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Table 4.1. Cross-reactivity between modified substrates and hGOAT mutants yields 
enhancement signals of enzymatic activity at specific ghrelin positions. Enhancement 
calculations of hGOAT alanine variants with mutated substrates for each enzyme-substrate 
mutation pair relative to the wildtype enzyme. Blue, alanine variants with octanoylation activity 
within 3-fold of WT hGOAT with an unmutated substrate; purple, alanine variants with impaired 
octanoylation activity (>3-fold loss compared to WT hGOAT) with an unmutated substrate; red, 
inactive alanine variants with an unmutated substrate. Errors indicate the average of a minimum 














ASSFLCacdan GVSFLCacdan GFSFLCacdan GWSFLCacdan GSS[Cha]LCacdan GSSWFLCacdan GSSCacdanLS
H98A 0 0 0 0 0 0 0
Y168A 0 0 0 0 0 0 0
S179A 1.0 ± 0.4 0.2 ± 0.1 0.9 ± 0.2 1.9 ± 0.05 0.4 ± 0.02 0.8 ± 0.06 1.8 ± 0.1
S182A 0 0 0 0 0 0 0
F183A 0 0 0 0 0 0 0
Y255A 0 1.5 ± 0.4 18.2 ± 7.9 1.2 ± 0.2 0.4 ± 0.02 1.0 ± 0.2 3.4
Y284A 0 0 0 0 0 0 0
S300A 0.7 2.4 ± 0.3 3.2 0 3.1 ± 3.1 0.5 ± 0.1 0
F302A 0 2.7 ± 0.7 6.7 6.6 ± 1.2 0.6 ± 0.2 1.8 ± 0.8 5.5 ± 1.6
W306A 0 0 0 0 0 0 0
F331A 0 0 0 0 0.8 0 0
F348A 1.3 ± 0.2 2.2 ± 0.8 0.6 0 30.0 ± 18.1 2.3 ± 1.2 2.2 ± 0.4
W351A 0 1.4 ± 0.3 1.2 0 1.7 ± 0.2 0 1.8 ± 2.2
R370A 0.8 ± 0.2 1.5 ± 0.5 4.9 1.5 1.2 ± 0.2 1.6 ± 0.5 1.8 ± 0.6
S2 F4
Fold Loss
Table 4.2. Specific loss of enzyme ractivity between modified substrates and hGOAT 
variants. Fold loss calculations of hGOAT alanine variants with modified substrates for each 
enzyme-substrate mutation pair relative to the wildtype enzyme. hGOAT variants are colored 





4.2.2 Location of ghrelin binding site within hGOAT suggested by ghrelin-GOAT cross 
mutation reactivity analysis 
 To qualitatively understand the significance of a detected rescue, enhancement signals for 
every pair was compared to the average and standard deviation of all enhancement values in this 
study. For example, the average enhancement (0.4) plus the standard deviation (0.9) for the 
entire enhancement study was determined to be 1.3, as shown in Figure 4.5. Consequently, any 
enhancement measured larger than 1.3 is interpreted as evidence that supports interaction of the 
enzyme and substrate mutation sites. Through analysis of specific enhancement data, we 
identified interaction pairs corresponding to S179A with GVSFLC, Y255A with GSS[Cha]LC, 
S300A with GSSWLFC and ASSFLC, F302A with GSS[Cha]LC, and F348A with ASSFLC as 
all show specific enhancement of reactivity higher than any other reactivity signal rescue. 
Similarly, specific losses of reactivity were calculated and are shown in Figure 4.6. for loss of 
reactivity, the average (1.3) plus standard deviation (3.7) of fold loss was calculated to be 5.0. 
Analysis of specific loss of reactivity supports the following interaction pairs: Y255A with 


























Figure 4.5. Specific reactivity enhancement analysis of GOAT-ghrelin mutation pairs. All 
enhancement data points were plotted (shown in blue dots), with the overall average (0.4, black) 
denoted by a thick black dotted line and the number for baseline for considering enhancement 
significance (1.3, gray) shown with the thin black dotted line. Data points above the threshold for 





























Figure 4.6. Specific reactivity loss analysis of GOAT-ghrelin mutation pairs. All 
enhancement data points were plotted (shown in orange), with the overall average (1.3, black) 
denoted by a thick black dotted line and the number for baseline for considering enhancement 
significance (5.0, gray) shown with the thin black dotted line. Data points above the threshold for 
consideration are labeled with the specific hGOAT alanine variant and mutated substrate. 
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4.3 Discussion and Conclusions 
 Uncovering GOAT’s substrate binding site and mechanistic identification of protein 
acylation remains a difficult challenge notwithstanding successes in experimentally 
determination of GOAT topology and the recent report of a computational structural model for 
GOAT.12, 14 Addressing this challenge, previous studies have applied structure−activity 
examination to determine components within ghrelin and acyl-donor substrates of hGOAT that 
are important for enzyme recognition. These studies provided the first molecular-level 
understanding of the chemical properties that hGOAT recognizes in the ghrelin GSSF target 
sequence.5-6, 15 Defining the interactions between hGOAT and ghrelin used to bind and recognize 
this peptide hormone will provide insight into the structure of the hGOAT active site and 
substrate binding sites. In this work, we applied mutational analysis of hGOAT to determine 
potential residues involved in ghrelin octanoylation activity. Cross mutation analysis of hGOAT 
variants and mutated peptide substrates has revealed a number of residues within the human 
isoform of GOAT that specifically impacted the reactivity of mutated ghrelin peptide substrate, 
providing functional linkages between amino acids in ghrelin and hGOAT.  
 Among these functionally linked residues, we investigated the partial rescue produced by 
the interaction of the N-terminal glycine in the GSSFL sequence of ghrelin and GOAT residues 
S300 and F348. In this study, the alanine mutation introduced in the context of the ASSFLC 
peptide substrate exhibited partially enhancement in reactivity with the S300A and F348A 
hGOAT variants. The ability of these alanine mutations within hGOAT to alter substrate 
specificity suggest that the insertion of a slightly larger residue than Gly in the substrate was 
functionally complemented by the space created upon alanine mutation of the S300 or F348 
residues. The specific enhancement of reactivity upon incorporation of the methyl group at the α-
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carbon in the ASSFLC substrate suggests that the N-terminal glycine of ghrelin contacts residues 
S300 and F438 within hGOAT.  
 For the second serine in the ghrelin sequence (S2), we observed functional linkages of 
amino acids S179 and F384 with the mutated peptide substrates GVSFLC and GFSFL sequence, 
respectively. S179A exhibited the strongest enhancement effect in our analysis when ghrelin 
peptide was mutated to GVSFLC. The elimination of the -OH group on GOAT potentially 
provided space for valine’s aliphatic group to be accommodated within the alanine-altered 
enzyme. This result, which indicates contact between S179 and the S2 residue in ghrelin, is 
intriguing in that the side chain hydroxyl of S179 could also interact with S2 via hydrogen 
bonding to its hydroxyl group, consistent with previous studies implicating such a contact in 
ghrelin recognition by hGOAT.6 The GOAT residue F348 also generated an enhancement with 
the S2 modified-substrate with a phenylalanine in place of S2 (GFSFLC). The F348A variant 
also provided reactivity enhancement activity with mutations at the G1 position as discussed 
above, further linking the F348 residue to the ghrelin substrate-binding site within GOAT.  
 Mutation of the fourth amino acid (F4) in the ghrelin sequence led to several different 
signals corresponding to interactions with hGOAT residues. Two enhancements were observed 
from hGOAT alanine variants Y255A and F302A with the substrate containing a modification 
on ghrelin’s F4 residue to the non‐natural Phe‐derivative amino acid, cyclohexylalanine (Cha), 
bearing a saturated alkyl 6‐member ring (GSS[Cha]LC). These results establish the interaction 
of residue Y255 and F302 with the ghrelin substrate at the F4 position probably by aromatic-
aromatic interactions. Similarly, S300A hGOAT variant showed reactivity enhancement rescued 
by a peptide substrate that incorporating a bigger tryptophan (GSSWLC) residue at the fourth 
position of the GSSFLC ghrelin sequence. This rescue of activity presents an essential amino 
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acid near the substrate-binding site of hGOAT that has been rescued by filling the space 
available after an alanine mutation in the enzyme.  
 Analyzing losses of reactivity induced by alanine hGOAT variants, we observed a 
significant loss of hGOAT reactivity signal with F348A hGOAT variant and (F4) 
cyclohexylalanine (Cha)-ghrelin peptide (GSS[Cha]LC). Previous studies have demonstrated 
that hGOAT is tolerant to large side chains mutations of F4 in ghrelin substrate, 6 which is not in 
accordance with the loss of activity observed here by the addition of bulky group at this F4 site. 
Yet, F348A variant did show enhancement of activity (Figure 4.5) with ghrelin mutations at 
positions G1 and S2 in the sequence. Therefore, we suggest that the GOAT residue F348 is 
possibly interacting with the end N-terminal sequence of ghrelin predominantly, rather than 
interacting with farther amino acids like F4. Similarly, interaction of (S2) peptide GFSFLC and 
Y255A variants resulted in a loss on reactivity, indicating no interaction at this position. Finally, 
the F302A variant demonstrated two loses of rescue reactivity with peptide (S2)-GWSFLC and 
(F4) peptide substrate GSSCLS, exhibiting no ability to accommodate the mutations. Combining 
these enhancement and loss of reactivity analyses together, we can generate a schematic 
illustrating the arrangement and nature of interactions between the hGOAT active site and its 
ghrelin substrate as depicted in Table 4.3 and Figure 4.7. 
 To gain a three-dimensional perspective of the arrangement of the residues implicated in 
the ghrelin binding site by these studies, we considered the position of these residues in our 
GOAT structural model. The residues whose mutation to alanine produced strong enhancement 
of activity with mutated substrates lie in or near the internal channel in our hGOAT model, as 
shown in Figure 4.8. The location of these residues within the channel support this region as a 
potential substrate-binding site for ghrelin within hGOAT. The linkages identified in this work 
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provide new constraints between hGOAT and ghrelin for refinement of the hGOAT structural 
model and will enable the development of further models of the hGOAT-ghrelin complex. This 
approach has proven robust in the prediction of the octanoyl-CoA substrate binding site as 
demonstrated in our published studies.12  
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Table 4.3. Summary of specific enhancements and losses of reactivity identified through 
analysis of hGOAT variant-mutated ghrelin substrate pairs.   
Ghrelin Sequence:  G1 S2 S3 F4  
     
Enhancement Reactivity  
 
Loss Reactivity  
         
GOAT Residue Ghrelin site   GOAT Residue Ghrelin site 
S300 G1   Y255 S2 
F348 G1   F302 S2 
S179 S2   F302 F4 
F348 S2   F348 F4 
Y255 F4     
S300 F4    
F302 F4    
     






Figure 4.7. Proposed interactions between enzyme and substrate residues in the ghrelin-
binding site within hGOAT. Proposed interactions between hGOAT residues and specific 






























Figure 4.8. Illustration of proposed ghrelin contacting residues within the hGOAT 
structural model contacting the internal enzyme channel. Amino acid residues (color code 
defined in table) that whose alanine variants exhibited specific enhancement of reactivity with 
mutated peptide substrates at specific ghrelin sites. 
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4.4 Experimental Methods 
4.4.1 General Methods 
 Data plotting and curve fitting were carried out with Kaleidagraph (Synergy Software, 
Reading, PA, USA). Octanoyl coenzyme A (octanoyl-CoA) was solubilized to 3 mM in 10 mM 
Tris-HCl (pH 7.0), aliquoted into low-adhesion microcentrifuge tubes, and stored at −80 °C. 
Methoxy arachidonyl fluorophosphonate (MAFP) was purchased from Cayman Chemical (Ann 
Arbor, MI) and solubilized with dimethyl sulfoxide (DMSO). Unlabeled peptide GSSFLCNH2 
was synthesized by Sigma-Genosys (The Woodlands, TX), solubilized in 1:1 acetonitrile:H2O, 
and stored at -80 °C. The ghrelin-mimetic peptides with substitutions at the S2, S3, and F4 
position were synthesized by Pepmic (Suzhou, China) and purified to >90% purity by HPLC, 
with peptide mass verified by mass spectrometry. Peptides were solubilized in a 1:1 mixture of 
acetonitrile/H2O and stored at −80 °C. Peptide concentrations were determined by reaction of 
the cysteine thiol with 5,5’-dithiobis(2- nitrobenzoic acid) and absorbance at 412 nm, using ε412 = 
14,150 M–1 cm–1.16  
 
4.4.2 Peptide substrate fluorescent labeling 
 Peptide substrates used in this hGOAT acylation assay contain a cysteine mutation in the 
desired site to allow chemoselective attachment of an acrylodan fluorophore using our previously 
reported protocols.7, 17 Acrylodan-labeled peptides were purified by semipreparative reverse 
phase HPLC (Zorbax Eclipse XDB column, 9.4 x 250 mm) using a gradient mobile phase of 
30%-100% acetonitrile in aqueous 0.05 % trifluoroacetic acid (TFA) over 30.2 minutes, at a flow 
rate of 4.2 mL/min. Labeled peptide elution was detected by absorbance at 360 nm, and collected 
fractions containing the labeled peptides were dried under vacuum at room temperature and 
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resuspended in 1:1 H2O: acetonitrile. GSSFLCNH2 labeling was confirmed by MALDI-TOF mass 
spectrometry (Bruker Autoflex III) using a matrix containing sinapinic acid in 0.1 % TFA and 50 
mM ammonium phosphate. The concentration of acrylodan labeled peptide was calculated using 
absorbance of acrylodan at 360 nm (ε= 13,300 M-1cm-1) per previous reports.7, 18 
 
4.4.3 Construction of plasmids encoding wild type hGOAT and hGOAT alanine variants 
 A gene encoding hGOAT with a C-terminal triple tag (FLAG, HA, His6) was cloned into 
the pFastBacDual vector (Invitrogen) using EcoRI and XbaI restriction sites, with the resulting 
vector used to produce the baculovirus expression system protocol (Invitrogen) as described 
previously (Chapter 2.4.6, table 3.1).7 PCR primers for site-directed mutagenesis are described in 
chapter 2.4.6. PCR mutagenesis reactions (50 μL total volume) contained the following 
components: 10x Pfu reaction buffer (5 μL), template plasmid DNA (10 ng), forward primer 
(125 ng), reverse primer (125 ng), dNTPs (1 μL, 1 mM stock), and Pfu Turbo DNA polymerase 
(1 μL, Agilent). The thermocycler program for PCR mutagenesis proceeded as follows: initial 
denaturation (95 °C, 1 min); 18 cycles of denaturation (95 °C, 50 sec); annealing (60 °C, 50 sec); 
extension (68 °C, 12 min); and final extension (68 °C, 12 min). Reaction were digested with 
DpnI (New England BioLabs, R0176S, 10 units) at 37 °C for 2 hours. After DpnI digestion, the 
PCR reaction mixture (5 μL) was transformed into a 100 L aliquot of chemically competent Z-
competent DH5 cells (Zymo Research) followed by incubation on ice for 30 minutes. 
Transformed bacteria were spread on LB-ampicillin plates (100 μg/mL) and incubated at 37 C 
overnight. Following overnight incubation at 37 °C, single colonies were inoculated into LB 
media (5 mL) containing ampicillin (100 μg/mL) in sterile culture tubes. These cultures were 
incubated overnight at 37 C with shaking (225 rpm). Following overnight growth, plasmids 
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were purified from the saturated cultures using EZ-10 Spin Column Plasmid DNA kit (Bio Basic 
Inc.) per manufacturer’s instructions. Single site mutations were verified by DNA sequencing 
(Genewiz). 
 
4.4.4 Expression and enrichment of hGOAT in membrane protein fraction 
 Sf9 insect cells (5.0 x 108 cells in a 500 mL total culture volume) were infected with 
hGOAT baculovirus at a multiplicity of infection of 10 followed by protein expression for 40 hr 
at 28 °C shaking 150 rpm described in previously published procedures. 6-7, 19  
 
4.4.5 Membrane fraction enrichment 
 Sf9 insect cell expression cultures were transferred to 50 mL conical tubes and harvested 
by centrifugation (500 xg, 5 min, 4°C); the resulting supernatant was discarded. The cell pellet 
was resuspended in 2.5 mL lysis buffer (50 mM Tris-HCl pH 7.0, 150 mM sodium chloride 
(NaCl), 1 mM sodium ethylenediamine (NaEDTA), 1 mM dithiothreitol (DTT), 0.01 μg/mL 
pepstatin A, 10 μM bis (4-nitrophenyl) phosphate, and 1 mini Roche protease inhibitor cocktail 
tablet/10 mL). The cells were then lysed with a 7 mL dounce homogenizer on ice, using 20 
strokes with a small pestle and 20 strokes with a large pestle.  Intact cells and cell debris were 
removed by centrifugation (3000 x g, 10 min, 4°C). The supernatant was transferred to a pre-
tared ultracentrifuge tube and the membrane fraction was isolated by centrifugation (100,000 x g, 
1 hour, 4°C).  The resulting supernatant was discarded, and the pellet was solubilized in 50 mM 
HEPES (pH 7.0) to reach 4 μL/mg of microsomal pellet. Membrane fraction suspensions are 
distributed into 80 μL aliquots in low-adhesion tubes and stored at -80°C. 7
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4.4.6 GOAT acylation activity assay 
 Membrane fractions from Sf9 cells expressing hGOAT mutants and wildtype were 
thawed on ice and passed through an 18-gauge needle ten times. Membrane fractions were then 
added to reaction mixtures. Assays were performed with 50 μg concentrations of membrane 
protein, 1.5 μM fluorescent peptide substrate, 3 mM octanoyl-CoA, 1 mM MAFP, and 50 μM 
HEPES pH 7.0 in a total volume of 50 μL and then incubated at room temperature for 30 min. 
Reactions were initiated by addition of 1.5 μM fluorescent peptide substrate and 300 μM 
octanoyl-CoA, then incubated at room temperature for 2 hours in the dark. Reactions were 
stopped with 50 μL of 20% acetic acid in isopropanol. The solutions were clarified by protein 
precipitation with 16.7 μL of 20% trichloroacetic acid, followed by centrifugation (1,000 x g, 2 
min). The resulting supernatant was then analyzed by reverse phase HPLC. 
 
4.4.7 HPLC analysis of hGOAT octanoylation reactions 
 hGOAT assay samples were analyzed on an Agilent 1260 HPLC with a C18 reverse 
phase HPLC column (Zorbax Eclipse XDB, 4.6 x 150 mm) using a gradient of 30% acetonitrile 
in 0.05 % TFA in upH2O to 100 % acetonitrile over 30.2 minutes.  Fluorescent peptides were 
detected by UV absorbance at 360 nm and fluorescence (ex 360 nm, em 485 nm), with the 
peptide substrate eluting with a retention time of 6 minutes and the octanoylated peptide eluting 
with a retention time around 12 minutes. Chromatogram analysis and peak integration was 
performed using Chemstation for LC (Agilent Technologies).7 Product conversion was 
calculated by dividing the integrated fluorescence for the product peak by the total integrated 
peptide fluorescence (substrate and product) in each run. Percent activity for each hGOAT 
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mutant was calculated by normalizing the product conversion for the mutant to that of wild type 
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Chapter 5: Remarkable ligand specificity for ghrelin O-
acyltransferase reveals unexpected enzyme interaction with 
extracellular peptides 
 
The work presented in this chapter is unpublished.  
 
Syntheses of all ligand peptides were completed by collaborator Marina Childs 
from the Luyt Laboratory (University of Western Ontario). Similarly, Marina 
Childs performed all GHS-R1a receptor-binding assays described here.  
 
Immunofluorescence imaging was performed with help of Erin Curtis (Hehnly 
Laboratory, Syracuse University). During these cell-imaging studies, we consulted 
Professor Heidi Hehnly for guidance in improving image quality and cell labeling 
protocols.  
 
In this chapter, there was also an experimental contribution from Yasandra 
Morales (Syracuse University undergraduate researcher) who assisted with 











 The regulation of hunger is controlled by many signals released in the bloodstream in the 
form of free fatty acids, glucose, and hormones.1-2 Ghrelin, the appetite stimulant hormone, 
regulates feeding-associated behaviors affecting energy homeostasis and fat storage while 
stimulating appetite and food intake.3-5 Research in the last decade has shown that ghrelin plays 
additional regulatory roles, with studies linking this peptide hormone to addictive behaviors 
through impact on reward processing within the brain.6-7 Other studies associated ghrelin with 
stress-related mechanisms, which affect psychological responses to prolonged exposure to 
stressors.8-10 Moreover, ghrelin is involved in neuroprotection11 as well as memory and learning 
processes.12, 13  
Ghrelin is a 28 amino acid peptide mainly released in the stomach14 but has also been 
found in other tissues like small intestine, pancreas, kidney, pituitary, ovaries, and 
lymphocytes.15-16 In the bloodstream, ghrelin exists in two forms: the acylated ghrelin with an 
uncommon eight-carbon fatty acid octanoate (C8:0) covalently linked to its third N-terminal 
serine and des-acylated ghrelin.17 Ghrelin is the only known peptide that undergoes this n-
octanoylation modification and it is required for binding to its endogenous receptor, growth 
hormone secretagogue receptor type 1 (GSH-R1a).16 
 The human GHS-R1 gene encodes for the seven transmembrane domain G-protein 
coupled protein (GHS-R1a), which functions in regulation of pituitary growth hormone 
release.18-19 GHS-R mRNA expressions revealed that the receptor type 1a is found in the 
pituitary region, brain, thyroid gland, pancreas, spleen, myocardium, and adrenal gland.18, 20-21 
Remarkably, higher levels of expression for this receptor have been identified in unhealthy 
tissues and tumors like prostate cancer,22 testicular and ovarian tumors,23-24 breast carcinomas,25 
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neuroendocrine tumors,26-27 among others.28 Expression of ghrelin and the GHS receptor shows 
to be widely distributed throughout the body, representing a potential functional role of ghrelin 
and its receptor in hormone-dependent cancers. Moreover, the specific interaction of ghrelin with 
the receptor creates a valuable imaging probe for tissues in which GH-R1a is highly expressed. 
Previous studies have developed ligands for GHS-R1a imaging as diagnostics using ghrelin 
analogs for in vivo imaging for heart tissues,29 prostatic neoplasms,30 and ovarian carcinomas.31 
Novel ghrelin probes specific to prostate cancer (PCa) cells with no association of normal 
prostate tissue were developed with high receptor affinity.30 Moreover, a truncated fluorescently 
labeled ghrelin was generated for probing of biopsies and distribution analysis of ovarian cells, 
with higher specificity and sensitivity compared to immunohistochemical approaches.31 
 To bind and activate the GHS-R1a receptor, ghrelin requires the acylation modification 
of its third serine (Ser3) by an octanoyl (C8) fatty acid group.17, 32 Des-acyl ghrelin or other 
ghrelin-related peptide such as obestatin, do not interact nor stimulate the GHSR1a receptor. The 
enzyme that catalyzes this acylation, ghrelin O-acyltransferase (GOAT)33-34, is the only known 
enzyme to modify ghrelin in the human proteome.35 GOAT is mainly expressed in the stomach 
and pancreas, but also in a numerous other tissues, including breast and prostate tissues.36-37 
Moreover, studies have detected GOAT overexpression in some tumor and cancer tissues like 
breast,36 pituitary, and endocrine tissues.38-39 Similarly, overexpression of GOAT was observed 
in prostatic cancer tissues and plasma/urine samples of PCa patients compared to healthy 
samples.37, 40-41 Additionally, detection studies of GOAT in circulation suggest that PCa cells can 
produce extracellular vesicles (EVs) encompassing integral membrane GOAT, which can be 
used as an attractive biomarker in cancer patients that frequently present increased numbers of 
circulating EVs.42-43 While canonical localization of GOAT has been recognized to the 
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endoplasmic reticulum ER,44 recent studies proposed GOAT expression and exposure to 
extracellular space through plasma membrane localization.45-46 Similar to the GHS-R1a receptor, 
GOAT possesses a potential target for imaging and diagnosis by exploiting the specificity of 
binding of ghrelin peptide to GOAT. While displaying high potency, peptide analogs for GOAT 
have pharmacologic challenges for in vivo applications due to their low ability to enter cell 
membranes and they can also act as potent agonists of the GHS-R1a receptor.  
 The goal of this work was to develop potent, specific, and biostable peptide ligands to 
enable GOAT detection by developing ghrelin-mimetic hGOAT inhibitors with no distinctive 
ability to have an agonist effect via binding the ghrelin receptor. We have optimized the 
synthetic peptide binding to hGOAT through sequence mutagenesis and chemical modification 
with a lead compound that demostrated high GOAT binding. We have constructed ligands for 
the detection of hGOAT in biological samples using a range of detection / imaging modalities.  
 
5.2. Results and Discussion 
5.2.1 Design of Dap-based ghrelin peptide ligand to bind GHS-R1a and hGOAT 
 The high affinity and specificity of ghrelin binding to the GHS-R1a receptor creates a 
significant tool for the development of ghrelin imaging agents targeting this receptor. Previous 
studies had developed a high affinity fluorine-containing ghrelin (1–8) analogue capable of 
binding this receptor.47-48 Similarly, GOAT participation in ghrelin activation creates a useful 
target for controlling ghrelin signaling and binding for the development of imaging agents; 
however, inhibitor GOAT design has been challenging due to the lack of information regarding 
the enzyme active site and substrate binding sites. There have been GOAT inhibitors reported 
that mimic acylated ghrelin peptide, with the first study describing a pentapeptide mimetic with 
an amidated C-terminal.49 The same study designed a potent ghrelin (1-5) peptide inhibitor with 
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a [Dap] ((S)-2,3-diaminopropionic acid), creating an octanoyl-amide that replaced the ester 
linkage of the acyl group.49 This modification significantly increased peptide stability and 
potency for binding to GOAT. Compilation of these results has guided our development of a 6-
mer (1-6) and 8-mer (1-8) derived human ghrelin-bearing peptides, with a Dap moiety to 
generate imaging agents that can target GOAT overexpressing cells. Table 5.1 demonstrates how 
the potency of Dap peptides changes minimally (1.4-fold less potent) from 6-mer to 8-mer 
peptide comparing compounds 1 and 2 against GOAT. Binding of Dap peptides 1 and 2 to the 
GHS-R1a receptor was not detected, demonstrating important interactions of the Dap moiety 
with GOAT. The development of an 8-mer peptide allows direct comparison against ligands with 
proven affinity for GHS-R1a receptor47, like the fluorine-bearing aromatic group of ghrelin (1-8) 
developed previously with very strong affinity to the GHS-R1a receptor (compound 4). By 
eliminating the 6-fluoro-2-pentafluorophenyl naphthoate (PFPN) prosthetic group at the serine 3 
position of GHS-R1a ligand 4, loss of affinity to the receptor was obtained while improving 
GOAT binding (compound 3). Similarly, structure activity analysis of the acyl group length at 
the serine 3 of ghrelin has demonstrated that octanoyl chain and large lipophilic groups 
contributes strongly to GOAT binding.35 Nevertheless, the addition of a C8 group to the amine in 




Table 5.1. Acyl changes within ghrelin peptide sequence. Substitutions of the acyl group with 












1 H-GS-Dap-FLS-NH2 >100 μM 74 ± 7 nM Hougland lab 
2 H-GS-Dap-FLSPY-NH2 >100 μM 104 ± 43 nM LCE00496 
3 H-GS-(C8-Dap)-FLSPY-NH2 65 nM 64 ± 21 nM  LCE00495 




5.2.2. Changes at the N-terminal amino acid (G1) and hGOAT recognition 
 GOAT recognizes the first four amino acids in the N-terminal motif of the native ghrelin 
peptide, near the site of octanoylation at serine 3. In a previous study, these four amino acids 
were shown to comprise the substrate recognition motif required for octanoylation by GOAT.49 
Particularly, structure-activity analysis of ghrelin-mimetic peptides has showed the importance 
of the N-terminal glycine,35, 49-50 where amino acid mutations entirely abolished peptide acylation 
by GOAT. To investigate importance of the first amino acid (G1) in our developed Dap peptides, 
the N-terminal glycine was replaced with two unnatural amino acids: aminoisobutyric acid (Aib) 
and isonipecotic acid (Inp). As shown in Table 5.2, incorporation of either Aib or Inp at the N-
terminus (compound 5 and 6) had a pronounced negative effect in peptide binding to GOAT 
when compared to ghrelin (1-8) [Dap]-mimetic (compound 2) that is consistent with previous 
SAR studies of G1 recognition.35, 49, 51 Conversely, GHS-R1a tolerated replacement of G1 with 
2-aminoisobutyric acid and isonipecotic acid as shown in previous work,47 where compound 7 
and 8 containing the PFPN prosthetic group for receptor binding demonstrated strong affinity 
towards GHS-R1a with no observable binding to the GOAT enzyme (Table 5.2). These results 
confirmed GOAT specificity towards G1, with possible substrate interactions occurring at the N-





Table 5.2. G1 modifications within ghrelin peptide sequence. Modifications of the N-terminal 












2 H-GS-Dap-FLSPY-NH2 >100 μM 104 ± 43 nM LCE00496 
5 H-Aib-S-Dap-FLSPY-NH2 >100 μM >100 μM LCE00498 
6 H-Inp-S-Dap-FLSPY-NH2 >100 μM >100 μM LCE00497 
7 H-Aib-S-(6FN-Dap)-FLSPY-NH2 9.2 nM ND  




5.2.3. Changes at E8 
 Previous alanine scanning investigation of a (1–14) ghrelin peptide with the recombinant 
human ghrelin receptor demonstrated that mutating native glutamic acid at position 8 to alanine 
resulted into the most potent ghrelin analogue against the GHS-R1a receptor.52 To investigate the 
effect in binding to GOAT at position 8 of the native ghrelin sequence (GSSFLSPE), ghrelin (1-
8) with a C8-Dap moiety peptide was modified with hydrophobic amino acid: tyrosine (Y) and 
polar uncharged amino acids: asparagine (N) and threonine (T). As shown in Table 5.3, the 
native sequence bearing glutamic acid (E) at position 8 (compound 9) demonstrated high affinity 
to the receptor and GOAT comparably. An E8T mutation (compound 11) increased binding 
potency to both GOAT and receptor. Likewise, E8Y and E8N mutations improved binding 
affinity to GOAT compared to the native peptide; however, all these mutations also improved 
binding to the GHSR-1a receptor. These findings suggested that the negative charge of E amino 
acid is detrimental towards ghrelin binding to both GOAT and GHS-R1a, with a polar uncharged 
side chain appearing optimal for stronger receptor and GOAT binding.  
  
155  
Table 5.3. E8 modifications within ghrelin sequence. Substitution of residue 8 in the ghrelin 
peptide shown to increase affinity to GOAT enzyme when threonine replaced the natural 












3 H-GS-(C8-Dap)-FLSPY-NH2 65 nM 64 ± 21 nM LCE00495 
9 H-GS-(C8-Dap)-FLSPE-NH2 200 nM 580 ± 60 nM LCE00488 
10 H-GS-(C8-Dap)-FLSPN-NH2 31.9 nM 59 ± 6nM LCE00489 




5.2.4. Changes at F4 
 Alanine or tyrosine modifications of phenylalanine at the 4 position (F4) in ghrelin have 
led to a decrease GHS-R1a binding affinity, illustrating the importance of phenylalanine at 
residue 4 for interaction with the receptor.47, 52-53 Preceding investigation of GOAT tolerance for 
mutations at residue 4 has identified a preference for a large hydrophobic/aromatic amino acid at 
the F4 position in ghrelin.35, 51 In this study, we explored the effects of larger and more 
hydrophobic side chains modifications at this position on binding of our Dap ligand to hGOAT. 
As shown in Table 5.4, substitution with 1-naphylalanine (Nal1) (compound 12) or 2-
naphylalanine (Nal2) of the phenylalanine in the ghrelin sequence (compound 13) increases 
binding to GOAT when compared to our previously described compound 2. Nal1 provides a 7-
fold increase in binding compared to F amino acid chain at position 4 (adjusted for 2.4 fold effect 
from Y-> T at E8). Binding of compounds 12 and 13 to the receptor was undetectable, likely due 
to the lack of a hydrophobic group at the acylation site on the Dap residue. These results further 
demonstrate a strong interaction of F4 aromatic groups with GOAT and show this interaction can 
be exploited to create more potent GOAT ligands (Table 5.5). 
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Table 5.4. Ghrelin sequence changes at F4. GOAT enzyme indicates strong affinity to large 












2 H-GS-Dap-FLSPY-NH2 >100 μM 104 ± 43 nM LCE00496 
12 H-GS-Dap-Nal1-LSPT-NH2 >100 μM 6 ± 1 nM LCE00500 
13 H-GS-Dap-Nal2-LSPT-NH2 >100 μM 16 ± 5 nM LCE00501 
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Table 5.5. Summary of ligands devised for GOAT binding. Ghrelin-derived peptide ligand 











1 H-GS-Dap-FLS-NH2 >100 μM 74 ± 7 nM 
Hougland 
Lab 
2 H-GS-Dap-FLSPY-NH2 >100 μM 104 ± 43 nM LCE00496 
3 H-GS(C8-Dap)-FLSPY-NH2 65 nM 64 ± 21 nM LCE00495 
4 H-GS(6FN-Dap)-FLSPY-NH2 9.9 nM >100 μM LCE00491 
5 H-Aib-S-Dap-FLSPY-NH2 >100 μM >100 μM LCE00498 
6 H-Inp-S-Dap-FLSPY-NH2 >100 μM >100 μM LCE00497 
7 H-Aib-S-(6FN-Dap)-FLSPY-NH2 9.2 nM ND  
8 H-Inp-S-(6FN-Dap)-FLSPY-NH2 9.6 nM ND  
9 H-GS(C8-Dap)-FLSPE-NH2 200 nM 580 ± 60 nM LCE00488 
10 H-GS(C8-Dap)-FLSPN-NH2 31.9 nM 59 ± 6nM LCE00489 
11 H-GS(C8-Dap)-FLSPT-NH2 3.3 nM 27 ± 8 nM LCE00490 
12 H-GS-Dap-Nal1-LSPT-NH2 >100 μM 6 ± 1 nM LCE00500 
13 H-GS-Dap-Nal2-LSPT-NH2 >100 μM 16 ± 5 nM LCE00501 
14 H-Inp-S(6FN-Dap)-1Nal-LSPT-NH2 0.11 nM >100 μM LCE00492 




5.2.5. Design of GHS-R1a and hGOAT-selective ligands 
 Towards the design of a specific GOAT recognizing ghrelin ligand, we have explored the 
chemo- and stereoselectivity of ghrelin recognition. By comparative binding studies, we 
identified key interactions for ligand selectivity for either GOAT or GHS-R1a binding and 
designed GOAT-specific peptide ligands such as compound 12 (Figure 5.1 and Table 5.5). 
Combining the most successful substitutions resulted in a lead peptide analogue with two 
chemical changes engendering ligand-binding orthogonally for hGOAT and GHS-R1a. First, 
compound 12 bearing a 2,3-diaminopropanoic acid (Dap) group at the site equivalent to serine 3 
and coupled with Nal-1 at phenylalanine at position 4 demonstrated preferential binding towards 
GOAT compared to the receptor. Compound 14 containing an acyl fluoronapthyl substitution 
shows strong binding to the receptor without detectable interaction with GOAT when assayed as 
an inhibitor. Second, substitutions at G1 exploited the discriminatory effect GOAT has towards 
alterations in this N-terminal amino acid compared to GHS-R1a, which is more tolerant to 
unnatural amino acid incorporation at this site (Figure 5.1). Finally, having a non-native 
threonine at position 8 of the ghrelin peptide sequence increased binding to both the receptor and 
GOAT. The developing of these selective peptide ligands resulted in a very potent  and selective 
nanomolar inhibitor for GOAT (12), providing a peptide-based platform for creating GOAT 


























12 H-GS-Dap-Nal1-LSPT-NH2 >100 μM 6 ± 1 nM LCE00500 
14 H-Inp-S-(6FN-Dap)-1Nal-LSPT-NH2 0.11 nM >100 μM LCE00492 
 
 
Figure 5.1. Orthogonal GHS-R1a and hGOAT selective ligands with associated IC50 
demonstrate a discriminatory binding effect towards modifications. a) Structure of potent 
ligands, showing key interactions at G1 and F4 positions in ghrelin mimetic ligand 14 that favor 
binding towards GOAT enzyme versus the ghrelin receptor (purple dotted circle) in ligand 12. b) 





5.2.6. Creation of fluorescent high-affinity selective GOAT ligand 
 Combining the most successful substitutions in these studies has generated a pair of 
selective ligands for GOAT and the GHS-R1a with nanomolar affinity (Figure 5.1). Each of 
these ligands exhibits >15,000-fold selectivity for its target over the other ghrelin-binding 
protein. To fluorescently label our most potent GOAT ligand (14), we synthesized a far-red 
ghrelin analog [(Dap), Lys9 (Cy5)]-ghrelin (1-9) (compound 15) containing a lysine at position 9 
for fluorophore attachment (Figure 5.2a). Earlier studies of labeled Cy5-ghrelin (1–19) has 
demonstrated strong binding to the GHS-R1a, with less susceptibility to photobleaching and high 
detection of GHS-R expression in live differentiating cardiomyocytes.54 We characterized the 
binding of our Cy5-ghrelin ligand to GOAT using our established hGOAT inhibitor assay 
(described in Experimental Methods section). The Cy5-labeled ligand exhibited nanomolar 
inhibition for hGOAT (Figure. 5.2b), supporting our ability to functionalize GOAT peptide 















































Figure 5.2. Fluorescent ligand designed for potent specific binding to hGOAT. a) Structure 
of H-GS-Dap-Nal1-LSPTK (SulfoCy5) (ligand 15) containing far-red fluorophore Cy5 added to 
position 9 lysine in the ghrelin peptide sequence. b) hGOAT inhibition plot with IC50 = 17 +/- 2 
nM by fluorescently labeled derived ligand 15. All reported IC50 values represent the average of 
three independent trials. 
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5.2.7. Analyzing interaction of GOAT ligand 15 with cells expressing hGOAT  
 To demonstrate the interaction between ligand 15 and hGOAT in a biologically relevant 
cellular setting, we characterized the binding of the Cy5-ghrelin compound to hGOAT with an in 
vitro assay using fluorescence signal of HEK 293 cells transiently transfected with either FLAG-
tagged hGOAT construct or empty vector. Following live cell incubation with the fluorescent 
ligand 15, cells were washed, fixed, and decorated with antibodies against FLAG. Using 
spinning-disk confocal microscopy, cells expressing FLAG-hGOAT showed robust far-red 
fluorescence when incubated with Cy5-ghrelin compound (Figure 5.3a, Table 5.6). Control cells 
transfected with empty vector excluded compound 15, showing no far-red fluorescence at the 
determined wavelength, consistent with GOAT expression being required for ligand binding and 
cellular uptake. In contrast, cells transfected with empty vector demonstrating that this peptide is 
not intrinsically cell permeable or nonspecifically associating with cellular membranes.  
 To explore ligand-enzyme interactions required for binding and cellular uptake, we have 
introduced three alanine mutations to functionally essential amino acids (Figure 5.3b). These 
three mutations previously have all resulted in complete loss of hGOAT enzyme activity, but 
through impact on different aspects of the hGOAT catalytic cycle.55 We altered histidine 338, 
which is an absolutely conserved histidine in MBOAT family members and is proposed to serve 
as a general base interacting with the serine hydroxyl group.55-56 We propose that the interaction 
between the Dap side chain amine and H338 is partially responsible for the tight binding 
observed for Dap-containing peptide ligands to hGOAT. In contrast, both arginine 304 and 
asparagine 307 form interactions within the octanoyl-CoA acyl donor-binding site, which would 
not directly impact ghrelin-mimetic peptide binding to hGOAT (Figure 5 and Table 5.6).  
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 The H338A hGOAT variant did not maintain cell uptake of ligand 15 when expressed in 
HEK293 cells, supporting that an interaction between the Dap amino group and H338 is required 
for tight ligand binding. In contrast to the H338A variant, both R304A and N307A variants 
supported ligand 15 internalization as expected for mutations predicted to compromise the 















































































Figure 5.3. Cell imaging and scoring of ligand uptake by transfected HEK293 cells. a) 
HEK293 cells were transfected with empty vector or FLAG-tagged hGOAT/ mutant hGOAT as 
indicated. At 40 hr post-transfection, cells were incubated with Cy5-ghrelin ligand 15 (Purple) 
for 30 min and immunostained with anti-FLAG (Cyan) for GOAT expression detection and 
DAPI (Gray) displaying micronuclei within a single cell. Wild type, N307A, and R304A 
hGOAT expressing cells showed binding and internalization of Cy5-ligand 15. Empty vector and 
H338A hGOAT variants do not support peptide uptake. Scale bar, 10 μm. b) Quantification of 
percent hGOAT-positive cells showing uptake of ligand 15 (n =100 cells, over n = 3 
experiments) for wild type, R304A, N307A, and H338A hGOAT variants. The locations of R304 
(olive green), N307 (forest green), and H338 (orange) are shown within the hGOAT structure. 
Dotted lines denote the average percent of each group. One-way ANOVA comparison test 
between wild type vs. H338A indicated significance with an adjusted P value < 0.0001 (*).  
b) 
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Table 5.6. Cell imaging and scoring for GOAT transfection and ligand 15 uptake.  
 
 





# Cells displaying 
hGOAT expression 
# Cells displaying 










Wild type 100 20 10 50 
Empty 
Vector 
100 0 0 N/A 
H338A 100 13 0 N/A 
R304A 100 26 6 23 
N307A 100 28 8 29 
     





# Cells displaying 
hGOAT expression 
# Cells displaying 










Wild type 100 21 12 57 
Empty 
Vector 
100 0 0 N/A 
H338A 100 16 0 N/A 
R304A 100 28 10 36 
N307A 100 24 9 38 
     





# Cells displaying 
hGOAT expression 
# Cells displaying 










Wild type 100 26 16 62 
Empty 
Vector 
100 0 0 N/A 
H338A 100 10 0 N/A 
R304A 100 21 8 38 





 Ghrelin and ghrelin receptor agonists have shown connections to main disorders 
including anorexia nervosa, cancer cachexia, chronic heart failure, and other related processes.57-
60 Developing ghrelin-imaging agents could be useful for non-invasive imaging detection of 
overexpressing GOAT systems. The two proteins most known for interacting with ghrelin, 
GOAT and GHS-R1a, exhibiting both similarities and distinctions in recognition elements within 
ghrelin which allows development of specific ligands for each protein. In this work, we have 
developed a potent hGOAT ghrelin (1-9) ligand bearing a 2,3-diaminopropanoic acid (Dap) 
moiety, which does not exhibit measurable binding to the GHS-R1a receptor. This compound 
exploits the strong interaction of F4 aromatic groups to GOAT with a 1-naphylalanine (Nal1) 
attached and a threonine mutation at position 8 that increased binding potency. Fluorophore 
attachment at distal end of this potent GOAT inhibitor minimally impacted potency, suggesting 
this peptide can serve as a platform for further development of GOAT ligands for imaging and 
diagnosis.  
 With this work we have demonstrated compound interaction with GOAT, providing the 
first functional connection between the active site of GOAT and ghrelin through the Dap amine-
H338 interaction. The enhancement in binding to hGOAT upon amine substitution at the 
acylation site could be explained by a formation of a ground state hydrogen bond to an enzyme 
side chain, which normally serves as a general base for serine acylation as shown in Figure 5.4. 
Furthermore, the loss of ligand uptake in the presence of H338A hGOAT expression argues 
against general loss of cell membrane integrity as the mechanism for ligand internalization. 
Given the integral membrane nature of GOAT,55, 61 we considered it possible that hGOAT 
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expression may destabilize or disrupt membrane integrity, which could allow ligand cell 
penetration without requiring direct binding to hGOAT.  
 Originally assigned as an ER-resident enzyme responsible for acylating ghrelin during 
hormone maturation prior to secretion,16 this study provides the first direct evidence for GOAT 
exposure to the extracellular space and interaction with soluble peptides. This indicates the 
presence of a subpopulation of GOAT available on the plasma membrane to interact with ghrelin 
and desacyl ghrelin located outside the cell. This is consistent with observations of the presence 
of GOAT in intracellular and plasma membranes of lipid trafficking vesicles in the blood 
marrow.45 This supports a new branch of ghrelin signaling pathway involving local re-acylation 
of desacyl ghrelin by plasma membrane exposed GOAT.62  
This localization could also provide a novel mechanism for intracellular drug/cargo 
delivery targeting GOAT expressing cells purposely. However, the GOAT ligand internalization 
mechanism is still unclear and will be the subject of further study. It is possible that GOAT could 
be serving as a pore or transporter to ghrelin mimetic peptides by undergoing a conformational 
change involving its continuous internal channel.55 This process presents a new and 
unanticipated function for integral membrane acyltransferases and argues for examining the 
potential involvement of other integral membrane enzymes currently proposed to perform 





















Figure 5.4. Proposed interactions within the GOAT active site of Ser3 with H338 and Dap3 
with H338. Strong binding interaction of ligands 14 and 15 ghrelin-mimetic is proposed to arise 
from interaction between the amine side chain of the Dap moiety and H338 in GOAT.  
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5.4 Experimental Methods 
 
General methods 
5.4.1 Peptide synthesis and characterization 
Note: Synthesis and characterization of all peptides were performed by collaborator Marina 
Childs from the Len Luyt’s Laboratory (University of Western Ontario). 
 Peptide synthesis was carried out using standard Fmoc solid-phase peptide synthesis on a 
Biotage SyroWave automated peptide synthesizer. Peptides were synthesized on a 0.1 mmol 
scale using Rink amide MBHA resin (0.39 mmol/g). The resin was initially swelled with 
dichloromethane (DCM), followed by Fmoc deprotection using 2 mL of 40% piperidine in N,N-
dimethylformamide (DMF) for two cycles (3 min, 12 min). Amino acids were coupled with 4 
equiv of Fmoc protected amino acid, 4 equiv. of O-(6-chlorobenzotriazol-1- yl)-N,N,N′,N′-
tetramethyluronium hexafluorophosphate (HCTU), and 8 equiv of N,Ndiisopropylethylamine 
(DIPEA) in N-methylpyrrolidinone (NMP). The mixture was added to the resin and vortexed for 
40 min. These cycles were repeated until all amino acids were coupled to the resin.  
 Allyloxycarbonyl deprotection of diaminopropionic acid was performed manually under 
inert atmospheric N2 conditions. DCM was dried over sieves for 24 h before adding 4 mL to the 
resin.  An amount of 24 equiv of phenylsilane was then added to the peptide resin and shaken 
for 5 min. An amount of 0.15 equiv of tetrakis(triphenylphosphine)-palladium(0) was then added 
and allowed to react for 10 min. If desired, the resulting free amine was then acylated using 3 
equiv of the corresponding acid (octanoic acid or 6-fluoro-2-naphthoic acid), 3 equiv of HCTU, 
and 6 equiv of DIPEA in DMF. The reaction mixture was left to couple overnight.  
 Full deprotection of the synthesized peptide was performed by adding a 2 mL mixture of 
95% trifluoroacetic acid (TFA), 2.5% triisopropylsilane (TIS), and 2.5% water to the resin and 
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allowing it to mix for 5 h. The cleaved peptide was precipitated from solution using ice-cold 
tertbutyl methyl ether (TBME) and centrifuged (3000 rpm, 10 min, 0 ˚C) resulting in a crude 
peptide 15 pellet. The supernatant was decanted, and the resulting peptide pellet was dissolved in 
20% acetonitrile in water, frozen at -78 °C, and lyophilized to a white crude powder. Purification 
was performed using preparative HPLC-MS, and purity of the resulting peptides was analyzed 
using analytical HPLC-MS. These results are summarized in Table 5.6, with all compounds 
determined to have ≥95% purity. 
 
Table 5.7 Analytical data for peptide ligands 









2 H-GS-Dap-FLSPY-NH2 855.4365 855.3387 99 36 
3 H-GS-(C8-Dap)-FLSPY-NH2 981.5409 981.4415 98 20 
4 H-GS-(6FN-Dap)-FLSPY-NH2 1027.4689 1027.54 99 25 
5 H-Aib-S-Dap-FLSPY-NH2 883.4678 883.3658 99 26 
6 H-Inp-S-Dap-FLSPY-NH2 909.4834 909.4159 99 28 
9 H-GS-(C8-Dap)-FLSPE-NH2 947.5202 947.82 96 22 
10 H-GS-(C8-Dap)-FLSPN-NH2 932.5205 932.85 99 25 
11 H-GS-(C8-Dap)-FLSPT-NH2 919.5253 919.8689 99 24 
12 H-GS-Dap-Nal-1-LSPT-NH2 843.4365 843.3524 99 10 















5.4.2 GHS-R1a receptor binding assays  
Note: All GHS-R1a receptor-binding assays were performed by collaborator Marina Childs 
from Len Luyt’s Laboratory (University of Western Ontario). 
 The affinity for the ghrelin receptor was determined using a radio ligand competitive 
binding assay. 47 Assays were performed using GHS-R1a transfected HEK293 cells as receptor 
source and human [125I]-ghrelin(1−28) (PerkinElmer Inc. NEX3888010UC) as the radioligand. 
Human ghrelin(1−28) was used as reference to ensure the validity of the results. A suspension of 
membrane from HEK293/GHS-R1a cells (100,000 cells per assay tube) were incubated with 
ghrelin(1−8) peptide analogues (at concentrations of 10−6 M, 10−7 M, 10−8 M, 10−9 M, 10−10 M, 
10−11 M and 10−12 M ) and [125I]-ghrelin (15 pM per assay tube) in binding buffer (25 mM 
HEPES, 5 mM magnesium chloride, 1 mM calcium chloride, 2.5 mM EDTA, and 0.4% BSA, pH 
7.4). The resulting suspension was incubated for 20 min under shaking (550 rpm) at 37 °C. 
Unbound [125I]-ghrelin was removed and the amount of [125I]-ghrelin bound to the membranes 
was measured by γ counter. IC50 values were determined by nonlinear regression analysis to fit a 
four-parameter dose−response curve using Prism 6 (version 6.0c). All binding assays were 
performed in triplicate. 
 
5.4.3. hGOAT inhibition assays  
 Assays were performed using previously reported protocols.50, 63 For each assay, 
membrane fraction from Sf9 cells expressing hGOAT was thawed on ice and homogenized by 
passage through an 18-gauge needle 10 times. Assays were performed with 50 μg of membrane 
protein, as determined by Bradford assay. Membrane fraction was pre-incubated with 1 mM 
methyl arachidonyl fluorophosphonate (MAFP) and unlabeled peptide inhibitor or vehicle as 
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indicated in 50 mM HEPES pH 7.0 for 30 minutes at room temperature prior to reaction 
initiation64. All reactions were initiated by the addition of 1.5 μM GSSFLCAcDan and 300 μM 
octanoyl CoA. Reactions were incubated for 30 minutes at room temperature under foil. All 
assays were stopped with the addition of 50 μL of 20% acetic acid in isopropanol, and solutions 
were clarified by protein precipitation with 16.7 μL of 20% trichloroacetic acid, followed by 
centrifugation (1,000 x g, 2 minute). The supernatant was then analyzed using reverse-phase 
HPLC with fluorescence detection as previously described.50, 63 Peak integrations for both 
substrate and product peaks were calculated using Chemstation for LC (Agilent Technologies). 
Data reported are the average of three independent determinations, with error as standard 
deviation. 
 For determination of IC50 values, the percent activity at each inhibitor concentration was 
calculated from HPLC integration data using equations 1 and 2: To determine an IC50 value for a 
given inhibitor, the plot of % activity versus [inhibitor] was fit to equation 3, with % activity0 
denoting hGOAT activity in the presence of the vehicle alone. All reported IC50 values represent 
the average of a minimum of three independent trials. 
 
(1) % activity = 
% peptide acylation in presence of inhibitor
% peptide acylation in absence of inhibitor
 
 
(2) % peptide octanoylation = 
Fluorescence of acylated peptide
Total peptide fluorescence (acylated and non‐acylated)
 
 






5.4.4. Construction of hGOAT WT and mutants  
Note: The pcDNA 3.1 (+) WT hGOAT used in this work was designed by Tasha Davis from 
the Hougland Lab (Syracuse University). 
 Site-directed mutagenesis was performed on pcDNA 3.1 (+) mammalian expression 
vector containing a hGOAT insert cloned from our previously reported pFastBacDual vector 
(Invitrogen) using the EcoRI and XbaI restriction sites, resulting in pcDNA3.1_Mb4.WT 
(hGOAT) construct.50 This construct contains a C-terminal FLAG epitope tag, a polyhistidine 
(His6) tag, and 3x human influenza hemagglutinin (HA) tags appended downstream of a TEV 
protease site.63 
 
5.4.5 hGOAT (WT and mutants) transfection in HEK293 cells 
 Mammalian cell line HEK293 (ATCC) was maintained in 75 mL vented tissue culture 
flasks (Celltreat) and kept to 70% confluency before splitting. All cells were cultivated in 
complete DMEM (Dulbecco's Modified Eagle's Medium supplemented with 10% fetal bovine 
serum (FBS) and 1% (v/v) penicillin-streptomycin (MediaTech)) in a humidified atmosphere 
with 5% CO2 at 37°C. For transfection of WT hGOAT, mutant hGOAT, and empty vector (EV) 
the cells were plated at a density of 1 × 106 in 2 mL of complete DMEM in a 6-well plate per 
well (Corning) with 1.5 glass coverslips 12 mm (Warne Instruments). The cells were incubated 
for 16 hours prior transfection. DNA-transfection reagent complex was prepared by incubating 4 
ug of the pcDNA3.1_Mb4.WT (hGOAT) or mutant plasmids in 9 μL of lipofectamine 2000 
transfection reagent (Invitrogen) for a total volume of 500 μL supplement free DMEM with 30 
minutes incubation at room temperature. The cells were then transfected with the prepared DNA-
transfection reagent complex by drop wise addition into the wells of the plate wells.  
176  
 
5.4.6. GOAT ligand labeling and immunofluorescence imaging 
Note: This immunoblotting procedure was adapted from Dr. Heidi Hehnly Laboratory, 
Syracuse University. 
  Following transfection for 40 hrs, coverslips with attached cells were removed from 
wells, washed with 1x phosphate-buffered saline (PBS) (Cellgro), and incubated with 10 μM 
Cy5-ghrelin (ligand 15) (500 μL/well) for 30 minutes at 37°C. Following washing with 1x PBS, 
cells were incubated with 4% paraformaldehyde for 20 minutes at room temperature, washed 
with 1x PBS, quenched in 50 mM NH4Cl for 10 minutes at room temperature, and washed with 
1x PBS. For antibody staining, all steps were performed in a Parafilm dark chamber at room 
temperature (unless specify) with humid atmosphere. Cells were blocked with PBSAT buffer 
(PBS + 1% Bovine serum albumin, 0.1% triton) for 30 minutes in the dark chamber, following 
aspiration of buffer avoiding coverslip to dry. Cells were then incubated with primary antibody 
Rabbit anti FLAG (DYKDDDDK) antibody (Sigma, F7425) diluted in 1x PBS overnight in the 
dark chamber at 4°C. The following day, cells were washed with 1x PBS and incubated with 
secondary antibody Alexa Fluor 488-conjugated goat anti-rabbit (Jackson Immuno Research, 
709-545-149) for 1 hour. Following antibody incubations, cells were washed three times, 
mounted on slides using ProLong Diamond Antifade Mountant (Life Technologies) containing 
DAPI, and analyzed by confocal microscopy. Images were taken on a Leica DMi8 STP800 
(Leica, Bannockburn, IL) equipped with an 89 North–LDI laser with a Photometrics Prime-95B 
camera taken with a Crest Optics: X-light V2 Confocal Unit spinning disk. Optics used were HC 
PL APO 63×/1.40 NA oil CS2 Apo oil emersion objective.  
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5.4.7. Image analysis 
Note: Immunofluorescence imaging was performed with help of Erin Curtis from the Hehnly 
Laboratory at Syracuse University. During these cell-imaging studies, we had consulted 
Professor Heidi Hehnly for guidance in improving image quality and cell labeling.  
 The entire cell was imaged at 0.2-μm step-intervals and displayed as maximum 
projections (ImageJ). The fluorescence range of intensity was adjusted identically for each image 
series. Graphs and statistical analysis (analysis of variance [ANOVA] as labeled) were 
completed using Graphpad Prism software. p < 0.0001 was considered to be statistically 
significant. All images were set to a resolution of 300 DPI or greater after image analysis from 
raw data. 
     
5.4.8. Confirmation of hGOAT expression by Western blot 
  hGOAT transfected cells were harvested by treatment with 0.25% trypsin-EDTA at 37°C 
for 5 minutes. Cells were transfer to an Eppendorf tube and collected by centrifugation at low 
speed at room temperature. The media was aspirated and cells were resuspended in 1x sample 
buffer (0.33 M Tris HCl, pH 6.8, 0.1 M SDS, 14% glycerol, and 0.5 M DTT) and 50 mM 
HEPES pH 7.0 in a total volume of 45 μL. Samples were heated to 50.2 °C for 5 minutes and 
then incubated at room temperature for 15 min prior to gel loading.63 Samples were loaded onto 
a 12 % Tris-glycine SDS-polyacrylamide gel and run at 110 V for 1.5 hrs. Each gel was loaded 
with a negative control (empty vector (EV) microsomal protein) and amino-terminal FLAG-BAP 
Fusion protein as a positive control (Millipore Sigma, P7582-100UG, 1:200 dilution, 50 μL total 
volume) as previously published protocol.63 Following SDS-polyacrylamide electrophoretic 
separation, proteins were transferred to a polyvinylidene difluoride (PVDF) membrane (BioRad, 
Trans-Blot turbo RTA transfer kit). The PVDF membrane was activated with methanol 
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incubation for 30 seconds followed by equilibration in transfer buffer (20% v/v methanol, 48 
mM Tris base, 39 mM glycine and 0.034% v/v SDS) before transfer. Proteins were transferred to 
the membrane for 30 minutes at 1.3 A / 25 V using a transfer kit per manufacturer’s instructions. 
Following transfer electroblotting, the PVDF membrane was blocked for 3 hours with 5% v/v 
nonfat milk in TBST buffer (Tris 10 buffered saline (TBS, 0.05M Tris and 0.14M NaCl) with 
0.1% v/v Tween 20). FLAG antibody (HRP-conjugated DYKDDDDK Tag Antibody, Invitrogen 
catalog number PA1-984B-HRP, 1:2000 dilution, 10 mL total volume) was prepared in 5% 
nonfat milk in TBST buffer and membrane was incubated with the antibody overnight at 4 °C. 
The membrane was washed with TBST (6 x 5 mL) and treated with West Pico 
Chemiluminescent substrate-imaging reagent (Thermo Scientific), followed by imaging on a 






















Figure 5.5 Western blot verification of hGOAT expression in HEK 293 cells. hGOAT 
variant expression confirmation by anti-FLAG Western blotting with expected size of hGOAT 
variants (49 kDa). Western blots were performed as described in the Experimental Methods 
section. WT, wild type hGOAT; EV, empty vector expression; FLAG, FLAG-BAP fusion 
protein positive control. 
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Chapter 6: Investigation of a Predicted Functionally 
Essential Loop Domain within Human Ghrelin O-
Acyltransferase 
 
The work presented in this chapter is unpublished. In this chapter, there was an 
experimental contribution from Natasha Tcheki-Jamgotchian (Syracuse University 







 Ghrelin is a peptide hormone whose signaling impacts the central nervous system while 
regulating metabolism and energy balance.1 Ghrelin was discovered in 1999 by Kojima and 
coworkers in their search for the endogenous ligand for the growth-hormone secretagogue 
receptor (GHS-R1a).2 Originally linked to growth hormone (GH) secretion and stimulation of 
appetite,3-4 ghrelin signaling has been linked to the gastrointestinal,5 cardiovascular,6 and 
immune systems, memory consolidation,7-9 amongst others.10-11 Based on ghrelin involvement in 
important signaling processes, inhibiting ghrelin signaling may offer a novel strategy for treating 
multiple ghrelin-related health conditions. 
 Ghrelin is initially translated as a 117-amino acid precursor (preproghrelin), that is 
trafficked to the endoplasmic reticulum (ER).12 To be biologically active, ghrelin requires a 
unique posttranslational modification of the third serine (Ser3) of the precursor des-acyl 
proghrelin, wherein this serine is acylated by an octanoyl (C8) fatty acid group (Figure. 6.1).2, 10 
The enzyme that catalyzes ghrelin octanoylation, ghrelin O-acyltransferase (GOAT), was 
discovered in 2008 by two research groups independently.12-13 GOAT is a member of the 
membrane bound O-acyltransferase (MBOAT) enzyme superfamily.14-16 These enzymes transfer 
fatty acids and other lipids onto hydroxyl groups of membrane-bound substrates.14 Three 
MBOAT members (Porcupine (PORCN), Hedgehog acyltransferase (Hhat), and ghrelin O-
acyltransferase (GOAT)) exclusively catalyze the transfer of a fatty acyl moiety onto secreted 
signaling proteins.12-13, 16-17 All three of these enzymes are present in the endoplasmic reticulum 
(ER) and acylate proteins within the luminal compartment as the substrate travels through the 
secretory pathway. These family members share a conserved homological domain containing an 
invariant histidine (H338 in GOAT) and highly conserved asparagine (N307 in GOAT).14 
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Mutation of these conserved residues in the mouse form of GOAT (mGOAT) led to a loss of 
ghrelin acylation activity demonstrating key participation in acylation.18 
 The active site structure and catalytic machinery of GOAT is not well understood. 
Membrane proteins have been proven to be difficult to study owing to their hydrophobic 
surfaces, flexibility, and lack of stability and crystallization of such membranes are extremely 
difficult. Determination of the structure of functionally important domains within GOAT is a 
critical step to define how GOAT binds to its substrate and catalyzes an octanoylation reaction. 
Nevertheless, in 2013 Taylor and coworkers combined phylogenetic analysis, computational 
calculations, epitope mapping, and induced glycosylation studies to establish the first topological 
construction of mGOAT.19 They determined that mGOAT comprises 11 transmembrane domains 
(TMDs) with one reentrant loop. Additionally, the enzyme contains numerous loop domains that 
are not embedded in the membrane, with the invariant H338 located in the ER lumen and the 
conserved Asn307 residue exposed to the cytosol (Figure. 6.2).19  
 Subsequent studies revealed a remarkable similarity in the topological structure of the 
MBOAT member Hedgehog acyltransferase (Hhat) and GOAT, where the overall organization 
and location of the TMDs and intermembrane loops is nearly identical in the C-terminal 
“conserved MBOAT” domain (Figure 6.3).20-21 Within this homology, a large conserved loop 
domain (residues I260-R316) resides within the cytoplasm, connecting helices 7 and 8 in GOAT. 
This loop also encompasses one of the two highly conserved residues in MBOAT proteins, N307 
in GOAT and D339 in Hhat. The topological similarity and conservation of functionally essential 
residues in this loop domain, herein named the CARLi (Conserved Asp/Asn Required Loop, 
intracytoplasmic) domain, make this region a compelling target for structural and biochemical 
investigation.   
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Figure 6.1.  Ghrelin octanoylation by ghrelin O-acyltransferase (GOAT). 
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 In our hGOAT computational model, we have docked octanoyl-Co to hGOAT and 
identified key interactions between the substrate and the enzyme.22 Amongst amino acids studied 
by alanine mutagenesis in chapter 3; amino acids R304, W306, N307, and R315 showed a 
complete loss of GOAT’s activity.  These residues form part of this small domain (showed in 
Figure 6.4), proposing the participation of this loop domain in acylation of GOAT, which 
suggests CARLi as an acyl-CoA binding domain. The main goal of the proposed research is to 
determine the functional role and structure of a conserved cytoplasmic loop domain within 
hGOAT. These studies will complement our computational model and advance our mechanistic 






Figure 6.2. GOAT model topology by Taylor et al. showing 11 transmembrane domains, one 
reentrant loop, and multiple loops in both the cytoplasm and ER lumen. Figure reproduced with 
permission from Reference 19 (Appendix XVII). © 2013 American Society for Biochemistry 






Figure 6.3. Membrane topology models for human Hhat (left) and GOAT (right). The 
conserved His and Asp residues are shown in red and yellow, respectively and CARLi region is 
enclosed in a box. The topological organization is most highly conserved between Hhat and 
GOAT in their C-terminal domains, as shown below the dotted line. Figure reproduced with 
permission from Reference 20 (Appendix XVIII). © 2015 The American Society for 




























Figure 6.4. CARLi loop domain binds the octanoyl-CoA acyl donor for ghrelin acylation. 
Pymol representation of CARLi loop domain (blue ribbon) with important residues (orange) that 
abolished acylation of ghrelin under standard reaction conditions when mutated to alanine, 
possibly interacting with octanoyl-CoA acyl donor.   
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6.2 Results 
6.2.1 Design of hGOAT loop variants. Expression of CARLi loop domain via a synthetic 
split mini-intein gene.  
 Previous research in the Hougland lab constructed and expressed hGOAT loop domains 
as fusion proteins coupled with maltose binding protein (MBP) or glutathione S-transferase 
(GST) in order to increase the solubility and stability of these domains. However, this approach 
did not yield any evidence for expression of the hGOAT loop fusion proteins, including the 
CARLi loop domain.23 To aid in the expression and stabilization of hGOAT domains, a synthetic 
DnaB split mini-intein gene was constructed for the cyclization of recombinant loop domain. 
Protein splicing is a post-translational modification including deletion of the intein sequence and 
connection of the flanking sequences (N- and C-exteins).24 While proteins are generally linear 
arrangements of amino acid residues, studies using techniques such as NMR have shown that 
cyclization between amino and carboxyl ends can increase protein stability.25-27 Stabilized 
proteins with circular topology can remain folded for longer periods of time in the presence of 
chaotropic agents.28-29 To study the function and structure of CARLi, we developed a bacterial 
expression system to obtain the loop domain as a circularized protein using a split intein system 
(Figure. 6.5).30-31 This method aids purification and expression procedures by mimicking the 
topological constraint provided by transmembrane helices TM7 and TM8 in hGOAT. This 
system has supported robust expression of CARLi compared to non-circularized constructs, 
presumably through stabilization of the loop conformation.  
 A pNW1120 vector encoding the reversed split protein intein was provided by Nicholas 
Dixon’s laboratory at the University of Queensland.30 The synthetic Synechocystis sp. PCC6803 
DnaB split mini-intein gene was used to construct the in vivo cyclic form of the CARLi protein. 
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This synthetic gene encodes a protein with the structure IntC-target-IntN, wherein the circularly 
permuted split intein splices to create a cyclized protein with its NH2 and COOH termini linked 
by a regular peptide bond and the combined excised intein. This approach has been demonstrated 
to cyclize proteins and peptides in vivo in several Escherichia coli systems.32-34 Based on this 
methodology, plasmid pNW1120_MB4_CARLi was constructed to directly express CARLi with 
split intein abilities. However, expression trials with this vector did not provide any evidence for 
expression of the loop domain intein fusion protein.  
 To explore an alternate route for expression of the loop domain with the split mini 
inteins, we transferred the complete split intein-CARLi gene cassette from 
pNW1120_MB4_CARLi to the pET system expression vector pET_23a(+).35 Following fusion 
protein expression, splicing of the InteinC-CARLi-InteinN precursor (26.8 kDa) by formation of 
an amide bond between the N and C intein domains termini is expected to yield the following 
protein species: covalently linked InteinC-InteinN (14.1 kDa) and cyclized CARLi (8.8 kDa) 
(Figure 6.5). To separate and detect these potential splicing products, expression of the InteinC-
CARLi-InteinN precursor was analyzed by Tris-tricine-SDS-PAGE with a color marker ultra-
low range ladder (M.W. 1,060-26,600)36(Figure 6.7a). Purification of the InteinC-CARLi-
InteinN precursor (26.8 kDa) was attempted by anion exchange chromatography (HiTrap DEAE 
Sepharose Fast Flow) based on the predicted acidic pI of the cyclized CARLi protein (pI= 6.18). 














Figure 6.5.  Circularization of CARLi by expression in a split intein construct. IntC-CARLi-
IntN precursor leads to production of a cyclized-protein with the connection of the flanking 
sequences (N- and C-).   
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6.2.2 Expression optimization of CARLi domain with a flexible internal hexahistidine 
affinity-tag  
 Flexible protein linkers have been used to increase the accessibility of an epitope to 
antibodies37 or to improve protein folding.38 Following this logic, flexible linkers using repeat 
“GGS” tripeptide sequences were added to the loop domain construct to provide conformational 
flexibility near the intein splicing junction/cyclization site, increase CARLi folding, and improve 
purification utilizing a hexahistidine affinity-tag (Figure 6.6a). Three different loop constructs 
were chosen based on multi sequence alignments and topological predictions: “long” loop 
domain including portions of TM7 and TM8 (residues F238-W337); “medium” loop domain 
including portions of TM7 and TM8 (residues W245-H320); and “small” cytosolic loop domain 
(I260-R316) (Figure 6.6b). Expression of pET23a_CARLi_Long Domain-His6-(GGS)2 (LS 
domain) and pET23a_CARLi_Small Domain-(GGS)-His6-(GGS) (SM domain) constructs was 
confirmed by SDS-PAGE with two gel bands at 11.5 kDa and 9.3 kDa, respectively (Figure 
6.7b). Comparison of these protein bands in the improved construct to the previous construct 
described in section 6.2.1 indicated a more robust generation of spliced proteins by addition of a 
more flexible linker (Figure 6.7). However, no protein bands or other evidence for expression of 
the CARLi_Medium Domain-His6 construct were observed under all conditions explored.  
 Recombinant protein expression of splicing products of the CARLi_SM construct (Figure 
6.8) were analyzed via immunoblotting using a 6x-His tag antibody. Both, the supernatant and 
expression pellet were collected after cell disruption with BPER and examined in order to verify 
the presence of the target protein. The supernatant was saved for gel investigation and the 
insoluble pellet was resuspended with 6M guanidine hydrochloride (GuHCl) or 8M Urea. 
Centrifugation of the resuspended pellet provided a denaturant solubilized supernatant that was 
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saved for investigation. It was confirmed the presence of polyhistidine affinity tag recombinant 
protein in two different bands that corresponds to cyclized CARLi_SM (9.3 kDa) shown in 
figure 6.9 within the denaturing agents. This observation describes the accumulation of CARLi 
protein in the aggregates or inclusion bodies of the insoluble portion of expression pellet.  
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Figure 6.6. Optimization of loop domain constructs with flexible linkers. a) New linker IntC-
Extein-IntN construct to produce cyclized-CARLi protein. b) Loop domain construct design with 
flexible GGS linker units (orange) between the loop domain, hexahistidine affinity-tag, and 
intein N domain.  
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Figure 6.7. Expression analysis of CARLi constructs in autoinduction media by 14% Tris-
tricine-SDS-PAGE. a) Initial construct InteinC-CARLi-InteinN expression. A green box 
highlights the spliced CARLi product from this construct. Lane 1: color marker ultra-low range. 
Lane 2: pET23 empty vector B-PER lysis supernatant. Lane 3: pET23a_IntC-CARLi-IntN BPER 
lysis supernatant. b) Expression of new loop domain CARLi constructs containing flexible GGS 
linkers. Lane 1: color marker ultra-low range. Lane 2: pET23 empty vector B-PER lysis 
supernatant. Lane 3: pET23a_CARLi_LS BPER lysis supernatant. Lane 4: pET23a_CARLi_SM 
B-PER lysis supernatant. The blue and yellow boxes highlight the spliced loop domain CARLi 
expected for each new construct. Sizes are represented with theit respective colors.  
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Figure 6.8. Predicted protein splicing products of the CARLi_SM (Small Domain Loop) 
construct with flexible peptide linker and genetically encoded internal His6 tag. Green color 
depicts Intein C, blue color depicts Inten N, red color depicts His6 tag. Connecting lines show the 
new connection of flanking sequences after protein splicing. Expected sizes of the splicing 





Figure 6.9. Western blot analysis of small CARLi construct expression. Cell lysates from 
expression trials were probed with an anti-His6 antibody in the context a BPER extract (soluble 
protein), 8M Urea insoluble pellet resuspension, and 6M GuHCl insoluble pellet resuspension. 
Lane 1: color marker ultra-low range (not shown). Lane 2: CARLi_SM (small construct) BPER 
lysis supernatant. Lane 3: 1:3 dilution sample of 8M Urea resuspension. Lane 4: 1:4 dilution 
sample of 8M Urea resuspension. Lane 5: 8M Urea resuspension only. Lane 6: pre-proghrelin-
His6 BPER lysis supernatant (positive control for His6 antibody).  Lane 7: 1:3 dilution sample of 
6M GuHCl resuspension. Lane 8: 6M GuHCl only. The blue box represent the spliced loop 
domain CARLi_SM expected size band. 
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6.2.3 Purification of cyclized CARLi domain  
 The insoluble inclusion bodies containing the cyclized CARLi construct were separated 
from soluble proteins by centrifugation and solubilized with 6M guanidine HCl. Direct 
purification of polyhistidine-tagged proteins has been attempted with His60 Ni Sepharose 6 Fast 
Flow Resin following a refolding step with 20 mM Tris buffer based on procedure of Kim et al.39 
Refolding was completed by transitioning from the washing buffer to a refolding buffer, which 
reduces the concentrating of the denaturing agent. All fractions with refolded CARLi were 
pooled and concentrated to 2 mL using an Amicon Ultra-15 Centrifugal Filter Unit (3 kDa 
MWCO). Figure 6.10 shows the ratio of protein in the soluble and insoluble fractions from the 
cell pellet along with the refolded and purified CARLi_SM protein. The purified protein gave 
two bands of ~26 and ~9 kDa. The molecular mass calculated for the precursor 
IntC_CARLi_SM_IntN is 26.6 kDa and CARLi_SM is 9.3 kDa, in agreement with the band 
sizes obtained by SDS–PAGE.  
 Isolated cyclized CARLi_SM obtained after Ni-IMAC purification was followed by size 
exclusion chromatography (SEC) using a HiLoad 16/60 Superdex 75 pg column (Figure 6.11). 
This purification led to isolation of a protein with single band purity with an estimated molecular 
weight of 7 kDa by SDS-PAGE. We hypothesized the folded and cyclized CARLi domain may 
run lower in SDS-PAGE than the expected size of 9.3 kDa as this protein cannot achieve the 






Figure 6.10. SDS-PAGE analysis of Carli_SM purification from inclusion bodies. Lane 1: 
color marker ultra-low range. Lane 2: Supernantant after cell disruption with sonication. Lane 3: 
Supernatant after resuspension with 2M Urea buffer. Lane 4: Supernantant after insoluble pellet 
resuspension in 6M GuHCl buffer (sample used for CARLi purification). Lane 5: Flow through 
following binding to Ni Sepharose 6 Fast Flow Resin. Lane 6: Washes with 20 mM Imidazole 
buffer. Lane 7: Washes containing 6M Urea. Lane 8: Wash with refolding buffer containing 20 
mM Tris-HCl. Lane 9: Elution buffer containing 500 mM Imidazole. Lane 10: Second wash with 
elution buffer containing 500 mM Imidazole. The blue box represent the spliced loop domain 
CARLi_SM expected size band. 
  
   1      2       3       4       5      6      7       8      9      10 
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Figure 6.11. SDS-PAGE analysis of Carli_SM size exclusion purification. Lane 1: color 
marker ultra-low range. Lane 2: Supernantant after resuspension with 6M GuHCl buffer (Sample 
used for Ni purification). Lane 3: Over night nickel resin flow through. Lane 4: Low MW range 
prestained protein ladder. Lane 5: Previously purified inteins spliced (~12 kDa). Lane 7: 
Concentrated cyclic CARLi after SEC purification. The blue box represent the spliced loop 
domain CARLi_SM expected size band. 
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6.2.4 Circular dichroism analysis of CARLi_SM loop domain  
 Circular dichroism (CD) was applied to determine the presence of secondary structural 
elements in purified CARLi. Analysis of the CD spectrum for CARLi supports partial α-helical 
character as indicated by the decrease in ellipticity at 222 nm for the protein in buffer when 
compared to spectra collected under denaturing conditions in the presence of 6M guanidium, 
with the latter spectrum consistent with a random coil conformation (Figure 6.12). These results 
indicate the presence of secondary structure within this conserved loop domain that potentially 





Figure 6.12. Circular dichroism analysis of circularized hGOAT CARLi domain. CARLi 
samples (27 mM, pH 8.0) were prepared in 300 μL of 50 mM Tris. Spectra were collected over 
the range of 200-260 nm. Pathlength of the quartz cuvette was 0.1 cm and three accumulations 
were collected for each spectrum. CARLi protein is shown in the absence (blue) and presence of 
















CARLi_SM (27 μM) 
CARLiSM in 5 M GuHCl
(27 uM)
CARLiSM in 50 mM Tris
(27 uM)
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6.3 Discussion and Conclusions 
 Multiple groups have described structural investigation of hGOAT and other MBOAT 
protein members.20, 40-41 However, high-resolution structural data for this family of enzymes 
remains elusive. Membrane topology studies of GOAT and Hhat revealed a common topology in 
the C-terminal portion of these enzymes share, establishing a characteristic “MBOAT domain”. 
Within this region, a conserved loop structure containing the highly conserved amino acid N307 
in GOAT and D339 in Hhat in the cytoplasm was recognized. We have designed a system for 
expression of this structural fragment of GOAT, denoted CARLi in our work, to investigate its 
potential participation in the catalytic mechanism of GOAT. The bacterial expression system and 
purification of CARLi resulted into a robust production of this protein domain by using a 
synthetic DnaB split mini intein gene. The system was used to cyclize the loop domain, 
stabilizing the nature of a linear protein into a circular one, mimicking the non-free protein 
topology of this loop linking transmembrane helices 7 and 8 in hGOAT. Cyclization was found 
to be efficient, with a small accumulation of precursor. The product was purified in high yield 
using a two-step purification process including Ni Sepharose 6 Fast Flow and size exclusion 
chromatography protocols. However, the purified product appeared at a smaller length than the 
expected size of 9,289 Da during SDS-PAGE analysis.  
 Studies of this purified CARLi loop domain using circular dichroism support the 
presence of an alpha helical secondary structure in this small protein. The structural signal 
demonstrated by this small protein is of interest since CARLi loop domain is located in the 
cytosol and shares a conserved sequence among MBOATs. Moreover, this domain is forming a 
potential interface for acyl-CoA substrate binding of GOAT showed by computational 
experiments in chapter 3. We suggest that this domain form potential key interactions between 
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cytosolic acyl-CoA donor and the enzyme, reiterating the participation of this loop domain in 
acylation of GOAT. However, the precise roles played by residues in this loop domain during 
ghrelin binding and acylation by hGOAT remain to be fully determined and represent a future 
goal of this research.   
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6.4 Experimental Methods 
 
 
6.4.1 Design of CARLi domain variants with flexible internal hexahistidine affinity-tag 
 Three different genes sequences of different loop domain sizes with flexible 
hexahistidine affinity-tag were commercially synthesized (Bio Basic), with the insert bracketed 
by NdeI and XhoI restriction sites for subcloning. 
Loop Domain Construct Gene sequence 
CARLi_Long (F238-W337) 
IntC-CARLi_L -(GGS)2 His6  (GGS)2-IntN 
M S P E I E K L S Q S D I Y W D S I V S I T E T G V E E V F D L 
T V P G P H N F V A N D I I V H N S I E F F E C I Y V V W T T 
A G L F K L T Y Y S H W I L D D S L L H A A G F G P E L G Q 
S P G E E G Y V P D A D I W T L E R T H R I S V F S R K W N Q 
S T A R W L R R L V F Q H S R A W P L L Q T F A F S A W W G 
S G G S G G S H H H H H H G G S G G S A S T R E S G C I S G 
D S L I S L A S T G K R V S I K D L L D E K D F E I W A I N E Q 
T M K L E S A K V S R V F S T G K K L V Y I L K T R L G R T I 
K A T A N H R F L T I D G W K R L D E L S L K E H I A L P R K 
L E S S S L Q L * 
CARLi_Medium (W245-H320) 
IntC-CARLi_M-(GGS) His6  (GGS)-IntN 
M S P E I E K L S Q S D I Y W D S I V S I T E T G V E E V F D L 
T V P G P H N F V A N D I I V H N S I E F W T T A G L F K L T 
Y Y S H W I L D D S L L H A A G F G P E L G Q S P G E E G Y 
V P D A D I W T L E R T H R I S V F S R K W N Q S T A R W L 
R R L V F Q H G S G G S H H H H H H G G S A S T R E S G C I S 
G D S L I S L A S T G K R V S I K D L L D E K D F E I W A I N E 
Q T M K L E S A K V S R V F S T G K K L V Y I L K T R L G R 
T I K A T A N H R F L T I D G W K R L D E L S L K E H I A L P 
R K L E S S S L Q L * 
CARLi_Small (I260-R316) 
IntC-CARLi_S-(GGS) -His6  (GGS)-IntN 
M S P E I E K L S Q S D I Y W D S I V S I T E T G V E E V F D L 
T V P G P H N F V A N D I I V H N S I E F I L D D S L L H A A G 
F G P E L G Q S P G E E G Y V P D A D I W T L E R T H R I S V 
F S R K W N Q S T A R W L R R G S G G S H H H H H H G G S 
A S T R E S G C I S G D S L I S L A S T G K R V S I K D L L D E 
K D F E I W A I N E Q T M K L E S A K V S R V F S T G K K L 
V Y I L K T R L G R T I K A T A N H R F L T I D G W K R L D E 
L S L K E H I A L P R K L E S S S L Q L * 
  
6.4.2 Double digestion of pUC57-Amp and pET23a  
 pUC57-Amp vectors containing targeted genes constructs and pET23a vector were 
double digested with NdeI and XhoI restriction enzymes. The double digest reactions were 
performed under the following conditions: the first tube had a total volume of 50 L solution 
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including pET23a (1.5 μg), NdeI (1 μL, 20 units), XhoI (1 μL, 20 units), NEB 10x Cutsmart 
buffer (5 μL), and ultrapure H2O (18 μL). Second tube had a total volume 50 L solution 
including pUC57_CARLi_constructs (2.0 μg), NdeI (1 μL, 20 units), XhoI (1 μL, 20 units), NEB 
10x Cutsmart buffer (5 μL), and ultrapureH2O (18 μL). Reactions were incubated for 3 hours at 
37C, followed by analysis of the vector digestions by agarose gel electrophoresis (0.8% 
agarose, 1X TAE buffer) to verify the size of the linearized pET 23a and pUC57 insert genes. 
The digested vector and insert genes cleaved from pUC57 were purified using an EZ-10 Spin 
Column DNA Gel Extraction Kit (Bio Basic Inc.) per the manufacturer’s instructions.  
 
6.4.3 DNA Ligation Procedure of insert gene for CARLi_constructs into pET23a(+) (New 
England Biolabs© Quick Ligation Kit) 
 Ligations were performed using a 1:3 molar ratio of vector to insert performed under the 
following conditions (20 μL total volume of ligation solution): double digested pET 23a (100 
ng), double digested CARLi_constructs insert (100 ng), ultrapure H2O (1.2 μL), 2x Quick Ligase 
buffer (10 μL), and T4 Quick Ligase (New England Biolabs, 1 μL). Solutions were then 
incubated at room temperature (25°C) for 5 minutes. The ligation mixture was then stored at -
20oC until use in transformation. 
 
6.4.4 Plasmid transformation into DH5-alpha competent E.coli cells 
 DH5-alpha Z-competent cells were thawed on ice, followed by the addition of 5 μL of 
quick ligation mixture prepared above to 100 μL competent cells aliquots. Cells were incubated 
on ice for 15 minutes and then spread onto pre-warmed LB agar plates containing 100 μg/mL 
ampicillin. The plates were incubated at 37°C O/N (overnight).  Following, single colonies 
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obtained were inoculated into LB media (5 mL) containing ampicillin (100 g/mL) in sterile 
culture tubes. These cultures were incubated overnight at 37C with shaking (225 rpm). Plasmids 
were purified from the saturated cultures using EZ-10 Spin Column Plasmid DNA kit (Bio Basic 
Inc.) per manufacturer’s instructions. The transformants were screened with digestion analysis 
by restriction enzymes using NdeI and XhoI, and analyzed by DNA sequencing, confirming 
successful ligation.    
 
6.4.5 Plasmid transformation into BL21-DE3 E.coli cells  
 Purified pET23a_CARLi_constructs plasmids containing CARLi_construct genes and 
BL21-DE3 Z-competent cells were thawed on ice, followed by addition of 200 ng of plasmid to 
100 μL aliquout of Z-competent cells. Cells were incubated on ice for 15 minutes and then 
spread onto pre-warmed LB-ampicillin plates (100 μg/mL). The plates were incubated at 37°C 
overnight (O/N) and then screened for colonies, indicating transformation.  
 
6.4.6 Expression of hGOAT CARLi_constructs (Small, Medium, and Long) using 
autoinduction media 
Following overnight incubation, single colonies were used to inoculate a 5 mL culture of 
autoinduction media (1% tryptone, 0.5% yeast extract, 25 mM Na2HPO4, 25 mM KH2PO4, 50 
mM NH4Cl, 5 mM Na2SO4, 2 mM MgSO4, 0.2x trace metals (0.01 mM FeCl3, 0.004 mM CaCl2, 
0.002 mM MnCl27H2O, 0.002 mM ZnSO47H2O), 0.5% glycerol, 0.05% glucose, 0.2% α-D-
lactose, and 100 g/mL ampicillin) in sterile culture tubes and incubated overnight at 37 C with 
shaking (225 rpm). A 3 mL aliquot of this starting culture was used to inoculate 1 L auto-
induction media prepared as above with 100 g/mL ampicillin and incubated at 28 C for 22 
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hours for expression. Following growth, bacteria were harvested by centrifugation (6000 x g, 15 
min), supernatant removed and the pellet was stored at -80C. Five 1 mL aliquots of bacterial 
culture were taken for protein expression analysis SDS-PAGE.  The 1 mL bacterial pellet was 
resuspended in B-PER lysis reagent (Thermo Scientific, 150 µL) followed by vortexing for 1 
minute and cell debris was separated by centrifugation (15,000 x g, 5 min) to remove residual 
cell debris. Supernatant from B-PER lysis was prepared for analysis by 14 % Tricine-SDS-
PAGE gel by adding 3X SB (sample buffer) and incubated for 2 min at 95°C. 
 
6.4.7 Purification and refolding for the solubilization of CARLi_SM protein expressed in 
E.coli 
 The pellet from 1L culture was resuspended on lysis buffer (20 mM Tris–HCl pH 8.0, 
500 mM NaCl, 2M urea, and 2% Triton X-100) and sonicated on ice using a sonicator (Misonix 
Cell Disrupter) per the following protocol: power setting of 12; 8 cycles of sonication for 30 
seconds followed by 30 seconds rest. The lysate was separated by centrifugation at 18,000xg for 
10 min. The supernatant was saved for gel analysis and the insoluble fractions containing 
insoluble proteins were resuspended again in 20 ml of ice-cold lysis buffer containing 20 mM 
Tris–HCl pH 8.0, 500 mM NaCl, 2M urea and 2% Triton X-100). The insoluble material was 
separated by centrifugation at 18,000xg for 10 min and the supernatant (SUP) was saved for 
analysis. The resulting washed pellet was resuspended in 20 ml Binding buffer (20 mM Tris– 
HCl pH 8.0, 500 mM NaCl, 6 M guanidine HCl, 5 mM imidazole and 1 mM 2-mercaptoethanol) 
and incubated at room temperature for 10 min. The solution was centrifuged at 18,000xg for 10 
min to remove unsolubilized material. The solubilized proteins were loaded onto a pre-
equilibrated (binding buffered) His60 Ni Sepharose 6 Fast Flow Resin (GE Healthcare, bed 
218  
volume, 5 ml) for purification and refolding of the protein. Resin and the sample were incubated 
over night, at 4 degrees, rocking. The lysate was separated by centrifugation at 500xg for 5 min 
and SUP saved. The resin was washed with 3 column volumes (CV) of binding buffer followed 
by 3 CV of washing buffer (20 mM Tris–HCl pH 8.0, 500 mM NaCl, 6M urea, 20 mM imidazole 
and 1 mM 2-mercaptoethanol). Refolding was completed by changing the washing buffer to a 
refolding buffer (20 mM Tris–HCl pH 8.0, 500 mM NaCl and 20 mM imidazole) using a 
gradient of 1:0, 1:1, and 0:1 binding buffer to refolding buffer respectively. After washing with 3 
CV of refolding buffer, the protein was eluted with 3 CV of elution buffer (20 mM Tris–HCl pH 
8.0, 500 mM NaCl and 500 mM imidazole). The fractions with refolded protein were pooled and 
concentrated to 2 ml using an Amicon Ultra-15 Centrifugal Filter Unit (3K MWCO). The 
concentrated samples were loaded on a HiLoad 16/60 Superdex 75 pg size exclusion column 
(GE) and eluted with buffer (20 mM NaH2PO4, 200 mM NaCl). Buffer was continuously run 
through the column for 120 mL after injection of 1 mL of sample and an elution profile was 
obtained. Fractions (5 mL each) were then analyzed by SDS-PAGE. 
6.4.8 SDS-PAGE analysis 
 3XSB lysis was performed by using cell lysate (50 μL) was mixed with 25 μL of 3X SDS 
sample buffer and heated to 95 °C for 5 min, followed by centrifugation (10,000 x g, 5 min) to 
pellet insoluble material. B-PER lysis was performed using BPER lysis reagent (Thermo 
Scientific, 150 μL), vortexed on high for 1 min, and cell debris was removed by centrifugation 
(12,000 x g, 5 mins). 25 μL of 3XSB was added and heated to 95 °C for 5 min, followed by 
centrifugation (10,000 x g, 5 min) to pellet insoluble material. Protein standards ladder (Thermo 
Scientific and Color Marker Ultra-low Ranging (M.W. 1,060-26,600), Sigma) and samples were 
loaded onto a 14% tris-tricine polyacrylamide gel and run at 150 V for 1 hr 30 min, until the dye 
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band had migrated to the bottom of the gel. Total protein in cell lysate samples was visualized by 
staining with Coomassie Blue stain and imaged on a ChemiDoc XRS+ BioRad gel imager. 
 
6.4.9 Coomassie Blue staining procedure 
 Each 14% tris-tricine polyacrylamide gel was rinsed with ultrapure water and covered in 
50 mL of destain solution (stock: 2 L water, 1.6 L methanol, 0.4 L acetic acid). The gel was 
microwaved for 18 sec, at which point the destain solution was removed and approximately 50 
mL of Coomassie blue stain was added (stock: 0.25g Coomassie Blue dye, 500 mL methanol, 75 
mL acetic acid). The gel was microwaved for 30 sec and rocked for 5 min. The stain solution 
was decanted, destain solution was added and rocked for 15 min, followed by wash of destain 
addition and rocking for 15 min. The gel was then placed into ultra pure water rocked overnight. 
Protein gels were then imaged using BioRad XRS+ gel imager. 
 
6.4.10 Anti-His6 Western blotting of inclusion bodies in CARLi_SM purification  
 Cell lysates were run on a 14% Tris-Tricine gel as described above. A polyvinylidene 
difluoride (PVDF) membrane was activated by immersion in methanol for 30 seconds, followed 
by equilibration in transfer buffer (20%v/v methanol, 48 mM Tris base, 39 mM glycine and 
0.034%v/v SDS) for 10 minutes. Filter papers and sponges were also soaked in transfer buffer. 
The gel was assembled into a transfer cassette and proteins were transferred to the PVDF 
membrane for 30 minutes at 350 mA, using a BioRad TransBlot Turbo RTA Transfer kit per 
manufacturer’s instructions. Following electroblotting, the PVDF membrane was washed in tris 
buffered saline (TBS, 0.05M Tris and 0.14M NaCl), TBST (TBS with 0.1% v/v Tween 20) and 
blocked for 4 hours in 10% v/v nonfat milk in TBST. The membrane was then probed with an 
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HRP-α- antiHis primary antibody (1:200 dilution, Rockland) in 10% milk TBST overnight at 4 
degrees Celsius. Following washing in TBST, the membrane was treated with the West Pico 
Chemiluminescent substrate-imaging reagent (Thermo Scientific) and imaged on a ChemiDoc 
XRS+ BioRad gel documentation system. 
6.4.11 Circular dichroism spectroscopy of circularized hGOAT CARLi domain 
 CARLi was purified to single band as assessed by SDS-PAGE from size-exclusion 
chromatography. Purified sample were buffered exchanged into a final buffer composition of 25 
mM Tris-HCl (pH 8.0) and protein concentration of 25 μM. Fractions were concentrated to 1/4 
of the volume, supplemented with buffer to original volume, spun down (2,500 x g, 4 °C) to ¼ of 
the volume, repeated until three volumes worth of buffer have been added. After buffer 
exchanging an A280 was taken (ε=17990 M-1cm-1). Spectra were collected using 1mm Suprasil 
High Resolution Quartz cuvet (Hellma Analytics, Müllheim, Germany). Three accumulations 
were used for each spectra collection. CD and turbidity (dynode voltage) data were recorded by a 
UV detector in a spectropolarimeter equipped with thermoelectric temperature control. Light 
scattering was recorded at the same wavelength as CD by an additional UV detector that is 
positioned at 90° to the direct beam and is a part of the fluorescence attachment; the filters from 
this attachment were removed. The data were normalized to protein concentrations and 
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 The acylation of biological proteins is essential for intercellular and organismal processes 
that are related to numerous diseases including diabetes and cancer.1-2 Ghrelin is a peptide 
hormone primarily secreted by the stomach that undergoes an acylation modification to be 
biological active and act as the endogenous ligand for the ghrelin receptor (GHS-R1a).3 
Ghrelin’s most well known role is as a hormone that stimulates food intake and adiposity both in 
rodents and humans.4-5 Similarly, this 28 amino acid peptide has been associated with 
cardiovascular, gastrointestinal, neuroendocrine, and immune systems.6-7 These characteristics of 
ghrelin make this hormone an attractive yet largely unexploited target for the investigation of 
small-molecule therapeutics.  
 Ghrelin O-acyltransferase (GOAT) was discovered to catalyze the octanoylation of the 
third serine (Ser3) of ghrelin side chain to generate the active form of this hormone.8-9 Therefore, 
GOAT is considered as a potential target for treatment of obesity and other disorders linked to 
the ghrelin peptide. Nevertheless, the active site architecture and mechanism for GOAT-
catalyzed ghrelin acylation are presently undetermined. Currently, the Hougland laboratory aims 
to establish the catalytic mechanism of ghrelin acylation as a key step in understanding ghrelin’s 
role in different disorders and targeting ghrelin-dependent pathways for therapeutic effect. The 
objective of this work was to define the structural and chemical basis for ghrelin acylation by 
GOAT within three main goals: determine the acyl donor and ghrelin binding sites within 
hGOAT, define hGOAT’s catalytic mechanism of acylation, and aid GOAT’s inhibitor 
development that targets essential ghrelin binding sites.  
 With this work we were able to provide crucial insights into GOAT’s structure by 
developing the first functionally validated structural model for a MBOAT protein 
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acyltransferase. We have also identified essential residues, which interact with ghrelin within the 
proposed catalytic core of hGOAT. This dissertation has provided a better understanding of the 
mechanism for transmembrane acylation by this enzyme. Hereafter, our work will establish a 
groundbreaking approach for the investigation of structurally challenging membrane proteins and 
advance the investigation of acylated secreted proteins as therapeutic targets for associated 
disorders. 
 
7.2 Development of the first structural model of human GOAT 
 
 As ghrelin requires acylation by GOAT to be biologically active, a detailed 
understanding of this transmembrane enzyme is essential. However, membrane proteins are well 
known for resisting structural studies due to their lack of solubility and instability in the absence 
of lipids or detergents. This is a common limitation encountered with similar membrane proteins 
that evade traditional methods of structure determination and underscore the need for new 
approaches of investigation.10-11 In this work, we have employed an interdisciplinary 
computational-biochemical approach to develop a three-dimensional model of GOAT. Using 
chemical and biochemical assays, we experimentally validated this computation-derived 
structure of hGOAT.12 We utilized metagenomics information of GOAT and related proteins to 
generate a set of co-evolutionary constraints to produce ~ 30,000 potential hGOAT structures.13-
15 These structures were examined and exposed to molecular dynamics calculations to create an 
energy-optimized structural model for hGOAT within a cellular membrane. 16  
 In this dissertation, we described our model as an eleven transmembrane domain enzyme 
with an ellipsoidal cone shape and a narrow end facing the ER lumen. Within this cone, we 
located an interior continuous channel connecting both the ER lumen and the cytoplasm. Inside 
this channel, we observed the absolutely conserved histidine residue (H338), indispensable for 
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GOAT's activity, indicating the significance of this amino acid in this pore. Moreover, we 
validated our computational model by alanine mutagenesis investigation of 42 amino acids 
together with our previously reported peptide-based acylation assay.17-18 By biochemical 
examination, alanine mutants with residues’ side chain contacting the void inside the channel 
produced significantly more loss of activity than the non void-contacting mutations with proven 
expression of mutants by Western blotting.12 This mutation profile demonstrates a functionally 
essential core within hGOAT, containing required amino acids for enzymatic activity. This new 
structural mode of investigation resulted in a structure consistent with previously reported GOAT 
mouse ortholog19 and the published crystal structure for the bacterial MBOAT DltB alanyl 
transferase.20  
 This work has established and verified a novel approach for the rapid development and 
validation of a structural model for an integral membrane protein, which can be applied to 
decode the three-dimensional structural configurations of other difficult-to-purify membrane 
enzymes like GOAT.  
7.3 Exploring the acyl donor-binding site within hGOAT  
 Previous studies of the acyl binding site of hGOAT has revealed the uncommon selection 
of a fatty acid bearing an eight-carbon chain as its acyl substrate however, other acylation 
enzymes display a preference for longer acyl groups fatty chains such as 14- or 16-carbons.21-23 
In fact, hGOAT differentiates against smaller and longer than eight-carbon chains,24 which 
suggest a distinct binding pocket that can accommodate this C-8 substrate exclusively. To 
investigate this selection by GOAT, we used our structural model described above to identify 
amino acids that potentially form part of this acyl-binding site.12 Based on results obtained from 
our model-oriented alanine mutagenesis, we have explored alterations that increase the potential 
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binding site pocket groove. Our screening resulted with the loss of appreciable octanoylation 
activity with amino acids W351 and F331 (Figure 7.1). Nevertheless, these mutations generated 
recognition of longer acyl donors, gaining activity with the C12 and C14 acyl chains. This 
altered selectivity demonstrated the modeled positions of W351 and F331 suggested to form the 
end of the acyl groove.  
 Moreover, with this work we have identified two different binding sites for the acyl 
substrate where previously described essential amino acids for GOAT’s activity have been 
found.19 Mutants W306A, D358A, N307A, and R315A were shown to completely eliminate 
GOAT activity at this sites, describing the direct potential interaction with the acyl-CoA 
substrate. In our model, the highly conserved N307 formed polar contacts near the pantothenic 
acid site of the acyl-CoA substrate, answering a long-lasting question of the location and 
functional role of this highly MBOAT conserved amino acid.  
 While these studies provide the first description of various essential amino acids for 
potential substrate binding to hGOAT, many aspects of the acyl transfer mechanism remain to be 
defined by ongoing studies. Based on our modeling and chemical studies, we hypothesize that 
the acyl substrate binds to GOAT inside the internal channel within the cytoplasmic side (See 
Figure 7.1). Within this pore, octanoyl-CoA communicates with ghrelin and transfers the acyl 
chain, with coenzyme A being released back to the cytoplasm following the acyl transfer 
reaction. Moreover, this substrate binds to the enzyme with the phosphoadenosine group binding 
into a discrete pocket while the phosphopantetheine chain is in contact with multiple polar amino 
acid side chains in a different opening of the pore open to the cytoplasm. This understanding of 
acyl-CoA recognition by GOAT can refine the hGOAT structural model by providing constrains 
and advancing the development of acyl-CoA inhibitors. 
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7.4 Identification of ghrelin binding to GOAT via cross-mutation analysis 
  
 Building upon multiple studies of ghrelin recognition by GOAT, the Hougland lab has 
developed a schematic model of ghrelin interactions with GOAT involved in substrate 
recognition.17, 24 For example, the lab has demonstrated important size recognition at several sites 
in the GSSFLC sequence of ghrelin substrate.24 However, the location and relationship of these 
interactions in a three-dimensional model have not been described. Using simultaneous alanine 
mutagenesis in both the enzyme and ghrelin peptide substrate, we investigated interactions 
between ghrelin and hGOAT. Several mutations presented rescue signals reflected by reactivity 
enhancements calculations for each enzyme-substrate mutation pair relative to the wild type 
enzyme and substrate. There was a significant enhancement of activity with amino acids S300 
and F348 and mutations at G1 of ghrelin. We were able to rescue an alanine mutation in the first 
glycine in ghrelin that previously has been proven to be detrimental for activity.17 By adding 
alanine to amino acids S300 and F348 we were able to recover the activity of GOAT with the 
enzyme, demonstrating an interaction within these regions of GOAT.  
 Similarly, amino acid S179 in GOAT presented the strongest signal for activity 
enhancement, establishing a significant interaction of this amino acid with the second serine in 
the ghrelin peptide. Incorporation of the hydrophobic side chain in valine at the S2 position 
decreased hGOAT activity in previous investigations.17, 24 We observed enhanced octanoylation 
activity with this substrate in the presence of an alanine mutation of S179, which we propose 
creates a spatial opening in the enzyme that more readily accommodates the valine side chain.  
 Interactions of Y255, S300, and F302 with the F4 position were defined with rescue of 
activity in our assay. Mutants Y255A and F302A demonstrated to be enhance steric tolerance, 
accepting the unnatural amino acid cyclohexylalanine which indicated that planarity and/or 
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aromaticity might not play a role in recognition at this position. As previously determined, the 
enzyme tolerates a range of bulky amino acids at this position.8, 17 Our investigation reiterated 
this result by showing activity a substrate with incorporation of acrylodan at this site. Building 
on this work, further investigations with conserved amino acid mutations are necessary to 
investigate GOAT-substrate interactions and their role in acylation activity. However, the 
findings in this work can provide direction in defining the specific location of recognition 
elements within ghrelin and the nature of the interactions leading to increased peptide binding to 
GOAT. 
 
7.5 Development of specific ghrelin O-acyltransferase ligand that exposed a new method of 
GOAT detection with extracellular peptides 
 Ghrelin, the endogenous ligand for the ghrelin growth hormone secretagogue receptor 
(GHS-R1a), provides a significant template as a starting point for the development of strong 
inhibitors. Moreover, since its discovery in 1999,3 ghrelin was found to be the only protein 
containing a unique posttranslational modification and it was the only predicted GOAT substrate 
in the human proteome.24 Given this and ghrelin’s role in metabolic regulation through binding 
to the receptor and its enzyme, many groups have explored different avenues to produce strong 
and specific hGOAT ghrelin inhibitors to control acylation by GOAT.  
 Recent students had identified expression of GHS-R receptors in human breast 
carcinomas and cell lines25-27 and overexpression of GOAT has been detected in some tumor and 
cancer tissues.28-29 All these new data argues towards GOAT and the receptor as available targets 
for a cancer cell biomarkers. The Luyt lab at Western Ontario University has developed new 
fluorescent imaging agents for the detection of GHS-R1a such as a truncated ghrelin analog 
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containing acylated ghrelin (1–8) analogue for use in PET imaging.30-31 However, peptides 
mimicking the sequence of octanoylated ghrelin effectively bind to both GOAT and the GHS-
R1a receptor,32-33 making them unsuitable for specific detection of GOAT. 
 To increase substrate specificity to hGOAT, we developed a new class of ghrelin-
mimetic inhibitors through incorporation of a free diaminopropanoic acid DAP amino group at 
the third acylation serine hydroxyl site, with this substitution shown to dramatically increase 
GOAT binding affinity.34 By combining this moiety and several other amino acid substitutions, 
we generated a potent GOAT ligand (nanomolar IC50) when evaluated as an inhibitor with an 
appended fluorescent group, which demonstrates our ability to functionalize GOAT peptide 
ligands with imaging groups without compromising GOAT binding ability.  
 To further investigate ligand binding in a cellular system, transiently transfected HEK293 
cells with hGOAT demonstrated uptake of our Cy5 fluorescence ligand; whereas empty vector 
control expressing cells did not. These results demonstrating that GOAT expression in these cells 
is essential for ligand binding. Moreover, GOAT is proposed to be restricted to the ER/Golgi 
complex with an integral membrane nature,12, 19 so this work provided the first evidence for 
GOAT exposure to the extracellular space. Nevertheless, we can also considered that hGOAT 
overexpression in these cells could destabilize or disrupt membrane integrity that permits ligand 
cell penetration without requiring direct binding to hGOAT. Overexpression of GOAT could 
also lead to abnormal cell surface localization of the enzyme in the cells. However, when 
transfected into HEK293 cells, the H338A hGOAT variant did not preserve cell uptake of the 
fluorescent ligand, supportive of an interaction between the Dap amino group and H338 and 
disputing against general loss of cell membrane integrity as the mechanism for ligand 
internalization. Additionally, other alanine variants did not demonstrated internalization of our 
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ligand, as expected for mutations not proposed to form part of the ghrelin-binding site within the 
hGOAT catalytic channel found in our model.12 In the future, the Hougland lab will investigate 
other cell lines that overexpress endogenously GOAT with methods including microscopy 
imaging and flow cytometry probing these questions of GOAT trafficking and ligand uptake.  
 Our work demonstrates the creation of a potent GOAT inhibitor that can serve as the 
foundation for an array of biostable high-affinity peptide ligands for detecting and imaging 
GOAT in many tissues and disease models. Whether the mode of transport of the GOAT:ligand 
complex into the cell is by membrane trafficking or GOAT serving as a pore/transporter using its 
internal channel, this process presents a new and unforeseen function for integral membrane 
acyltransferases and may provide a novel avenue for intracellular drug/cargo delivery targeting 
cells expressing GOAT.  
 
7.6 Define the structure and function of a catalytically required hGOAT loop domain  
 
 Structural studies of GOAT revealed a remarkable similarity in the topological structure 
of (Hhat), where the location of the TMDs and loops are nearly identical in the C-terminal part of 
the enzymes.35-36 Within this homology, a large cytosolic loop containing the highly conserved 
Asn/Asp residue is located, making this region a compelling target for structural and biochemical 
investigation to aid in the construction GOAT’s structure. In our study, we have described this 
large conserved loop domain (residues I260-R316) within the cytoplasm that includes the highly 
conserved N307 in GOAT. Our model describes this loop as located in the cytosol and 
potentially forming an interface for acyl-CoA substrate binding of GOAT.  
 To study the function and structure of this loop, we expressed the conserved cytoplasmic 
domain via a synthetic reverse DnaB split mini-intein, constructed for the cyclization and 
stabilization of the protein to mimic the topological constraint provided by transmembrane 
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helices in hGOAT. We successfully expressed recombinant polyhistidine-tagged cyclic domain 
within aggregates or inclusion bodies (IBs) in the expression pellet. With a direct purification of 
the proteins solubilized in GuHCl and purified by His60 Ni Superflow Resin, we obtained two 
different size proteins corresponding, the precursor parent and the loop domain. This circularized 
loop expressed at levels sufficient to support structural and functional characterization and 
circular dichroism (CD) of the purified domain has supported partial -helical structure 
consistent with computational predictions for this domain.12 With these results we suggest that 
this cytosolic loop provides a flexible region for essential contacts with the acyl-donor, 
potentially providing a substrate passage to the ER membrane for acyl transfer to ghrelin, 
however this hypothesis have not been proven with experiment data.  
   
7.7 Summary and future directions 
 With this work we have made several advances in the study of ghrelin acylation by 
hGOAT, including the development of the first high-resolution structural understanding of this 
enzyme, uncovering key substrate bindings sites domains within hGOAT for acyl donor binding 
as shown in Figure 7.1, determination of specific residues required for ghrelin interaction, and 
the discovery of a new class of ghrelin-mimetic inhibitors. These outcomes will aid the 
generation and testing of hypotheses regarding the mechanism for GOAT-catalyzed ghrelin 
octanoylation. Moving forward, the Hougland lab will utilize these approaches to refine the 
structural model for hGOAT. For example, other researchers are currently investigating the 
potential involvement of a serine or threonine nucleophile in the acylation process of ghrelin as a 
covalent catalyst. Likewise, the lab will investigate modeling structural interactions that will 
stabilize GOAT structure for purification in a catalytically active form from the cell membrane. 
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Moreover, these findings of GOAT could describe the acylation processes of other MBOAT 
family members that are also intractable to current structural studies, especially those that also 
acylate protein substrates and share remarkable similarities in their topologies like Hhat and 
PORCN.  
 This work has laid the foundation for structure-based rational drug design targeting 
hGOAT specifically; exploring new avenues of ghrelin binding. Another avenue of research that 
is exciting from the Hougland lab is the development of a potential biomarker for non-invasive 
detection of overexpression of ghrelin O-acyltransferase (GOAT) in cancer cells. By developing 
GOAT specific ligands, our work has create biostable high-affinity peptide ligands for detecting 
and imaging this enzyme and providing avenues for complementary studies of GOAT expression 
in cell lines, tissues, and disease models. Preliminary data with our fluorescent ligand in (prostate 
cancer) PC3 cells has shown a large subpopulation of PC3 cells that display membrane 
associated Cy5 fluorescence. Even though this initial study does not conclusively demonstrate 
plasma membrane-localized GOAT in the cells, it does support the potential of fluorescent 
GOAT ligands to label GOAT in biological samples. In the future, the Hougland lab and 
collaborators will investigate cell trafficking inside these cells via membrane staining and flow 
cytometry for a complete investigation of ligand uptake by these cells. I believe this work will 
influence molecular understandings concerning peptide ligand binding to GOAT and generate 














Figure 7.1 Proposed model for substrate interaction with ghrelin O-acyltransferase. The 
reaction is initiated by the binding of ghrelin (via the top, luminal side of the channel) and the 
acyl donor (via bottom, cytosolic side) substrates to the active center of the membrane that is 
formed in the channel within hGOAT’s core. Amino acids illustrated here have shown important 
interactions between substrates and hGOAT. Essential amino acids shown in red abolish 
acylation activity upon alanine mutagenesis. hGOAT residues shown in purple demonstrate 
reduced acylation activity. Red and blue cylinders represent perimeter helices, the green cylinder 
represents intramembrane domains forming the cytoplasmic surface of hGOAT including the 
CARLi domain (TM7-TM8) presented in this work. Dotted lines represent binding interactions 
between the octanoyl-CoA acyl donor and its binding site within hGOAT.  
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